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Therapeutic hypothermia decreases neurological damage in patients experiencing out-of-hospital 
cardiac arrest (CA).  In addition to hypothermia, critically ill patients are treated with an 
extensive pharmacotherapeutic regimen.  The majority of these medications are hepatically 
eliminated via the cytochrome P450 (CYP450) system.  Changes in drug clearance could limit 
the putative benefit of hypothermic therapy. With the increased use of therapeutic hypothermia 
and the fact that critically ill patients receive multiple medications, it is crucial to understand the 
effects of hypothermia on the disposition and metabolism of drugs used in this population.  Thus, 
it was the overall aim of this research to investigate the effects of therapeutic hypothermia on 
CYP450-mediated metabolism in an animal model of CA, in human liver microsomes, and in 
normal healthy subjects.  Specifically, hypothermia produced a ~2 fold decrease in the systemic 
clearance (ClS) of intravenous chlorzoxazone, a specific CYP2E1 probe substrate, in a CA rat 
model when compared to CA rats treated under normothermic temperatures.  The mechanism 
behind this decrease in ClS was a hypothermia-mediated decrease in the affinity of CYP2E1 for 
chlorzoxazone.  We extended the experimental period to investigate the effects of hypothermia 
after re-warming, on CYP2E1 and CYP3A2 activity and expression.  Our results indicate that 
rats with CA treated under normothermic temperatures demonstrated a significant decrease in the 
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activities of CYP2E1 and CYP3A2, 24 hrs after injury compared to control.  Furthermore, CA 
significantly decreased the expression of CYP3A2, but not the expression of CYP2E1.  CA also 
produced a ~ 10-fold increase in plasma concentrations of interleukin-6 (IL-6) compared to 
Control.   The CA-mediated reduction in CYP3A2 and CYP2E1 activity, mRNA, and the 
increase in IL-6 plasma concentrations was attenuated by hypothermia.  We also investigated the 
effects of mild and moderate hypothermia on CYP2E1 and CYP3A4 enzyme kinetics in human 
liver microsomes.  Both mild and moderate hypothermia significantly decreased the Vmax of 
CYP2E1 and CYP3A4.  However, hypothermia increased the Km of CYP2E1 but not CYP3A4.  
These data demonstrate that mild and moderate hypothermia may produce isoform specific 
alterations of human CYP450-mediated metabolism.  Lastly, in a pilot analysis, we showed that 
mild hypothermia may potentially alter the ClS and the volume of distribution (Vss) of midazolam 
in mildly hypothermic normal healthy volunteers. 
Collectively, this work provides evidence that therapeutic hypothermia alters CYP450-
mediated metabolism both during cooling and after re-warming.  Based on the magnitude of 
these changes it is clear that intensivists should be cognizant of these alterations and monitor 
drug levels and outcomes in their patients when possible.  In addition to increased clinical 
attention, future research efforts are essential to delineate precise dosing guidelines and 
mechanisms of the effects of hypothermia on drug disposition, metabolism, and response. 
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INTRODUCTION AND BACKGROUND 
 
 
 
Determining the effects of a new chemical entity on the disposition and metabolism of other 
drugs is an essential component in the new drug approval process according to the Food and 
Drug Administration (FDA) (FDA 1997).  For non-pharmacological therapies implemented into 
clinical practice, the same stringency of investigation is not as clear.  Frequently, non-
pharmacological therapies, such as therapeutic hypothermia, are clinically utilized with limited 
understanding of the effects on the disposition and metabolism of the most commonly used drugs 
in patients.  This creates the potential for therapy-drug interactions.   
Therapeutic hypothermia has long been used in cardiac surgery and as a second tier 
therapy for refractory raised intracranial pressure (ICP) in traumatic brain injury (TBI) (Clifton, 
Allen et al. 1993; Tonz, Mihaljevic et al. 1995).  Recently, mild and moderate hypothermia has 
demonstrated benefit in both adults and infants experiencing cardiac arrest (CA) and may have 
some application in TBI and stroke, which has greatly expanded the scope of this therapy in the 
intensive care unit (ICU) setting (Clifton, Allen et al. 1993; Tonz, Mihaljevic et al. 1995; Clifton, 
Miller et al. 2001; Bernard, Gray et al. 2002; Group 2002; Dalton Dietrich and Kuluz 2003; 
Samson, Nadkarni et al. 2006).  In the CA population, therapeutic hypothermia has been shown 
to decrease secondary neurological damage (Bernard, Gray et al. 2002; HACSG 2002).  Data in 
TBI and stroke has also been promising and has begun to increase the role of therapeutic 
hypothermia as a potential therapy (Clifton, Allen et al. 1993; Marion, Penrod et al. 1997; 
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Clifton, Miller et al. 2001; Berger, Schabitz et al. 2002; Dalton Dietrich and Kuluz 2003; De 
Georgia, Krieger et al. 2004).  Hypothermia in surgery requiring CPB has been used to decrease 
the underlying inflammatory reaction due to cellular activation by the material of the 
extracorpeal circuit and the surgical trauma (Westaby 1987; Tonz, Mihaljevic et al. 1995).  The 
evidence provided in these studies has led to an increase in the clinical implementation of 
hypothermia and has spurred ongoing trials to determine the optimal depth, duration, and re-
warming rate required for full benefit of this intervention. 
With the increased use of therapeutic hypothermia and the fact that critically ill patients 
are subjected to an extensive pharmacotherapeutic regimen, there is an increased probability that 
alterations in drug concentrations will occur during treatment.  These alterations can result in 
toxic or sub-therapeutic dosing, thereby, limiting the optimal application of hypothermia.  
Therefore, it is important for the intensivist to understand the effects of therapeutic hypothermia 
on the disposition of drugs as a guide for dosing patients being treated with therapeutic 
hypothermia.  As depicted in Figure 1, the effects of hypothermia on drug disposition are a 
complex interplay of two major effects, during cooling and the effects post re-warming.  As will 
be evident throughout this dissertation, the hepatic metabolism of certain drugs is decreased 
during cooling, more specifically CYP450-mediated metabolism.  This suggests that intensivists 
should decrease the dose of drugs that rely on CYP450-mediated metabolism in order to achieve 
optimal plasma concentrations.  However, studies have shown that the potency and efficacy of 
certain drugs is decreased during cooling, suggesting the potential need for increased dosage to 
achieve an optimal response.  Hypothermia also produces regulatory effects by mitigating 
cellular damage caused by injury and returning drug metabolism to normal.  It is the purpose of 
this introductory chapter to discuss the known effects of hypothermia on both drug disposition 
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and response during the acute and chronic phase to set the foundation for the studies presented in 
the following chapters of this dissertation.  Specifically, we have focused this chapter on drugs 
commonly employed in critical care that are eliminated via CYP450-mediated metabolism.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: The effects of therapeutic hypothermia on drug disposition and response 
 
The acute effects (during cooling ranging from 12-48 hours) are shown to decrease metabolism and 
 response.  Intensivists should monitor for toxicity and response and appropriately change the dose of drugs 
 accordingly.  The chronic effects (after re-warming) result in the mitigation of cellular damage by 
 hypothermia with normalization of  otherwise altered drug metabolism. 
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1.1 THERAPEUTIC HYPOTHERMIA 
Clinical neurological injury caused by insults such as CA and TBI, contributes significantly to 
the morbidity and mortality of patients and is a major burden on health care in the United States 
(Narayan, Michel et al. 2002; Rea, Pearce et al. 2004; De Keyser, Uyttenboogaart et al. 2005).  
Reports have shown that approximately 200,000-500,000 patients experience an out-of-hospital 
CA each year (Rea, Pearce et al. 2004).  Traumatic brain injury accounts for 500,000 cases 
annually in the United States (Doppenberg and Bullock 1997).  The common cause of morbidity 
in survivors of these insults is secondary neurological damage (Levy, Caronna et al. 1985; 
Jorgensen and Holm 1998).  Drug therapy has been largely supportive and has not targeted this 
secondary neurological damage (Laver, Farrow et al. 2004).   
Therapeutic hypothermia decreases multiple pathological processes which occur after 
clinical neurological injury (Karibe, Chen et al. 1994; Lei, Tan et al. 1994; Aibiki, Maekawa et 
al. 1999; Bernard, Gray et al. 2002; Group 2002).  The Advanced Life Support Task Force of the 
International Liaison Committee on Resuscitation (ILCOR) and recently the European 
Resuscitation Council has recommended mild hypothermia for unconscious adult patients with 
restoration of spontaneous circulation (ROSC) following out-of-hospital cardiac arrest due to 
ventricular fibrillation and the AHA Advisory Committee for CRR suggested it as class IIa 
recommendation (Nolan, Morley et al. 2003).  This recommendation is based on the findings of 
two landmark clinical trials reporting neurological benefit of hypothermia in patients 
experiencing out-of-hospital cardiac arrest (Bernard, Gray et al. 2002; Group 2002).  A multi-
center trial conducted by The Hypothermia After Cardiac Arrest Study group, investigated the 
effects of mild hypothermia on neurological outcome and mortality in 273 patients resuscitated 
after CA due to ventricular fibrillation (Group 2002).  Patients treated with mild hypothermia 
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had a more favorable neurological outcome compared to normothermic patients, six-month post-
CA (Risk Ratio: 1.4, p<0.009) Furthermore, mortality was decreased in the hypothermia group 
compared to the normothermia group, (Risk Ratio; 0.74 (confidence interval = 0.58-0.95)).  
Bernard et al showed that mild hypothermia improved cardiovascular effects in survivors of out-
of-hospital CA (Bernard and Buist 2003).  This study evaluated 77 patients who experienced out-
of-hospital CA and were randomized to receive 12 hours of mild hypothermia (32oC) or standard 
supportive care (37oC). Results demonstrated 49% of patients treated with hypothermia were 
discharged to home or a rehabilitation facility, as compared to 26% of those not treated with 
hypothermia, (p=0.046).  Germaine to this dissertation, the temperatures shown to be efficacious 
in these studies were between 32oC to 34oC, and were applied for 12 to 24 hrs.  Recently, mild 
hypothermia (34oC) applied for 72 hours was shown to improve long-term neurological outcome 
in perinatal asphyxia, expanding the use of this novel therapy (Shankaran, Laptook et al. 2005).   
Use of hypothermia in TBI has demonstrated benefit in patients with elevated intracranial 
pressure (ICP).  Marion et al. showed that TBI patients with Glascow coma scale (GCS) scores 
of 5 to 7, who were treated with hypothermia (32oC to 33oC) had improved  neurological 
outcomes compared to patients maintained under normothermic conditions (Marion, Penrod et 
al. 1997).  However, Clifton et al. failed to show a beneficial effect of moderate hypothermia 
(33oC) compared to normothermic management in patients with TBI (Clifton, Miller et al. 2001).  
Efficacy of mild or moderate hypothermia in TBI and other traumas as a secondary therapy for 
control of refractory raised ICP remains controversial (Kochanek and Safar 2003).  Sources of 
variance that have been identified include the pathophysiologic mechanisms, secondary insults, 
and stress associated with other non-pharmacological therapies Relevant to this dissertation, one 
source of variance identified as a potential confounder is the use of pharmacological agents such 
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as sedatives, narcotics, and neuromuscular blockers during hypothermia, which may produce 
pharmacologic interactions.  Changes in drug clearance due to hypothermic therapy could lead to 
a key toxicity which may limit the putative benefit of this novel therapy.  With an increase in 
clinical implementation of hypothermia, changes in drug disposition could result in significant 
adverse drug events in ICU patients. 
1.2 ADVERSE DRUG EVENTS IN CRITICAL CARE MEDICINE 
In addition to non-pharmacological measures, such as hypothermia, patients experiencing critical 
care insults are subjected to an extensive pharmacotherapeutic regimen (Cullen, Sweitzer et al. 
1997).  The approach to therapy in this patient population is divided into multiple phases 
including support in the acute phase, measures to mitigate the pathologic process, and chronic 
administration during rehabilitation (Bradberry and Fagan 2002; Stringer and Lopez 2002).  
Table 1 lists the most commonly used medications in the critical care population along with their 
major metabolic routes of elimination.  The most commonly employed drug classes in this 
patient population include anti-arrhythmics, neuromuscular blockers, sedatives/hypnotics, 
anesthetics, vasodilators, and anti-coagulants.  Since critical care patients are subjected to a 
myriad of drug therapy, they are the prime candidates for altered drug disposition, metabolism 
and response as a result of hypothermia.   
Cullen et al showed that adverse drug events in ICU patients are nearly two-fold higher 
than in patients on general care units (Cullen, Sweitzer et al. 1997).  They also stratified adverse 
drug events based on drug class and determined that significant differences in adverse events 
between ICU and non-ICU patients were observed for sedatives, cardiovascular drugs, anti-
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arrhythmic drugs, muscle relaxant, and anticoagulant medications.  Kopp et al, performed a 
study investigating medication errors and adverse drug events in the ICU (Kopp, Erstad et al. 
2006).  They found that drug interactions comprised one of the major categories of medication 
errors in critically ill patients in the ICU.  Pharmacokinetic drug interactions include interactions 
affecting the absorption, distribution, metabolism, and excretion of drugs.  Furthermore, TBI 
patients are exposed to a greater number of pharmacotherapeutic agents as compared to CA 
patients.  This creates the potential for increased probability for drug-therapy interactions in TBI 
patients and may account for some of the variance in benefit observed with the application of 
hypothermia after TBI.  The most clinically relevant pharmacokinetic drug interactions are those 
which affect the metabolism and excretion (both renal and biliary) of a drug.  Multiple drug 
interactions which occur in the ICU are due to changes in the metabolism and excretion of drugs, 
specifically involving the CYP450 enzyme system (Boucher and Hanes 1998; Pea and Furlanut 
2001; Krishnan and Murray 2003).  Therefore, we can conclude that the addition of therapeutic 
hypothermia into clinical practice in the ICU could increase the probability of therapy-drug 
interactions due to the temperature effects on CYP450 functionality.  Based on the importance of 
the CYP450 enzyme system in the disposition of multiple clinically relevant and potentially 
toxic medications, the focus of this work will be on the CYP450 system. 
1.3 CYTOCHROME P450 ENZYMES  
Cytochrome P450 enzymes are a ubiquitous super-family of monooxygenases which are critical 
in the metabolism of a wide variety of xenobiotics and endobiotics (Guengerich 1991; 
Anzenbacher and Anzenbacherova 2001).  In 1958, Klingenberg demonstrated that when rat  
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Table 1: Commonly used ICU medications and their pathway of 
elimination
 
 
Drug Class Medication Elimination Pathway
Antiarrythmics Amiodarone CYP3A4
Bretylium Excreted unchanged
Procainamide N-acetyltransferase
Lidocaine CYP1A2 & CYP3A4
Sotalol Renal Excretion
Beta-blockers Metoprolol CYP2D6 & CYP2C9
Atenolol Renal Excretion
Inotropic agents Digoxin CYP3A4
Calcium channel blockers Verapamil CYP3A4
Diltiazem CYP3A4
Amlodipine CYP3A4
Nifedipine CYP3A4
Benzodiazepines Midazolam CYP3A4
Alprazolam CYP3A4
Anesthetics Propofol CYP2B6
Opioids Morphine CYP2C & CYP3A
Codeine & derivatives CYP2C & CYP3A
Fentanyl CYP3A4
Anticonvulsants Phenytoin CYP2C9 & CYP2C19
Carbamezipine CYP3A4
Antimicrobials Glycopeptides Renal Excretion
Aminoglycosides Renal Excretion
β-lactams Renal Excretion
Macrolides CYP450s
Fluroquinolones CYP450s
Rifampin CYP3A4
Tetracyclines CYP450s
Proton pump inhibitors Pantoprazole CYP3A4 & CYP2C19
Omeprazole CYP3A4 & CYP2C20
Lansoprazole CYP3A4 & CYP2C21
H2-blockers Famotidine CYP450s
Ranitidine CYP450s
Corticosteriods Methyprednisolone CYP450s
Prednisone CYP450s
Dexamethasone CYP450s
Neuromusclar blockers Vecuronium CYP450s
Atracurium Renal Excretion
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liver microsomes were incubated with carbon monoxide (CO) a peak at 450 nm was observed 
(Klingenberg 1958).  This finding was unique in that heme proteins typically absorb light at 420 
nm.  In the early 1960s, the studies of Omura and Sato identified the peak at 450 nm as a 
hemoprotein they named cytochrome P450 (Omura and Sato 1962; Omura and Sato 1964).  In 
addition, Mason et al demonstrated that CYP450 was responsible for incorporation of one 
oxygen atom into progesterone, describing this CYP450 enzyme as a monooxygenase enzyme 
(Mason, North et al. 1965). 
CYP450 enzymes perform critical functions in multiple forms of life including 
vertebrates, invertebrates, fungi, plants, as well as prokaryotic organisms.  CYP450 enzymes 
play key roles in steroid hormone biosynthesis, the activation and detoxification of many drugs 
and environmentally contaminating chemicals, the metabolism of polyunsaturated fatty acids 
(such as arachidonic acid), activation of vitamins A and D3 to biologically active hormones, the 
synthesis of a vast array of secondary metabolites in plants and insects and the metabolism of 
contaminating environmental chemicals to toxic and carcinogenic agents (Estabrook 2003).  This 
wide range of physiological functions is due to the ability of CYP450 enzymes to metabolize 
various substrates. 
The ability of CYP450 enzyme to metabolize multiple substrates is due to the mechanism 
of catalytic activity (Gonzalez 1997).  The CYP450 enzyme is comprised of an apoprotein coat 
and a protoporphyrin IX heme moiety as depicted Figure 2A.  The heme protoporphyrin IX is 
non-covalently bound to the P450 protein and is the same heme protein found in hemoglobin, 
myoglobin, cytochrome c, and other enzymes such as xanthine oxidase and myeloperoxidase.  
The heme is covalently bound through a thiol linkage to a cystiene residue on the CYP450 
protein via its complexation with molecular iron.  The apoprotein coat and the heme iron form a 
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functional P450 enzyme with the iron complexed heme acting as the enzymes catalytic center.  
Figure 2B depicts the monoxygenation reaction carried out by the CYP450 enzyme.  The first 
step in the process is the binding of the substrate to the Type 1 binding site on the apoprotein 
coat.  The binding of substrate then allows the sequential transfer of 2 electrons and oxygen (O2) 
to the ferrous iron in the heme center.  The source of the electrons comes from the transfer of two 
electrons from NADPH to the FAD/FMN containing cytochrome P450 reductase or to the 
cytochrome b5 reductase.  The reductase then transfers one electron at a time to the CYP450 
substrate complex.  Subsequent removal of one molecule of oxygen creates a highly 
electronegative and highly reactive oxygen species bound to the high spin state of the ferric iron.  
The presence of this highly reactive oxygen in close proximity to the substrate ultimately leads to 
its incorporation and the monooxygenated substrate is released from the binding site.   
CYP450 enzymes have a conserved heme functional group.  The CYP450 isoforms differ 
based on the apoprotein coat, which allows for the binding of different substrates in a specific 
manner.  There have been 18 gene families identified in mammals which encode for 57 
individual CYP genes (Nebert and Russell 2002).  There are only three families, CYP1, CYP2, 
and CYP3, which are responsible for the majority of CYP450-mediated drug metabolism.  The 
work involved in our studies focuses on the CYP2E1 and CYP3A isoforms.  The relative 
contributions of these isoforms to drug metabolism are presented in Figure 3, and the 
characteristics of these isoforms presented in Table 2 (Bertz and Granneman 1997; Gonzalez 
1997; Venkatakrishnan, Von Moltke et al. 2001; Rendic 2002; Lewis 2003). 
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Figure 2: CYP450 structure and enzymatic reaction 
 
Panel A is a schematic of a cytochrome P450 enzyme containing the apoprotein coat and iron containing 
 heme catalytic center.  Panel B depicts the enzymatic reaction carried out by CYP450 enzymes. 
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Table 2: Major drug metabolizing CYP enzymes in humans 
Figure 3: Contribution of the major human CYP450 isoforms to drug metabolim 
Abbreviations: CYP, cytochrome P450 isoform 
Adapted from (Bertz and Granneman 1997; Gonzalez 1997; Venkatakrishnan, Von Moltke et al. 2001; Rendic 2002; 
Lewis 2003). 
1A2
3% 2C
18%
2A6
1%
2D6
25%
2E
1%
3A
52%
Location Substrates
CYP450
1A2 Liver Acetaminophen, caffeine, heterocyclic arylamines
theophylline
2A6 Liver Coumarin
2B6 Liver, heart Nictotine, bupropion
2C8 Liver, kidney Tolbutamide, R- mephenytoin
2C9 Liver Warfarin, phenytoin, tolbutamide, losartan, ibuprofen
flurbiprofen, indomethacin, diclofenac, 
2C19 Liver, heart Omeprazole, S -mephenytoin, diazepam
2D6 Liver, kidney Codeine, debrisoquine, desipramine, dextromethorphan,
fluoxetine, paroxetine, metoprolol, propranolol
2E1 Liver, kidney, Ethanol, acetaminophen, chlorzoxazone, nitrosamines
brain
3A4/5 Liver, intestine, Cortisol, testosterone, midazolam, cyclosporin, tacrolimus,
kidney, brain, cisapride, nifedipine, fluconazole, erythromycin, itraconazole
lung terfenadine, ketoconazole, verapamil, simvastatin
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CYP2E1 
 CYP2E1 is the only isoform present in the CYP2E subfamily and contributes to 7% of 
total human hepatic CYP content.  CYP2E1 metabolizes some important drugs including 
acetaminophen, ethanol, and chlorzoxazone, which are listed in Table 2.  Interestingly, CYP2E1 
plays a large role in endogenous substrate metabolism, including the metabolism of arachidonic 
acid (Adas, Salaun et al. 1999; Poloyac, Tortorici et al. 2004).  Furthermore, CYP2E1 has the 
ability to metabolize xenobiotics to hepatotoxic or carcinogenic products (Lieber 1997).  In rat, 
CYP2E1 demonstrates 78% amino acid homology with the human form of CYP2E1 (Rendic 
2002).  In both rats and humans the regulation of CYP2E1 is complex, involving transcriptional 
(via hepatocyte nuclear factor-1α (HNF-1α)), and post-translational (protein stabilization) events 
(Eliasson, Johansson et al. 1988; Eliasson, Mkrtchian et al. 1992; Roe, Poloyac et al. 2001).  The 
CYP2E1 probe substrate, chlorzoxazone, has been shown to provide validated phenotypic 
analysis of both rat and human CYP2E1 activity both in vivo and in vitro, thereby allowing for 
comparison (Poloyac, Tosheva et al. 1999; Rockich and Blouin 1999; Tanaka 2001).  Analysis of 
CYP2E1 in rats can also be correlated with humans and was one reason we chose to focus our 
attention on CYP2E1 in the work presented throughout this dissertation.  
 
CYP3A 
 The CYP3 family consists of four genes in humans, CYP3A4, CYP3A5, CYP3A7, and 
CYP3A43,(Venkatakrishnan, Von Moltke et al. 2001; Nebert and Russell 2002) and is 
considered the most important CYP family involved in the metabolism of drugs.  CYP3A 
comprises 30 % of total liver CYP450 content and 70% of total intestinal CYP450 content, and 
metabolizes greater than 50% of all clinically relevant medications (Bertz and Granneman 1997; 
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Venkatakrishnan, Von Moltke et al. 2001).  Human CYP3A4, which is the CYP3A isoform that 
carries out the metabolism of the majority of these substrates, is ~72% homologous with the rat 
CYP3A2 isoform and metabolizes similar substrates including testosterone and midazolam 
(Rendic 2002).  The large inter-individual variability demonstrated with CYP3A4 activity may 
be due to differences in the expression pattern and metabolic capacity of CYP3A4 compared to 
other CYP3A isoforms as well as the existence of genetic polymorphism.  CYP3A4 in the human 
is constitutively regulated via multiple transcriptional factors including CCAAT/enhancer 
binding protein (C/EBPalpha), and hepatic nuclear factor-3 (HNF3) (Rodriguez-Antona, Bort et 
al. 2003; Bombail, Taylor et al. 2004).  Interestingly, CYP3A2 in the rat is regulated through 
transcriptional mechanisms via hepatic nuclear factor 4 (HNF-4) (Ogino, Nagata et al. 1999).  
As depicted in Figure 4, alterations in CYP450 functional regulation due to genetic, 
environmental, drug co-administration, and/or disease state factors have all been shown to 
produce clinically significant effects on pharmacotherapeutic outcome.  Each of these factors has 
been shown to alter the CYP450 enzyme system by increasing or inhibiting the enzymatic 
activity of individual or multiple isoforms.  There has been extensive research performed 
investigating the effects of multiple disease states on CYP450 activity and expression (Morgan, 
Sewer et al. 1998; Blouin, Farrell et al. 1999).  Interestingly, TBI,  sepsis, and  other models of 
inflammation have been shown to alter CYP450-mediated activity (Boucher and Hanes 1998; 
Poloyac, Perez et al. 2001; Roe, Poloyac et al. 2001; Harbrecht, Frye et al. 2005).  These insults 
regulate CYP450 enzymes through the production of the acute phase response (APR), namely 
the release of cytokines including interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis 
factor-α (TNF-α).(Toler, Young et al. 1993)  The APR is a cascade of events which occurs 
following tissue damage due to traumatic or microbial insult.  The APR results in local or 
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systemic effects, which affects nearly every organ through the APR mediators.  These mediators 
include cytokines, complement, coagulation factors, antiproteases, transport proteins, growth 
factors, and other proteins (Gabay and Kushner 1999).  Cytokines have been shown to 
dramatically alter the expression of CYP450s in multiple models.  Of the pro-inflammatory 
cytokines, IL-6 mediates the majority of the hepatic alterations of the APR and has been shown 
to be the most potent inhibitor of CYP450s. 
Intracellular signaling alterations following IL-6 receptor binding affect multiple 
transcription factors.  The primary transcription factors activated during IL-6 binding are NF-IL6 
(from the family of C/EBP binding proteins) and AP-1.  Increases in IL-6 have been shown to 
produce decreases in the expression and activity of both CYP2E1 and CYP3A isoforms, through 
transcriptional alterations (Toler, Young et al. 1993).  Many critical care insults, such as CA and 
TBI have been shown to produce increases in IL-6.  In addition, IL-6 increases production of 
nitric oxide (NO), which has been shown to decreases the activity of multiple CYP450 isoforms 
(Carlson and Billings 1996; Khatsenko 1998; Binda, Lasserre-Bigot et al. 2003).   
 
 
 
 
 
 
 
Figure 4: Variables affecting CYP450 expression and activity 
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1.4 THE EFFECTS OF THERAPEUTIC HYPOTHERMIA DURING COOLING ON 
DRUG DISPOSITION AND METABOLISM 
Studies have evaluated both the effects of hypothermia during cooling, and the effects of 
hypothermia post-rewarming in the acute phase (immediately after re-warming, 5 hr after injury), 
sub-acute phase (12-24 hrs after injury), delayed phase (24-72 hrs after injury), and the chronic 
phase (>72 hrs after injury), on the disposition and metabolism of multiple medications.  
Hypothermia also alters drug response by affecting the interactions of the drug with its target 
receptor.  In this chapter we will consider both the effects of hypothermia on drug metabolism 
during cooling and after re-warming, focusing on drugs germane to critical care medicine.   
1.4.1 CYP450 Probe Substrates 
Midazolam 
Midazolam is a member of the benzodiazepine drug class and is used as an anesthetic 
adjunct and a hypnotic.  It is exclusively metabolized by CYP3A4 and CYP3A5 and is used as a 
probe substrate to assess CYP3A4 activity in human subjects and for in vitro analysis (Yuan, 
Madani et al. 2002; Eap, Bouchoux et al. 2004).  Fukuoka et al. demonstrated that as TBI 
subjects core temperature was lowered below 35oC, midazolam plasma concentrations were ~5-
fold higher compared to when core body temperature was above 35oC.(Fukuoka, Aibiki et al. 
2004)  This study was conducted in 15 TBI Japanese subjects, with an average GCS score of 7.3 
± 1.  Eight of these subjects were treated with mild hypothermia (32oC-34oC) and seven subjects 
were maintained at normothermic temperatures (37oC).  Each subject was started on a continuous 
infusion of midazolam at 5µg/kg/min.  Subjects who were maintained normothermic 
temperatures achieved steady state concentrations of ~1500 ng/ml.  Interestingly, the 
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hypothermia group demonstrated a dramatic increase in midazolam concentrations when body 
temperature was below 35oC.  Pharmacokinetic analysis demonstrated ~100-fold decrease in ClS 
of midazolam in the period when subjects’ core temperature was less than 35oC.  The well-stirred 
model of hepatic clearance (ClH) states that for probe substrates, which are typically low 
clearance drugs and exclusively metabolized by CYP-mediated mechanisms, the ClH 
approximates the ClS which is dependent upon the fraction of unbound drug and the intrinsic 
clearance of the CYP450 isoform (Pang and Rowland 1977; Pang and Rowland 1977; Pang and 
Rowland 1977).  Therefore, since midazolam is a low clearance drug and exclusively 
metabolized by CYP3A4 and CYP3A5, higher midazolam concentrations are likely due to either 
depressed CYP3A4 activity or a decrease in the protein binding when a subject’s core 
temperature is mildly hypothermic. 
1.4.2 Drugs Commonly Used in the ICU 
 Anesthetics/Sedatives 
Fentanyl 
Fentanyl is clinically used as an analgesic and is a member of the opioid drug class.  Like 
midazolam, fentanyl is primarily metabolized by CYP3A4; however it is classified as a high 
clearance drug with a large volume of distribution.  According to the well-stirred model, ClH of 
high clearance drugs, is primarily dependent upon hepatic blood flow (Pang and Rowland 1977; 
Pang and Rowland 1977; Pang and Rowland 1977).   Since fentanyl is commonly used clinically, 
there has been considerable research on the effects of hypothermia on fentanyl concentrations in 
both experimental models as well as patients (Lunn, Stanley et al. 1979; Bovill and Sebel 1980; 
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Koska, Romagnoli et al. 1981; Koren, Barker et al. 1987; Gruber, Laussen et al. 2001; Pettifer 
and Hosgood 2004; Kussman, Zurakowski et al. 2005). 
With the onset of CPB, fentanyl concentrations have been shown to be lowered by 53% 
(Bovill and Sebel 1980).  Other studies have also demonstrated dramatic alterations in the 
plasma concentrations of fentanyl during CPB (Lunn, Stanley et al. 1979; Koska, Romagnoli et 
al. 1981).  Lunn et al. was one of the first to measure plasma fentanyl concentrations during CPB 
(Lunn, Stanley et al. 1979).  Eighteen patients undergoing two-vessel coronary artery bypass 
were cooled to 32oC during extracorporeal support and re-warmed to 37oC at its conclusion.  
Fentanyl (75µg/kg IV) was administered and plasma concentrations were 37% lower at the onset 
of CPB compared to pre-CPB concentrations.  As patients were made hypothermic during CPB 
surgery, fentanyl concentrations remained unchanged and gradually increased over time.  This 
study did not perform a pharmacokinetic analysis on this data.  The initial low fentanyl plasma 
concentrations could be due to hemodilution via the administration of large volumes of fluids 
commonly performed during CPB.  Secondly, once hypothermia was started during CPB, 
concentrations were higher, which could be due to either a decrease in hepatic blood flow during 
surgery or a decrease in hepatic metabolic activity, both of which were not measured.   
A study by Koska et al. demonstrated that fentanyl concentrations were higher during 
CPB surgery (Koska, Romagnoli et al. 1981).  This study investigated the pharmacokinetics of 
low dose (5-8 µg/kg) fentanyl in two groups of six patients, one group undergoing CPB surgery 
and one group not undergoing CPB surgery (Koska, Romagnoli et al. 1981).  These authors did 
not report body temperature, however they noted three important findings; 1) a rise of ~30% in 
fentanyl concentrations after CPB surgery termination, 2) a prolonged elimination half-life of 
fentanyl after CPB, 5.2 ± 2.7 hours compared to 3.3 ± 1.1 hours in surgical controls, and 3) a 
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decrease of 30% in hepatic perfusion as measured by indocyanine green, both during and after 
CPB (Koska, Romagnoli et al. 1981).  The authors concluded that in this study, the higher 
plasma concentrations and the prolongation of the t1/2 are due to decreases in hepatic blood flow 
and as well as hepatic metabolic function.   
In most animal studies of therapeutic hypothermia in experimental TBI demonstrating 
neuronal protection, isoflurane anesthesia is used as the anesthetic (Kochanek and Safar 2003).  
However, Statler et al demonstrated that hypothermia was not neuroprotective after experimental 
TBI in rats anesthetized with fentanyl.  Surprisingly, an increase in lesion volume vs. 
normothermia was observed under fentanyl anesthesia (Statler, Alexander et al. 2003).   In 
addition serum concentrations of fentanyl were higher in the hypothermic vs. the normothermic 
animals.  High fentanyl concentrations have been shown to produce electrical seizure activity 
and neurological damage in patients (Tempelhoff, Modica et al. 1992).  One possible explanation 
of these results is that higher fentanyl concentrations in the brain may have increased damage in 
experimental brain injury (Kofke, Garman et al. 1999).  This study demonstrates the need for full 
knowledge of the potential pharmacological effects of therapeutic hypothermia in order to 
optimize its use both in clinical use and in further therapeutic trials. 
There have been a number of studies which have investigated the effects of therapeutic 
hypothermia on fentanyl concentrations in pediatric patients undergoing cardiac surgery.  Koren 
et al. (Koren, Barker et al. 1987) demonstrated fentanyl concentrations to be unchanged in 18 
pediatric patients undergoing cardiac surgery who were made hypothermic (18oC – 25oC), 
compared to pre-surgery concentrations.  Patients received a fentanyl IV bolus of 30-50 µg/kg 
followed by a continuous IV infusion of 0.15 – 0.30 µg/kg/min and profound hypothermia 
(<20oC) was induced at the commencement of CPB.  This study discontinued the infusion of 
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fentanyl at the initiation of CPB and hypothermia, in order to evaluate the effect of hypothermia 
without confounding influences of the infusion.  Since the infusion was stopped and there were 
no changes in plasma fentanyl concentrations observed during this period, these data 
demonstrated that during profound hypothermia, the ClS of fentanyl was very low.  Even if 
hepatic blood flow was decreased by hypothermia and CPB, there still should have been 
metabolism occurring resulting in a decrease of fentanyl concentrations, unless profound 
hypothermia produced complete inhibition of CYP3A4 enzymatic activity.   
Koren et al. performed a study in piglets to identify the effects of hypothermia on 
fentanyl concentrations, without the multiple variables of CPB surgery.  Results showed that 
fentanyl plasma concentrations were considerably higher in hypothermic (29oC) versus 
normothermic (37oC) piglets.  Furthermore, fentanyl ClS was decreased during hypothermia 
(0.65 ± 0.12 ml/kg/min) compared to normothermia (2.42 ± 0.22 ml/kg/min).  The authors 
concluded that the decrease in fentanyl ClS in piglets could be due to decreases in cardiac output 
resulting in a decrease in liver blood flow, as the cardiac output has been shown be decreased by 
42% during hypothermia (29oC) (Koren, Goresky et al. 1984).  However the decrease in fentanyl 
ClS in this study (73%) due to hypothermia far exceeded the decrease in cardiac output 
previously reported (42%).  It is likely that hypothermia decreases CYP3A-mediated metabolism 
of fentanyl in addition to the observed blood flow alterations. 
Kussman et al. (Kussman, Zurakowski et al. 2005) showed that plasma fentanyl 
concentrations were significantly lower at the onset of CPB and then recovered to pre-CPB 
levels after 30 minutes in infants.  This study measured changes in fentanyl concentrations 
during infant cardiac surgery using a bypass circuit and examined the relationship of plasma 
fentanyl concentrations and temperature to Bispectral Index (BIS) as index of conscious level 
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(Kussman, Zurakowski et al. 2005).  Fifteen neonates and infants undergoing cardiac surgery 
with hypothermic CPB were administered a bolus dose of fentanyl, 30µg/kg, followed by a 
continuous infusion of 0.3 µg/kg/min.  Hypothermia was defined as mild (>32oC), moderate 
(25oC – 32oC), or deep (<25oC).  Median plasma fentanyl concentrations were significant 
lowered from 17 ng/ml, at aortic cannulation, to 10 ng/mL after 4 minutes of CPB.  However, 
after 30 minutes of CPB, plasma fentanyl concentrations were significantly higher and remained 
constant for the remainder of the surgery.  Results also showed that there was no correlation of 
BIS to fentanyl concentrations and temperature and BIS continued to decrease throughout the 
entire study period.  There was no pharmacokinetic or hepatic blood flow analysis performed in 
this study to identify the mechanisms behind these alterations; however these results are 
consistent with the previous mentioned studies (Lunn, Stanley et al. 1979; Koska, Romagnoli et 
al. 1981; Koren, Barker et al. 1987).    
Another study by Gruber et al., demonstrated that fentanyl concentrations were higher 
during the hypothermic period in infants undergoing corrective cardiac surgery (Gruber, Laussen 
et al. 2001).  Forty-five neonates and infants, less than 6 months of age, undergoing deep 
hypothermic cardiopulmonary bypass (DHCB) were included in this prospective, randomized 
double-blinded study.  Patients were randomized to one of three groups, Group 1 received 
fentanyl (25µg/kg) IV bolus (n=15), on initiation of DHCB.  Group 2 received fentanyl IV 
infusion (bolus dose:25µg/kg; infusion rate:10µg/kg/hr) upon initiation of CPB.  Group 3, n=15, 
received IV bolus of fentanyl (25µg/kg) and IV bolus of midazolam (200µg/kg) followed by 
midazolam IV infusion (100 µg/kg/hr) and fentanyl IV infusion (10 µg/kg/hr), upon initiation of 
DHCB.  The results showed that when subjects in both Groups 2 and 3, were made hypothermic 
during DHCB, the fentanyl concentrations were significantly higher at the end of surgery.  
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Furthermore, there were multiple physiological changes during DHCB including increases in 
epinephrine, norepinephrine, and cortisol plasma concentrations, which the authors conclude is 
due to an increase in the stress response during surgery.  However, the change in cortisol is in 
contrast to previous studies, which actually have shown a decrease in cortisol concentrations 
with high dose opioid administration during cardiac surgery (Anand and Hickey 1992).  Another 
explanation is a decrease in the metabolism of cortisol to 6β-hydroxycortisol by the CYP3A4 
isoform (Ged, Rouillon et al. 1989; Baron, Goh et al. 2001).  The ratio between cortisol and 6β-
hydroxycortisol, has been used as a measure of CYP3A4 activity (Joellenbeck, Qian et al. 1992).  
Despite the fact that 6β-hydroxycortisol was not measured in this study and that only 1% of all 
cortisol metabolites recovered in the urine are the 6β-hydroxy metabolite, these changes in 
cortisol levels could potentially be due decreases in CYP3A4 activity. 
Collectively, these studies demonstrate two important findings.  First, there appears to be 
consistent findings of the effects of CPB on fentanyl concentrations in both infants and adults.  
The above mentioned studies demonstrated an initial decrease in fentanyl concentrations at the 
initiation of CPB, due to hemodilution, followed by an increase, likely due to the hypothermic 
period during CPB.  However, the complexity of CPB surgery makes it difficult to clearly 
identify the mechanisms behind the observed alterations, as there are multiple factors which can 
influence plasma fentanyl concentrations including; the priming volume of the circuit, binding of 
fentanyl to the circuit tubing and membrane oxygenator, sequestration of fentanyl within 
pulmonary circulation, altered protein binding after hemodilution, and variable metabolism and 
excretion secondary to hypothermia (Kussman, Zurakowski et al. 2005).  Therefore, in the CPB 
model, it is difficult to quantify the contribution of these variables to alterations in fentanyl 
concentrations.  However, inhibition of fentanyl metabolism was also examined in a carefully 
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controlled study in piglets to identify the effects of hypothermia on fentanyl concentrations, 
without the multiple variables of CPB surgery (Koren, Barker et al. 1987).   Fentanyl plasma 
concentrations were ~2-fold higher in hypothermic (29oC) vs. normothermic piglets (37oC).  
Furthermore, the ClS of fentanyl was decreased ~3.7-fold during hypothermia compared to 
normothermia.  The decrease in ClS in piglets was caused by a decrease in cardiac output with 
reduced hepatic perfusion resulting in a decrease in hepatic blood flow (Koren, Goresky et al. 
1984).  However, the decrease in ClS in this study (73%) far exceeded the decrease in cardiac 
output previously reported (42%).  It is likely that hypothermia-produced decreases the CYP3A-
mediated metabolism of fentanyl in addition to the observed blood flow effects. 
 
Remifentanil 
Remifentanil is a derivative of fentanyl and is a potent opioid and an anesthetic adjunct 
with a short half-life due to rapid hydrolysis to a minimally active metabolite by nonspecific 
blood and tissue esterases (Burkle, Dunbar et al. 1996; Hoke, Cunningham et al. 1997).  
Michelsen et al. reported that the ClS of remifentanil decreased as temperature was decreased 
below 37oC in 68 patients undergoing CPB with hypothermia (Michelsen, Holford et al. 2001).  
Remifentanil was administered at 1, 2, or 3 µg/kg/min and CPB was conducted with varying 
degrees of hypothermia.  Remifentanil ClS decreased by 6.37% for each degree Celsius below 
37oC.  The decrease in ClS was likely due to a hypothermia-mediated decrease in remifentanil 
metabolism by blood and tissue esterases.  In addition, this study simulated remifentanil 
concentrations for two hypothetical 70-kg patients receiving an infusion of 1 µg/kg/min for 60 
minutes at which time CPB was initiated with cooling and maintenance of temperature at 32oC 
or 27oC.  The simulation demonstrated that there was a proportional decrease of 6.37% in ClS 
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with each degree Celcius in temperature below 37oC, with a prediction error for all data points of 
17.5%.  Both simulations demonstrated that under moderate hypothermia, the infusion rate of 
remifentanil can be decreased almost immediately after the institution of CPB to achieve target 
blood levels.  For mild hypothermia, the infusion rate may be decreased after ~20-30 min.  
Collectively, target remifentanil concentrations may be obtained by decreasing the infusion rate 
approximately 30% for each 5oC decrease in temperature.  This study was one of the first to not 
only demonstrate hypothermia-induced increases in remifentanil concentrations but to provide a 
potential dosing nomogram for remifentanil for clinicians use.  Currently, no such dosing 
algorithms exist for any drug for the use of mild hypothermia after CA and TBI.  
 
Pentobarbital & Phenobarbital 
Pentobarbital is a member of the barbiturate drug class and is metabolized primarily via 
side-chain oxidation by multiple CYP450 isoforms.  One of the first studies to investigate the 
effects of hypothermia on drug metabolism demonstrated that in an isolated perfused rat liver 
maintained at 30oC, 25oC, or 20oC, the metabolism of pentobarbital was decreased by half, one-
third, and one-fourth the rate, respectively,  vs. normothermia (Kalser, Kelly et al. 1969).  In the 
same study, radioactive C14-pentobarbital was infused at a dose of 0.5 to 1 mg into an isolated 
perfused rat livers maintained at 37oC, 30oC, 25oC, or 20oC.  The rate of uptake of pentobarbital 
in the liver was also decreased in hypothermic compared to normothermic preparations.  The rate 
of metabolism was inversely proportional to temperature and hypothermia markedly reduced the 
amount of pentobarbital metabolites of appearing in blood and the bile.   
Kadar et al performed a study in critically injured children and found that moderate 
hypothermia decreases the metabolism of phenobarbital (Kadar, Tang et al. 1982).   Four boys 
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between the ages of 5 and 15 years suffering from TBI were treated with moderate hypothermia 
(30oC to 31oC) for six to nine days.  Urinary concentrations of phenobarbital and its metabolites 
were determined during the hypothermic period and during the normothermic period.  There was 
a 48% decrease in the rate of urinary excretion of hydroxyphenobarbital during hypothermia 
versus normothermia.  The urinary excretion rate of the parent drug was higher (~52%) during 
hypothermia vs. normothermia.  Since the urinary excretion rate of hydroxyphenobarbital was 
decreased and phenobarbital was increased when the core temperature was lowered, this lends 
evidence that hypothermia likely decreased the rate of metabolism of phenobarbital.   
 
Propofol 
Propofol is used as a sedative in adult critical care and is primarily metabolized by the 
CYP2B6 isoform and further glucuronidated by UDP-glucuronosyltransferase (UGT) 1A9.  
Hypothermia increases propofol concentrations in normal healthy volunteers and patients on 
CPB (Russell, Wright et al. 1989; Leslie, Sessler et al. 1995; Leslie, Bjorksten et al. 2002).  A 
study in 1989 set out to investigate the effects of CPB on propofol concentrations (Russell, 
Wright et al. 1989).  Ten males were scheduled for coronary artery surgery.  Propofol was 
administered as continuous infusion at a rate of 10 mg/kg/hour and then reduced to 3 mg/kg/hour 
for approximately 250 minutes.  Upon initiation of CPB, propofol concentrations decreased 
sharply as a result of hemodilution, which has been previously shown with other medications 
(Lunn, Stanley et al. 1979; Koska, Romagnoli et al. 1981).  During the period of deep 
hypothermia (25oC-27oC), which lasted approximately 50 minutes, propofol concentrations were 
consistently higher.  The reason for these changes could be due to a decrease in propofol 
metabolism via CYP450-mediated mechanisms, as well as a decrease in hepatic blood flow.  
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Leslie et al. performed a series of studies investigating the effects of mild hypothermia on 
propofol blood concentrations (Leslie, Sessler et al. 1995; Leslie, Bjorksten et al. 2002).  The 
first study demonstrated that propofol concentrations were dramatically higher when 
hypothermia was induced in normal healthy volunteers (Leslie, Sessler et al. 1995)  Six healthy 
volunteers were administered an IV bolus of 1 mg/kg followed by a 4-hour infusion at 0.5 
mg/kg/hr and core temperature was maintained at either 37oC or cooled to 34oC.  Indocyanine 
green was administered as a 1 mg IV bolus followed by a 12 mg/hr infusion for hepatic blood 
flow assessment.  Results demonstrated that propofol concentrations were 28% higher at 34oC 
compared to 37oC.  Using a three-compartment model, total body clearance, central and 
compartmental Vd were not changed, however inter-compartmental clearance was significantly 
decreased during hypothermia.  Thus, mild hypothermia increased propofol concentrations by 
decreasing propofol metabolism, either P450 or UGT1A9-mediated, without altering hepatic 
blood flow or Vd.  While no differences in the hepatic blood flow were observed, these results 
suggest that the higher propofol concentrations observed during hypothermia were due to a 
decrease in propofol metabolism.  The follow-up study investigated the effects of mild 
hypothermia on propofol requirements in patients undergoing intracranial tumor surgery (Leslie, 
Bjorksten et al. 2002).  Forty patients were anesthetized with a propofol infusion and an IV bolus 
of alfentanil, and were randomized to a core temperature 37oC or 34oC.  The results 
demonstrated that in the hypothermia group, propofol concentrations were significantly lower 
than compared to the normothermia group, 2.25 (1.5-3.5) µg/ml versus 3.25 (2.0-4.5) µg/ml, 
respectively.  Furthermore, propofol concentrations, but not core temperature, predicted loss of 
response to command (odds ratio, 11.76).  Core temperature did not alter the relationship 
between BIS and response to command.  The authors concluded that propofol infusion regimens 
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may not require adjustment during mild hypothermia for patients undergoing intracranial tumor 
surgery.   
These two studies report contrasting results regarding the effects of mild hypothermia on 
propofol pharmacokinetics and pharmacodynamics.  Further investigation of the differences in 
these studies may explain the variable results.  The first study set out to examine the effects of 
mild hypothermia on the pharmacokinetics of propofol in healthy volunteers.  They 
demonstrated that core temperature was associated with higher propofol concentrations.  The 
second study set out to examine the effects of mild hypothermia on propofol requirement 
measured as response to commands in neurosurgical patients.  In this study, the authors targeted 
different concentrations in the hypothermia group versus the normothermia group (2.25 µg/mL 
versus 3.25 µg/mL, respectively).  Therefore, the dose of propofol was dictated by the response 
of the patient; however the doses of propofol administered were not indicated.  Therefore, we 
can conclude from these studies that 1) mild hypothermia increased propofol concentrations by 
decreasing propofol metabolism without altering hepatic blood flow and 2) the target propofol 
concentrations were less in patients treated with mild hypothermia compared to patients treated 
under normothermic conditions to achieve the same response, potentially due to alterations in the 
pharmacodynamic response of propofol, which will be discussed later in this chapter.  Clinically, 
we can conclude that lower target plasma concentrations are needed to provide a similar 
response.  
  
Isoflurane 
Isoflurane is a member of the volatile anesthetic drug class.  Previous studies have 
demonstrated that hypothermia decreases the minimal alveolar concentrations (MAC) of volatile 
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anesthetics such as halothane and isoflurane required for clinical response potentially due to 
alterations in the metabolism resulting in higher concentrations present (Vitez, White et al. 
1974).  Extrapolation of these results indicates that hypothermia itself would act as a complete 
anesthetic at temperature between 18-21oC (Regan and Eger 1967).  Antognini et al. determined 
that when temperature is decreased, the anesthetic requirements of isoflurane are decreased 
(Antognini 1993).  Eight female goats were anesthetized with isoflurane and underwent CPB 
surgery.  MAC was initially determined at baseline and re-determined when animals were cooled 
to 29oC.  At this time animals were then further cooled to 20oC, at which time MAC was re-
assessed.  The results showed that as temperature was lowered, the MAC was also decreased.  
Furthermore, when the temperature reached 20.1oC, anesthetic requirements of isoflurane were 
completely eliminated.  The authors referred to the fact that these differences in MAC could be 
due to temperature-induced changes of the solubility of isoflurane in lipid materials.  However, 
they stated that this conclusion is speculative and there may be other mechanisms behind these 
alterations, such as a decrease in metabolism.  Expanding upon this concept, it is known that 
isoflurane is metabolized by CYP2E1 (Kharasch, Hankins et al. 1999).  The work described in 
Chapter 2, demonstrates that moderate hypothermia (30oC) decreased the ClS of a CYP2E1 probe 
substrate, chlorzoxazone, in a CA rat model by ~2-fold (Tortorici, Kochanek et al. 2006). 
Furthermore, we found that the mechanism behind this alteration in the ClS of chlorzoxazone was 
a decrease in the intrinsic clearance (Clint) of CYP2E1.  A decrease in the CYP2E1-mediated 
metabolism of isoflurane will likely contribute to the decrease in MAC due to hypothermia.    
 
Neuromuscular Blockers 
Vecuronium 
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Neuromuscular blocking agents are commonly used in the ICU.  During the use of mild 
hypothermia they are often employed to prevent shivering.  Vecuronium is primarily eliminated 
via the liver by carrier-mediated transport (p-glycoprotein) and metabolized by CYP450 
enzymes (Smit, Schinkel et al. 1998).  Studies have investigated the effects of hypothermia on 
vecuronium pharmacokinetics and pharmacodynamics in patients undergoing elective surgery 
(Heier, Caldwell et al. 1991; Heier, Caldwell et al. 1994).  In these studies, surgical patients 
treated with hypothermia demonstrated a 3-fold increase in the duration of action of vecuronium 
as compared to normothermia patients (Heier, Caldwell et al. 1991; Heier, Caldwell et al. 1994). 
Caldwell et al., also evaluated the effects of hypothermia on vecuronium 
pharmacokinetics (Caldwell, Heier et al. 2000).  Healthy volunteers were randomized to <35oC, 
35.0-35.9oC, 36.0-36.9oC, and ≥ 37oC.  Hypothermia reduced the plasma clearance of 
vecuronium by 11.3% per oC.  Hypothermia also decreased the rate constant for equilibration 
between plasma and effect site (0.023 min-1 per oC).  Furthermore, the slope of the concentration-
response curve was increased during hypothermia by 0.43 per oC, indicating that recovery of 
neuromuscular function will be delayed by hypothermia.  However, tissue sensitivity was not 
influenced by core temperature.  Reduced clearance can explain the increased duration of action 
vecuronium with reducing core temperature that was previously demonstrated in the study 
conducted by Heir et al. (Heier, Caldwell et al. 1991).  Furthermore, the authors concluded that 
the pharmacokinetic alterations observed could be due to changes in hepatic metabolism.  
 
Rocuronium 
Rocuronium is primarily eliminated via the bile.   Beaufort et al. examined the influence 
of hypothermia on the time-course of action and the pharmacokinetics of rocuronium in human 
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neurosurgical patients (Beaufort, Wierda et al. 1995).  The duration of action of rocuronium was 
increased by 5 min per oC as measured by neuromuscular function.  Pharmacokinetic analysis 
revealed a ~2-fold decrease in the ClS of rocuronium with hypothermia.  Hypothermia 
significantly prolonged the time-course of action of rocuronium and influenced the 
pharmacokinetics of rocuronium by decreasing the ClS.  Hypothermia also decreases the biliary 
excretion of other drugs, such as atropine, thereby, suggesting that biliary transport mechanisms 
of elimination may be similarly reduced during hypothermia in patient (Kalser, Kelvington et al. 
1965).   
 
Atracurium 
Atracurium is metabolized by non-enzymatic decomposition in the blood or by Hoffman 
elimination.  An alternative elimination pathway is via enzymatic ester hydrolysis (Fisher, 
Canfell et al. 1986).  Leslie et al. observed that mild hypothermia (34oC) significantly increased 
the duration of action of atracurium in normal healthy volunteers (Leslie, Sessler et al. 1995).  
Six volunteers (2 women and 4 men) were studied on two randomly assigned days, one where 
core temperature was decreased to 34oC and one where core temperature was maintained at 
37oC.  Atracurium was administered as an IV bolus of 0.5 mg/kg and hypothermia was induced 
via surface cooling for approximately 200 minutes.  Hypothermia significantly prolonged the 
time to recovery of the first twitch in the train-of-four test from 44 ± 4 minutes to 68 ± 7 
minutes.   
Despite the fact that the three above mentioned neuromuscular blocking agents are 
eliminated by different pathways, each agent demonstrated an increase in duration of action by 
mild hypothermia caused by decreases in drug ClS.  In light of the significant increase in the 
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duration of action, these studies indicate that clinicians using neuromuscular blocking agents in 
hypothermic patients should reduce doses and monitor neuromuscular function to avoid 
overdose.   
 
Cardiovascular Drugs 
Atropine 
Atropine, a competitive antagonist of the actions of acetylcholine at the muscarinic 
receptors, is commonly used for intubation and is also used in cardiopulmonary resuscitation.  
Atropine is eliminated primarily via the kidneys with some contribution by biliary excretion.  
There were a series of studies in the 1960s which were the first to investigate the effects of 
hypothermia on hepatic drug metabolism, biliary excretion, and hepatic uptake of drugs (Kalser, 
Kelvington et al. 1965; Kalser, Kelvington et al. 1965; Kalser, Kelvington et al. 1968; Kalser, 
Kelvington et al. 1968; Kalser, Kelly et al. 1969).  The first of these studies showed that 
moderate hypothermia decreased biliary excretion of atropine in the nephrectomized rat.(Kalser, 
Kelvington et al. 1965)  A follow-up study in 1965, determined that hypothermia decreases the 
uptake, metabolism, and excretion of atropine in the isolated perfused rat liver (Kalser, 
Kelvington et al. 1965).  Lastly, it was shown that as temperature was decreased to 25oC and 
17oC, there was an increase in the percent of atropine recovered in the liver, indicating decreased 
transport out of the liver.   These results could be due to a decrease in hepatic blood and/or bile 
flow as temperature is decreased.   Therefore, hypothermia decreases four processes in drug 
disposition and excretion of atropine; blood flow, uptake of drug, metabolism of drug, and 
excretion of atropine.   
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Propranolol  
Propranolol is a β-adrenoreceptor antagonist that is commonly used in the ICU 
(Carmona, Malbouisson et al. 2005).  Propranolol is predominately metabolized by CYP2D6.  
Hypothermia alters plasma propranolol levels in models of CPB (McAllister, Bourne et al. 1979; 
McAllister and Tan 1980; Carmona, Malbouisson et al. 2005).  Carmona et al. demonstrated that 
mild hypothermia increased the t1/2 and Vd of propranolol in CPB patients (Carmona, 
Malbouisson et al. 2005).  Eleven patients receiving propranolol before surgery (80-240 mg) and 
postoperatively (10mg) were evaluated.  Mild hypothermia (32-34oC) was started after initiation 
of CPB and maintained until the end of coronary grafting.  Results demonstrated that there was 
an increase in t1/2 and Vd, post-operatively compared to pre-operatively, and no changes were 
observed in the ClS at these time-points.  The authors concluded that the increase in t1/2 is 
possibly due to mild hypothermia effects on hepatic metabolism of propranolol.  Furthermore, 
the changes in the Vd could be due to the hemodilution effects of CPB, making it difficult to 
identify the effects of hypothermia on drug metabolism compared to the direct effects of CPB. 
(Kussman, Zurakowski et al. 2005).   
McAllister et al. demonstrated that deep hypothermia in patients undergoing CPB 
resulted in higher propranolol concentrations compared to patients who were normothermic 
(McAllister, Bourne et al. 1979).  However, the variability due to CPB surgery did not allow 
them to perform a formal pharmacokinetic analysis.  Therefore, they extended the study to 
evaluate propranolol kinetics in mongrel dogs undergoing CPB surgery at deep hypothermia 
(26oC) after IV bolus administration.  Dogs maintained under deep hypothermic conditions 
demonstrated a marked decrease in the ClS of propranolol compared to paired normothermic 
controls, 0.0323 ± 0.0072 L/kg/min vs. 0.0644 ± 0.0110 L/kg/min, respectively.  Furthermore, 
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the Vd and t1/2 were decreased and the elimination rate constant of propranolol was significantly 
increased.     
 In order to evaluate the mechanisms behind these alterations in ClS of propranolol, 
McAllister et al. performed an enzyme kinetic study in rat liver microsomes incubated with 
propranolol, at 37oC and 26oC, which match the temperatures used in their animal study 
(McAllister and Tan 1980).  They demonstrated that when rat liver microsomes were incubated 
with propranolol at hypothermic temperatures (26oC), there was a decrease in metabolism at all 
concentrations compared to normothermia (37oC) (McAllister and Tan 1980).  Furthermore, the 
mechanism behind this decrease in metabolism was due to alterations in the affinity of both 
substrates (propranolol and verapamil) for the CYP2D6.  There were no changes in the Vmax for 
both substrates.  The work presented in chapter 2 demonstrates similar results in CYP2E1-
mediated chlorzoxazone (CZN) metabolism in rat liver microsomes incubated at normothermia 
(37oC) or moderate hypothermia (30oC) (Tortorici, Kochanek et al. 2006).  We showed a 2-fold 
increase in the Km and no change in Vmax when rat liver microsomes were incubated at moderate 
hypothermic temperatures (Tortorici, Kochanek et al. 2006).  This series of studies provides 
evidence that the application of hypothermia decreases the ClS of propranolol and the mechanism 
of this decrease is due to changes in the activity of CYP2D6.  Furthermore, the decrease in the 
activity of CYP2D6 is due to a decrease in the affinity of CYP2D6 for the substrate, propranolol.     
 
Anticonvulsants 
Phenytoin 
Phenytoin is a commonly used anticonvulsant in the ICU.  A unique characteristic of the 
disposition of phenytoin is the known saturable hepatic metabolism observed within the typical 
therapeutic range.  The result of this saturable metabolism is non-linear increases in phenytoin 
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plasma concentrations with increases in dose.  The ClS of phenytoin depends primarily on the 
unbound drug fraction and the activity of hepatic CYP2C9 and CYP2C19.  The metabolism of 
phenytoin is influenced by many factors, such as the administration of other drugs, changes in 
albumin levels, and concurrent illnesses.  Iida et al. examined the effects of hypothermia on the 
pharmacokinetics of phenytoin in patients with TBI (Iida, Nishi et al. 2001).  Fourteen patients 
were cooled to 34oC and phenytoin was given as a loading bolus dose.  Patients were also dosed 
with phentyoin 7-8 days after injury when core temperature was normothermic (36oC).  Both 
total and unbound phenytoin concentrations were higher at 34oC than at 36oC, consistent with a 
reduction in the intrinsic clearance of the drug by liver enzymes.  In addition, the AUC was 
increased by 180% at 34oC versus 36oC.  The elimination rate constant, ke, and the ClS were 
decreased by 50% and 67% at 34oC compared to 36oC, respectively.   Furthermore, the plasma 
concentrations of phenytoin metabolites were markedly lower at 34oC compared to 36oC.   no 
change was observed in the plasma protein binding of phenytoin.  This study demonstrated three 
important findings; first, hypothermia dramatically altered the pharmacokinetics of phenytoin.  
Second, the decrease in ClS was due to decreased CYP450 metabolism and was not due to 
alterations in plasma protein binding.  Third, the concentration of the metabolites was reduced in 
hypothermia vs. normothermia, providing further evidence that a decrease in CYP450 activity 
was an important mediator of the observed pharmacokinetic changes.  In light of the common 
use of phenytoin in neurointesive care, vigilance towards monitoring for toxic levels of this agent 
should be heightened during use of hypothermia.  
 
Theophylline 
One study that did not demonstrate a significant change in CYP450-metabolized drug 
elimination was a study conducted by Koren et al. investigating moderate hypothermia effects on 
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theophylline concentrations in piglets (Koren, Barker et al. 1985).  Theophylline is a 
bronchodilator and is a drug with a narrow therapeutic index and an increased chance for toxicity 
and adverse events, such as tachycardia, cardiac arrhythmias, palpitations, seizures, agitation, 
depression and nervousness.  The primary mechanism of elimination of theophylline is via 
hepatic metabolism through the CYP1A2 and CYP3A4 isoforms and to a smaller extent, the 
CYP2E1 isoform.  In seven piglets treated with moderate hypothermia (29oC), theophylline was 
administered as an IV bolus.  Results demonstrated that there were no changes in the ClS and 
elimination rate constant in hypothermic animals compared to normothermic animals.  This 
study also demonstrated that cardiac output was decreased in a linear fashion as temperature was 
also decreased.  Since theophylline is a low extraction drug and there is no change in the 
pharmacokinetics of theophylline in this animal model, the authors concluded that moderate 
hypothermia does not alter CYP450 metabolism of theophylline.  However, the results of this 
study were limited by the short duration of plasma sampling and the timing of sampling relative 
to induction of hypothermia.  For example, the duration of blood collection in both normthermic 
and hypothermia piglets was 360 minutes.  However, the calculated t1/2 in normothermic animals 
was 1019 ± 285 minutes, which is ~ 2.5 times greater than the actual sampling time.  This short 
sampling time results in the estimates of AUC only during the initial period after dosing without 
the ability to determine the influence of hypothermia on hepatic clearance.  A longer duration of 
sampling in future studies under continuous infusion dosing regimens would allow for an 
appropriate determination of the effects of moderate hypothermia on theophylline elimination.    
 
Antimicrobials 
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There have been several studies which have investigated the effects of hypothermia on 
the renal clearance (ClR) of antimicrobial agents in multiple models (Koren, Barker et al. 1985; 
Klamerus, Rodvold et al. 1988).  Koren et al. performed a study investigating the effect of 
hypothermia on the pharmacokinetics of gentamicin in piglets (Koren, Barker et al. 1985).  
Gentamicin is an aminoglycoside antimicrobial agent that is almost completely renally excreted 
unchanged.  In seven piglets treated with moderate hypothermia (29oC), gentamicin was 
administered as an IV bolus dose of 5 mg/kg.  The serum concentrations of gentamicin were 
consistently higher in hypothermic piglets compared to normthermic piglets.  The t1/2 of 
gentamicin was increased from 135 ± 19 min in piglets kept normothermic to 187 ± 7 min in 
piglets were treated with moderate hypothermia.  Furthermore, this study showed a rank order 
decrease in cardiac output as temperature is decreased, which could cause a decrease in the 
glomerular filtration rate.  Since gentamicin is both filtered and secreted, a decrease in the GFR 
contributes to an alteration in the CLR of gentamicin.  The authors suggested that the decrease in 
cardiac output due to hypothermia could be a potential mechanism of a decrease elimination of 
gentamicin in hypothermic piglets.  
Klamerus et al. performed a study in 10 patients undergoing elective coronary artery 
bypass grafting or cardiac valve replacement surgery investigating the effects of CPB on  the 
disposition of vancomycin and netilmicin (Klamerus, Rodvold et al. 1988).  Vancomycin is a 
glycopeptide antimicrobial agent commonly used in clinical practice and is eliminated mainly 
through renal excretion.  Netilmicin is a member of the aminoglycoside antibiotic class and is 
also primarily elimination through renal excretion.  CPB surgery involved moderate hypothermia 
(27-28oC) for an average of 157 ± 49 minutes.  Vancomycin concentrations in serum decreased 
upon initiation of CPB, likely due to hemodilution, followed by an increase in concentrations 
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after aortic clamping.  Pharmacokinetic analysis demonstrated that the CLR of vancomycin 
decreased with hypothermia during CPB; however this was not significant.  The changes in 
vancomycin serum concentrations strongly correlated with the changes in body temperature 
(r=0.92).  This study was also performed in patients undergoing CPB surgery treated with 
netilmicin and results demonstrated a decrease in netilmicin serum concentrations upon initiation 
of CPB.  Netilmicin CLR decreased during CPB compared to pre-CPB, however these results did 
not demonstrate significance.  These two studies provide evidence that ClR of antimicrobial 
agents is decreased during hypothermia due to a reduction in cardiac output in CPB patients, 
leading to subsequent decreases in glomerular filtration rate. 
All the studies presented in this section investigated the effects of hypothermia during 
cooling on drug disposition and metabolism; thereby providing evidence that hypothermia alters 
the pharmacokinetics of multiple drugs clinically utilized in CPB, TBI, and CA.  Three major 
conclusions can be drawn from these studies.  First, hypothermia affects multiple routes of drug 
elimination.  For instance, hypothermia decreases ClH, specifically CYP450-mediated 
metabolism.  Hypothermia also decreases biliary and renal excretion, both of which can alter the 
pharmacokinetics of drugs eliminated via these pathways.  Second, alterations in the disposition 
of medications are specific to the disease for which hypothermia is being employed as is 
evidence by the findings in CPB since there are multiple factors affecting drug disposition  in 
these patients (Lunn, Stanley et al. 1979; Koska, Romagnoli et al. 1981; Koren, Barker et al. 
1987).  This points to the difficulty in evaluating the effects of hypothermia on drug disposition 
and metabolism using certain models of injury that are more complicated; however they illustrate 
important insight into the complexity of these patients and the multiple factors which can affect 
the disposition of medications.  Third, dosing nomograms are needed for a number of drugs used 
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in the ICU in order to optimize treatment in these patients.  From these studies, we can conclude 
that mild to moderate hypothermia decreases the ClS of commonly used drugs between 7.1% and 
22.3% per degree Celsius from the ClS and 37oC.  Although this general reduction in ClH is 
observed, detailed studies of specific classes of medications used in the ICU are lacking.  In 
addition mechanistic studies are needed to determine how hypothermia affects the CYP450 
enzyme system.      
1.4.3 Mechanisms of the Effects of Therapeutic Hypothermia During Cooling on 
CYP450-Mediated Metabolism 
Hypothermia alters multiple aspects of enzymatic function (Somero 1975; Jaenicke 1991; 
Zachariassen 1991; Somero 2003).  A model has been developed which shows that hypothermia 
can also decrease the substrate binding ability of multiple enzymes (Somero 2003).  A potential 
mechanism behind the hypothermia-induced effects on CYP450-mediated metabolism is through 
changes in the binding pocket conformation.  Hypothermia can decrease the affinity of the 
CYP450 for specific substrates (McAllister and Tan 1980; Tortorici, Kochanek et al. 2006).  The 
effects of hypothermia during cooling on drug metabolism may also be mediated via a decrease 
rate of redox reactions performed by the CYP450 enzyme.  Other potential mechanisms of 
hypothermia-induced alterations in CYP450 functionality include; changes in NADPH P450 
reductase activity, cytochrome b5 activity, or the affinity of O2 for the ferric iron, as well as 
changes in the lipid membrane fluidity.  Although these proposed mechanisms lend some insight, 
careful mechanistic studies at clinically relevant temperatures are needed to confirm and/or 
refute these theoretical alterations in enzyme function.   
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Despite the wealth of data demonstrating significant alterations in drug disposition during 
therapeutic hypothermia, drug dosing is not typically altered in patients receiving hypothermia.  
In the case of CPB, the short duration of hypothermia is unlikely to produce significant drug 
toxicity due to the acute changes in disposition, with the exceptions of depth of anesthesia as is 
evident in the above mentioned studies.  However, the recent use of therapeutic hypothermia in 
patients after CA, TBI, and stroke with durations ranging from 12 to 48 hours, is likely to 
produce significant alterations in drug concentrations and potentially increase the toxicity of 
medications commonly employed in this patient population.  Currently, limited information is 
available about the magnitude of the alterations with respect to specific drugs and only a few 
studies provide recommendations for dosage adjustment during the acute phase of hypothermia.  
Future studies are needed to delineate the alterations and to develop guidelines for dosage 
adjustment in patients undergoing hypothermia.  As will become evident in the remainder of this 
chapter, the changes in drug disposition due to hypothermia are not only limited to the "during 
cooling" effects on drug metabolism and elimination.  Therapeutic hypothermia has been shown 
to alter drug efficacy and potency.  Furthermore, therapeutic hypothermia also alters the 
pathogenesis of disease, thereby, altering the regulation of drug metabolizing gene expression in 
response to a given disease in the chronic (post-rewarming) phase.  As is detailed below, these 
effects on drug response and the post-warming regulatory effects have been demonstrated in 
clinical and animal models, and require further study to determine the effects and implications of 
these alterations in patients receiving therapeutic hypothermia.  
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1.5 EFFECTS OF THERAPEUTIC HYPOTHERMIA ON DRUG EFFICACY AND 
POTENCY 
We have reviewed the effects of therapeutic hypothermia on drug disposition and metabolism 
during cooling; however, there is also literature which has investigated the effects of 
hypothermia on drug response, particularly the potency and efficacy of commonly used drugs 
(Puig, Warner et al. 1987; Heier, Caldwell et al. 1991; Heier, Caldwell et al. 1994).  The 
following section will review these articles and provide some mechanistic insight into these 
changes. 
 
Morphine 
Morphine is one of the most commonly used opioids and anesthetic adjuncts in clinical 
practice and is primarily metabolized by hepatic glucuronidation.  Puig et al. demonstrated that 
the potency of morphine was decreased at 30oC compared to 37oC in the guinea-pig ileum 
preparation.  This study investigated how changes in temperature would affect the interaction of 
morphine with its specific receptors in the electrically stimulated myenteric plexus-longitudinal 
muscle guinea-pig ileum.(Puig, Warner et al. 1987)  Opioid receptor binding leads to a decrease 
in the ganglionic release of acetycholine, thereby, exerting the drug response.  At 30oC; 
morphine was one-fifth as potent compared to 37oC, as the IC50 was significantly increased, 8.8 
X 10-8 mol/L at 37oC vs. 41 X 10-8 mol/L at 30oC.   There was also a large decrease in the 
affinity of morphine for its receptor as is evident by a six-fold increase in the dissociation 
constant at 30oC (45.5 ± 15 x 10-7 mol/L) compared to 37oC (8.3 ± 2.45 x 10-7 mol/L).   This 
change in potency of morphine could be related to a hypothermia-mediated change in the 
dissociation constant for the mu receptor.  Although hypothermia could decrease the metabolism 
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of morphine through glucuronidation, if hypothermia decreases the pharmacodynamic response, 
higher levels may be necessary to achieve an adequate response.  This suggests that the dose 
response curve of morphine may be shifted, which indicates a change in drug response, however 
further research is needed to fully elucidate these changes.  An important general axiom of drug 
therapy during mild or moderate hypothermia may be dawn from this study, suggesting that 
clinicians must carefully select drug with the lowest possible toxicity for use with hypothermia 
since higher concentrations may be needed to achieve a therapeutic effect.   
 
Vecuronium 
However, not all drugs show reduced potency with mild hypothermia. Heier et al. 
investigated the effects of mild hypothermia on neuromuscular junction sensitivity to 
vecuronium and determined the potency and efficacy (Heier, Caldwell et al. 1994).  Five subjects 
were cooled to ~34oC and five subjects were normothermic ~37oC.  Vecuronium was 
administered as an IV infusion at a rate of 3 µg/kg/min for 10 min.  Although there was an 
increase in the duration of action of vecuronium at 34oC, there were no differences between 
hypothermic and normothermic subjects as measured by the steady-state concentration producing 
50% depression of twitch tension on the train-of-four test.  The equilibrium rate constants of 
vecuronium between the plasma and the neuromuscular junction were 0.27 ± 0.14/min at 34.4oC 
and 0.26 ± 0.11/min at 36.8oC.  Thus, hypothermia-mediated increases in the duration of action 
of vecuronium are not due to changes in drug potency and efficacy, but more likely due to a 
change in the pharmacokinetics of vecuronium.  Consequently, it would be important to 
determine which drugs used in the ICU exhibit reduced potency with hypothermia, since these 
hypothermia-mediated effects seem to show substantial variability between drugs.  We believe 
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that this is an important area for future research that would be critical to the development of 
optimal dosing recommendations for each of the agents.   
1.6 THE EFFECTS OF HYPOTHERMIA ON DRUG DISPOSITION AND 
METABOLISM AFTER RE-WARMING 
Figure 5 demonstrates the stages of the effects of hypothermia on drug metabolism and 
disposition that we have identified after an injury, such as CA, TBI or stroke.  We believe that 
not only is hypothermia producing alterations in drug disposition during cooling; there could be 
significant changes during each of the phases we have identified after cooling.  This section 
examines these effects of hypothermia on the metabolism of drugs commonly used in the ICU. 
The most complete clinical study investigating both the effects of hypothermia during 
cooling and after re-warming on drug disposition and metabolism evaluated phenytoin 
pharmacokinetics during and post-hypothermia in TBI patients.  Mild hypothermia was induced 
to a target temperature at 34oC and maintained for 4 hrs.  Fourteen patients were cooled to 34oC 
and phenytoin was given as a loading bolus dose.  Patients were also dosed with phentyoin 7-8 
days after injury when core temperature was normothermic (36oC).  Hypothermia produced 
increases in AUC and a decrease in the ClS of phenytoin vs. normothermia.  After re-warming, 
(7-8 days) phenytoin pharmacokinetic parameters were normalized to pre-hypothermia levels.    
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Russell et al. performed a study investigating the effects of CPB on propofol 
concentrations in ten male patients (Russell, Wright et al. 1989).  Propofol was administered as 
continuous infusion at a rate of 10 mg/kg/hour and then decreased to 3 mg/kg/hour for 
approximately 250 minutes.  Hypothermia was induced (25oC-27oC) for approximately 50 
minutes followed by re-warming.  Propofol concentrations were higher during the hypothermic 
period.  Once re-warming was started propofol blood concentrations declined to pre-
hypothermia/CPB concentrations.  This study demonstrated that propofol concentrations are 
returned to normal levels once normothermia was reached.   
Collectively, these studies show that plasma concentrations of the drugs studied return to 
pre-hypothermia levels once the patient’s core temperature is returned to normal.  Though future 
trials are needed to fully elucidate the mechanisms behind the effects of hypothermia on drug 
disposition and metabolism, these studies can provide the clinician with an insight into the time-
course of hypothermia-induced alterations.   
1.6.1 Mechanisms of the Effects of Therapeutic Hypothermia after Re-warming on 
CYP450-Mediated Metabolism 
Data in Chapter 3 demonstrates that CA produces a decrease in CYP2E1-mediated metabolism 
of chlorzoxazone 24 hrs after insult, in the sub-acute phase after injury (Tortorici, Kochanek et 
al. 2006).  TBI has also been shown to produce an initial decrease in CYP450 functionality 
followed by a hyper-metabolic state (Boucher and Hanes 1998; Harbrecht, Frye et al. 2005).  As 
mentioned in the previous section, the studies investigating the effects of hypothermia after re-
warming on the disposition of drugs during ICU-relevant insults demonstrate that drug 
concentrations return to normal (Russell, Wright et al. 1989; Gruber, Laussen et al. 2001; Iida, 
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Nishi et al. 2001).   This indicates that hypothermia is producing a protective effect by mitigation 
of cellular damage after injury with normalization of otherwise altered drug metabolism.   
Cardiac arrest and TBI produce increases in pro-inflammatory cytokines (Boucher and 
Hanes 1998; Adrie, Adib-Conquy et al. 2002; Tortorici, Kochanek et al. 2006).  Hypothermia 
reduces pro-inflammatory cytokines, including interleukin-6 (IL-6) and interleukin-1β, after CA 
and TBI in both experimental and clinical models (Marion, Penrod et al. 1997; Aibiki, Maekawa 
et al. 1999; Truettner, Suzuki et al. 2005; Tortorici, Kochanek et al. 2006).  These pro-
inflammatory cytokines decrease both the expression and activity of multiple CYP450 isoforms 
(Abdel-Razzak, Loyer et al. 1993; Projean, Dautrey et al. 2005).  Thus, mild hypothermia may 
reduce tissue damage; thereby normalizing drug metabolism in the sub-acute phase after injury.  
This suggests that after various insults such as CA, benefits of mild hypothermia may favorably 
alter the natural cause of disease, normalizing drug metabolism.    
1.7  CONCLUSION 
This chapter has demonstrated that therapeutic hypothermia dramatically affects drug disposition 
involving a complex interplay between the effects on drug metabolism, elimination, and response 
during cooling and after re-warming.  For example, the studies outlined in this Chapter indicate 
that during cooling, drug metabolism is dramatically decreased.  This may lead to the conclusion 
that the dose of the drug should be reduced in order to avoid toxicity.  However, the effects of 
hypothermia on drug response are less predictable; demonstrating both reduced potency or no 
change in the potency depending on drug class.  Overall, the effects of hypothermia during 
cooling may suggest a narrowing of the therapeutic index of multiple drugs used in the ICU.  
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After re-warming drug metabolism is returned to normal.  Based on these variable time-
dependent changes, it is essential that intensivists are cognizant of the potential changes in drug 
disposition during and after cooling, monitor drug levels when possible, and monitor outcomes 
(i.e. depth of neuromuscular blockade, sedation scores) during and after hypothermia.  The value 
of other modalities such as the bispectral index (BIS) should be studied during hypothermia. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Time-course of hypothermia-induced effects on cytochrome-P450 activity 
Therapeutic hypothermia (solid line) demonstrates a decrease in cytochrom-P450 activity followed 
 by a return to normal activity after re-warming.   
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opportunities for future research to systematically evaluate these effects.  These included clinical 
trials with the primary objective to identify hypothermia-mediated changes in the 
pharmacokinetics of commonly used drugs in the ICU.  Furthermore, in current and future 
clinical trials investigating the beneficial effects of therapeutic hypothermia in insults such as 
stroke and TBI, it will be essential to also explore the pharmacokinetics of the drugs used during 
these studies to determine if certain drugs are beneficial or harmful during hypothermia.  
 Collectively, the studies outlined throughout this review can provide us with a theoretical 
time-course of alterations on drug disposition and metabolism (specifically CYP450-mediated) 
produced by therapeutic hypothermia.  As depicted in Figure 6, hypothermia produces a 
dramatic decrease in CYP450 activity during the period of cooling, followed by a rebound of 
CYP450 activity once core temperature is returned to normothermia.  Future studies are needed \ 
in order to provide specific dosing nomograms for clinically utilized medications during 
hypothermia.  These data imply that clinically significant hypothermia-drug interactions are a 
likely factor to be considered in the therapeutic course of these patients.  
The work presented throughout this dissertation aims to systematically investigate the 
effect of therapeutic hypothermia on drug metabolism in experimental and clinical models.  As 
presented throughout this Chapter, hypothermia can affect metabolism, absorption, elimination, 
distribution and response of many drugs.  We have chosen to focus this work on the effects of 
cooling on the CYP450 enzyme system.  Many of the historical studies have demonstrated that 
hypothermic temperatures affect drugs metabolized by CYP450’s during cooling; however there 
has never been a systematic evaluation to elucidate the mechanisms behind these changes.  In 
addition we have focused our work in an animal model of cardiac arrest, since the use of mild 
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hypothermia in patients experiencing out-of-hospital cardiac arrest has been shown to decrease 
mortality and morbidity.  
Based on this, we hypothesize that therapeutic hypothermia produces time-dependent 
alterations in CYP450 activity resulting in significant alterations in the disposition of 
medications used in critically ill patients.  In order to evaluate this hypothesis the following 
specific aims have been proposed by chapter; 
 
Specific Aim 1: Determine the in vivo effect of moderate hypothermia on the pharmacokinetics 
of the CYP2E1 substrate, chlorzoxazone, in a rat model of cardiac arrest. 
  
Specific Aim 2: Determine the effects of cardiac arrest and moderate hypothermia in a rat model 
on the functional activity and expression of CYP3A2 and CYP2E1 and examine the regulation of 
these isoforms after injury. 
 
Specific Aim 3: Evaluate the effects of mild and moderate hypothermia on the in vitro enzyme 
kinetics of CYP3A4 and CYP2E1 in human hepatic microsomes and therefore predict in vivo 
changes in humans. 
 
Specific Aim 4:  Investigate the effects of mild hypothermia on midazolam pharmacokinetics in 
normal healthy subjects. 
The body of work presented in this dissertation begins to answer these specific aims by 
evaluating the effect of mild to moderate hypothermia in a systematic method via utilizing 
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multiple animal models, in vitro/in vivo correlations, and a model of hypothermia in normal 
healthy volunteers.   
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2.0  CHAPTER 2 
 
 
 
 
Therapeutic Hypothermia Induced Pharmacokinetic Alterations on CYP2E1    
Chlorzoxazone Mediated Metabolism in a Cardiac Arrest Rat Model 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[Tortorici, MA, Kochanek PM, Bies RR, and Poloyac SM.  Therapeutic Hypothermia 
 Induced Pharmacokinetic Alterations on CYP2E1 Chlorzoxazone Mediated Metabolism 
 in a Cardiac Arrest Rat Model. Crit Care Med 2006;34(3)785-791.] 
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INTRODUCTION 
 
 
 
 
Chapter 1 reviewed the beneficial effects of therapeutic hypothermia in patients experiencing 
out-of-hospital cardiac arrest and other ischemic injuries, such as TBI and stroke.  Clinical 
implementation of hypothermia has increased as a result of two landmark clinical trials that 
showed that the use of mild hypothermia as a therapy in out-of-hospital CA patients decreased 
morbidity and mortality and improved survival (Bernard, Gray et al. 2002; Group 2002).  In 
addition to therapeutic hypothermia, patients experiencing CA are subjected to an extensive 
pharmacotherapeutic regimen.  The majority of these agents used are eliminated via hepatic 
metabolic pathways, more specifically the cytochrome P450 (CYP450) system.  As described in 
detail in Chapter 1, prior clinical and in vivo animal studies have suggested that therapeutic 
hypothermia alters the pharmacokinetics of medications metabolized by the CYP450 system, 
however a thorough mechanistic evaluation of the effects of hypothermia on the CYP450 system 
has not been reported (Koren, Barker et al. 1985; Koren, Barker et al. 1987; Leslie, Sessler et al. 
1995; Caldwell, Heier et al. 2000; Iida, Nishi et al. 2001; Fukuoka, Aibiki et al. 2004).     
With the increase in clinical implementation and the paucity of information that exists on 
the effects of therapeutic hypothermia on drug metabolism, we set out to mechanistically 
examine the effects of therapeutic hypothermia on CYP2E1-mediated metabolism in a clinically 
relevant CA rat model.  As previously mentioned, CYP2E1 plays a major role in the metabolism 
of multiple compounds such as ethanol, isoniazid, and theophylline, as well as the metabolism of 
arachidonic acid (Lieber 1997).  Chlorzoxazone (CZN) is a drug that is exclusively metabolized 
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by CYP2E1 and is used as a probe substrate to assess the activity of this enzyme.  The systemic 
clearance (ClS) of CZN approximates the instrinsic clearance (Clint) by the CYP2E1 enzyme.  
The Clint is defined as the inherent ability of the enzyme to remove drug from the body.  Based 
on this, the objectives of this study were to 1) evaluate the effects of therapeutic hypothermia on 
the pharmacokinetics of CZN during the hypothermic period in a rat model of CA and 2) to 
identify the mechanisms underlying these alterations in the ClS, by evaluating the effects of 
hypothermia on CZN plasma protein binding and the Clint of CYP2E1, using in vitro techniques. 
2.1 METHODS 
2.1.1 Materials and Chemicals 
Male Sprague-Dawley rats (body weight, 300-400 g) were purchased from Hilltop Laboratories 
(Scottdale, PA). Chlorzoxazone (CZN), 6-hydroxychlorzoxazone (6-OH CZN), and 
umbelliferone, were purchased from Sigma Aldrich (St Louis, MO.)  Organic solvents were 
purchased from Fisher Scientific (Pittsburgh, PA).  All other chemicals were purchased from 
Sigma Aldrich unless otherwise specified. 
2.1.2 Animal Cardiac Arrest and Hypothermia Protocol 
Rats were allowed free access to food and water before and after surgery.  The University of 
Pittsburgh Animal Care and Use Committee approved all studies.  Sterile technique was used for 
all surgical procedures.  
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CA was conducted as previously described (Fink, Alexander et al. 2004; Katz, Young et 
al. 2004).  Rats were anesthetized with 3% halothane via a nose cone, endotracheally intubated, 
and mechanically ventilated to maintain PaCO2 between 35 to 45 mmHg.  Halothane 
concentration was then reduced to between 0.5 to 1%.  The right femoral artery was cannulated 
for measurement of mean arterial pressure and the femoral veins were cannulated bilaterally for 
drug administration and blood sampling.  Neuromuscular blockade was induced with 
vecuronium 2 mg/kg (IV).  A rectal probe was inserted for body temperature measurements.  
After preparative surgery, halothane was washed out with 100% O2 for 3 minutes and room air 
for 2 minutes.  Rats were randomized to receive either, CA with normothermia (CA 
Normothermia), or CA with hypothermia (CA Hypothermia), n=6.  Animals received another 
vecuronium 1 mg/kg IV dose and CA was initiated by asphyxiation via disconnection of the 
mechanical ventilation.  Asphyxial arrest was conducted for 8 minutes, with 5 minutes of 
asystole, confirmed by ECG trace as previously described (Fink, Alexander et al. 2004).  
Resuscitation was started by reconnecting the rat to the ventilator, administering epinephrine 
(0.005 mg/kg), IV and bicarbonate (1mEq/kg), IV and performing manual chest compressions 
for about one minute until restoration of spontaneous circulation (ROSC).  Halothane was not 
resumed after asphyxiation based on prior documentation of a burst-suppression pattern on EEG 
during early recovery (Fink, Alexander et al. 2004).  Arterial blood gases and glucose 
measurements were taken prior to asphyxia and at the end of the re-warming phase.  Acidosis 
was corrected via bicarbonate replacement to maintain pH at 7.4.   
After ROSC, rats were either maintained at 37oC normothermia or body temperature was 
decreased to 30oC hypothermia over 15 minutes via surface cooling.   Once body temperature 
had stabilized, CZN (15mg/kg) was administered IV as a single dose via the right femoral vein.  
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CZN was given at approximately 35 minutes after the end of asphyxial arrest and 45 minutes 
after halothane washout.  Blood samples (0.3 ml) were obtained via the left femoral venous 
cannula with a heparanized syringe at 0, 10, 20, 30, 60, 90, 120, 150, and 165 minutes after drug 
administration and urine was obtained by collection of the first urine sample upon recovery from 
neuromuscular blockade.  Rats remained hypothermic over the entire 3 hour period after 
temperature stabilization, during drug administration, and blood collection.  Intensive care 
management was performed in all animals and included as needed doses of vecuronium, 
bicarbonate, and butorphanol.  Re-warming was conducted over 1 hour and rats were gradually 
weaned from mechanical ventilation, extubated, recovered, and then returned to their cages.  
Urine was collected at the end of re-warming by a collection dish placed under the bladder as 
rats recovered from neuromuscular blockade.  Rats were sacrificed 24 hours post-insult via 
decapitation and liver, kidney, and brain tissue were retrieved for a separate study.  
 
2.1.3 Chlorzoxazone Analysis 
Plasma concentrations of CZN were measured by a modified HPLC method described by 
Rockich et al (Rockich and Blouin 1999).  Briefly, 100 µl of plasma or urine from each sample 
was added to 900 µl of 10 mM sodium acetate buffer (pH=4.5) and incubated with 500 µl of β-
glucoronidase (1000 units) for 3 hours in a 37oC circulating water bath in order to cleave the 
glucoronide from the 6-hydroxylated metabolite in the urine and plasma.  Internal standard, 
umbelliferone, was added to each plasma and urine sample and then extracted with 5 ml of 
diethyl ether.  The organic phase was transferred and evaporated to dryness under a stream of 
nitrogen.  Samples were then reconstituted with 200 µl of mobile phase A, consisting of 78% of 
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a 0.25% acetic acid solution and 22% acetonitrile, and 20 µl was injected onto the HPLC system.  
Mobile phase B consisted of 95% acetonitrile and 5% of a 0.25% acetic acid solution and a 
gradient was established.  CZN, umbelliferone, and 6-OH CZN were separated using a Nova Pak 
C-18 reverse phase (5µm, 3.9 X 150mm) column (Waters, Millford, MA).  The HPLC system 
consisted of a Waters 2695 with a 2487 UV detector, set at 287 nm for CZN and 296 nm for 6-
OH CZN.  The ratio of CZN or 6-OH CZN to umbelliferone was used for quantitative analysis. 
The C.V. was less than 10% for this assay 
2.1.4 Protein Binding Analysis 
Protein binding of CZN in rat plasma was determined by the ultrafiltration technique as reported 
by Rockich and Blouin (Rockich and Blouin 1999).  Each sample (n=4) consisted of 1.5 ml of 
control rat plasma, spiked with a stock solution of CZN, to give a final concentration of 10 
µg/ml.  The samples were incubated for 15 minutes at 37oC or 30oC, and 1-ml aliquots were 
placed into an ultrafiltration device (Amicon, Beverly, MA) equipped with an ultrafiltration 
membrane.  The remaining 500 µl was analyzed for total CZN concentration. The samples were 
then centrifuged at 3200 rpm at 37oC or 30oC, respectively, for 30 minutes or until 250 µl of 
filtrate was collected.  Concentrations of CZN in the filtrate, the 1-ml aliquot, and the remaining 
original 1.5 ml plasma sample were determined by the HPLC method described above.  The 
fraction of unbound (fu) CZN was calculated by dividing the concentration in the filtrate/ 
concentration in the original plasma sample, which represents unbound concentration/ total 
concentration. 
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2.1.5 CYP2E1 Enzyme Kinetic Analysis 
Liver tissue was collected from 4 untreated rats and microsomes were prepared as previously 
described by Rockich and Blouin (Rockich and Blouin 1999).  All microsomal incubations 
contained 400 µg microsomal protein and 1 mM NADPH.  CZN was added to microsomal 
samples in increasing concentrations of 50, 75, 100, 200, 300, 400, and 500 µM.  These samples 
(n=4 per temperature group) were either incubated for 20 minutes at 37oC or 30oC in a 
circulating water bath.  The reaction was stopped by adding 50 µl of 42.5% o-phosphoric acid, 
followed by the addition of the internal standard, umbelliferone.  Samples were analyzed as 
stated above. 
2.1.6 Pharmacokinetic and Enzyme Kinetic Analysis 
The plasma concentration-time curves for CZN were fit to a one-compartment model and were 
analyzed using the computer program WinNonlin Pro 4.1 (Pharsight Corp, Mountain View, CA).                      
          Ct = Co e-kt                                                           (1) 
The area under the plasma concentration-time curve (AUC) for CZN was determined by the 
trapezoidal rule with extrapolation to infinity, linear up and logarithmic down.  The ClS was 
calculated as dose/area under the plasma concentration-time curve.  The half-life was calculated 
using 0.693 divided by the elimination rate constant (K).  Visual inspection and sum of squares 
residuals were determined for model fitness and weighting.   
The effect of incubation temperature on CYP2E1 enzyme kinetics was analyzed in order 
to investigate the mechanism of the alterations of the clearance values as observed in the CA 
Hypothermia versus CA Normothermia groups.  A formal Michaelis-Menten kinetic analysis 
 58 
was performed from the formation rates using WinNonlin (Pharsight Corp, Mountain View, 
CA).  Maximum velocity (Vmax) and the concentration Michaelis-Menten constant (Km) were 
calculated via non-linear regression of the raw data.  The data was then linearized for visual 
inspection, via an Eadie-Hofstee plot.  
The following equation was used for analysis: 
                                      v =  Vmax * [S] / (Km + [S])                                                (2) 
where v is the velocity and [S] is the substrate concentration. 
The Clint (ml/min) was calculated using the equation: 
                                  Clint = (Vmax/Km) * mg microsomal protein                              (3) 
The in vitro Clint was used to estimate the in vivo ClS in a rat as described by Tong et al 
(Tong, Abbott et al. 2001).  The following equation explains the predicted in vivo parameters 
from in vitro estimates: 
Clint’ = Clint in vitro*(mg microsomal protein/g of liver)* 
(liver weight g/ body weight kg)*(ml incubation/ mg microsomal protein)                (4) 
Where Clint’ is the estimated in vivo intrinsic clearance.  The estimated Cls was then 
calculated by multiplying the Clint’ and the fu.  All results are given as means ± S.D. 
2.1.7 Statistical Analysis 
For comparisons of physiologic parameters over time a two-way ANOVA for repeated measures 
with a Bonferroni correction was used.  For individual comparisons a Student’s t-test was 
utilized, assuming equal variances, to compare the CA Normothermia group and the CA 
Hypothermia group.  We considered p<0.05 to be statistically significant.  Data are presented as 
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mean ± S.D. All analyses were conducted using the software program Prism (GraphPad 
Software, San Diego, CA). 
2.2 RESULTS 
2.2.1 Time-Course of Hypothermia in Cardiac Arrest Treated Rats 
As depicted in Figure 7, rats were either maintained at 37oC or were cooled to 30oC over 15 
minutes.  Hypothermia was maintained for 3 hours followed by 1 hour of re-warming.  
 
 
 
 
 
 
 
 
 
  Figure 7: Time-course of temperature in the rat 
 
 
2.2.2 Physiological Parameters in Cardiac Arrest Rats 
Physiological parameters (MABP, blood pH, PaO2, PaCO2, and glucose) were measured at two 
time points (Table 3).  The pre-CA/hypothermia measurements were drawn after preparative 
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surgery and immediately prior to the initiation of CA.  The post-CA/hypothermia measurements 
were drawn after 3 hours of hypothermia and 1 hour of re-warming.  The data demonstrates that 
pre-CA/hypothermia showed no significant alterations in physiologic parameters between 
groups.  However, post-CA/hypothermia parameters demonstrate that both groups have an 
anticipated increase in PaO2 and decrease in PaCO2, when compared to pre-CA/hypothermia 
parameters (**p<0.01) (Fink, Alexander et al. 2004).  All other parameters demonstrated no  
statistical differences. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3: Physiological Parameters in Cardiac Arrest and Hypothermia Rats 
Abbreviations: MABP, mean arterial blood pressure; PaCO2, pressure of carbon 
 dioxide; PaO2, pressure of oxygen 
Experimental Group Pre-CA/Hypothermia Post-CA/Hypothermia
MABP (mmHg) CA Normothermia 101.17 ± 9.60 114.83 ± 10.23
CA Hypothermia 104.33 ± 10.13 104.17 ± 27.46
pH CA Normothermia 7.39 ± 0.02 7.39 ± 0.04
CA Hypothermia 7.38 ± 0.02 7.41 ± 0.07
PaCO2 (mmHg) CA Normothermia 38.17 ± 2.64 29.58 ± 4.13
CA Hypothermia 40.00 ± 0.63 25.50 ± 3.89
PaO2 (mmHg) CA Normothermia 224.83 ± 32.37 414.67 ± 49.99
CA Hypothermia 227.50 ± 46.12 491.33 ± 51.15
Glucose (mg/dL) CA Normothermia 119.83 ± 18.42 116.00 ± 19.37
CA Hypothermia 121.00 ± 10.58 146.67 ± 28.79
***
***
***
***
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2.2.3 Effect of Hypothermia on the Pharmacokinetics of Chlorzoxazone in Cardiac Arrest 
Treated Rats 
The linear plot of CZN concentration-versus-time profile followed a simple mono-exponential 
decline for both the CA Normothermia and CA Hypothermia groups. As depicted in Figure 8, 
Panel A, CA Hypothermia significantly altered the plasma concentration-versus-time profile 
compared to the CA Normothermia group.  Table 4 depicts the pharmacokinetic parameter 
results and demonstrates that CA Hypothermia significantly altered a number of pharmacokinetic 
parameters, such as ClS, K, and Vd.  ClS in the CA Hypothermia group (0.580 ± 0.37 ml/min) 
was decreased vs. the CA Normothermia group (1.26 ± 0.34 ml/min; **p<0.01)   The 
elimination rate constant (K) in the CA Hypothermia group (0.00210 ± 0.0015 min-1) was 
decreased vs. the CA Normothermia group (0.00614 ± 0.0019 min-1; **p<0.01).  The volume of 
distribution (Vd) in the CA Hypothermia group (288 ± 42 ml) was increased vs. the CA 
Normothermia group (211 ± 35 ml; **p<0.01). 
Figure 8, Panel B, depicts the urinary excretion rate of 6-OH CZN over 165 minutes for 
both groups. This data shows the rate of excretion of 6-OH CZN in the CA Hypothermia group is 
0.255 ± 0.24 µg/min vs. 1.05 ± 0.74 µg/min for the CA Normothermia group ;*p<0.05.   
2.2.4 Effect of Temperature on Protein Binding of Chlorzoxazone 
The total, bound, and unbound concentrations were analyzed.  The fu at 37oC was 0.0458 ± 
0.0061 compared to 30oC which was 0.0422 ± 0.0041, demonstrating no statistical difference as 
depicted in Figure 9. 
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Figure 8: Pharmacokinetic profile of chlorzoxazone and urinary excretion rate of 6-
 hydroxchlorzoxazone. 
 
Panel A depicts the linear plot of the chlorzoxazone plasma concentrations-versus-time curve in cardiac 
 arrest normothermia vs. cardiac arrest hypothermia treated rats after treated with IV bolus dose of 
 chlorzoxazone (15mg/kg).  Each point represents the mean ± S.D.; n=6.  Panel B depicts the urinary 
 excretion rate of 6-hydroxychlorzoxazone in both groups.  Data shows a significant decrease in cardiac 
 arrest hypothermia rats (0.255 ± 0.24 µg/min) vs. cardiac arrest normothermia (1.05 ± 0.74 µg/min)  
 p<0.05.   
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Table 4: Pharmacokinetic parameters in cardiac arrest treated rats 
 
 
 
 
 
 
 
Abbreviations: Cls, systemic clearance; Vd, volume of distribution; K, elimination rate constant; AUC, area 
under the plasma concentration-time curve. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Protein binding of chlorzoxozone at 37oC and 30oC. 
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Parameters CA Normothermia CA Hypothermia
Cls (ml/min) 1.26 ± 0.34 0.58 ± 0.37 **
t1/2 (min) 125.36 ± 48.92 620.98 ± 597.22 
Vd (ml) 211.17 ± 34.76 288.12 ± 42.25 **
K (min-1) 0.0061 ± 0.0013 0.0021 ± 0.0015 **
AUC (min*ug)/ml/kg 12.63 ± 3.77 29.94 ± 18.3 *
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Table 5: Michaelis-menten enzyme kinetic parameter estimates in rat liver microsomes 
  
Figure 10: Eadie-hofstee plot of enzyme kinetic analysis of CYP2E1 
 
Constructed from the non-linear regression analysis of raw data reported in Table 5.  The 
difference in Km can be observed by the difference in slopes of the 2 lines. 
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37 DEGREES 30 DEGREES
Vmax (nmol/mg/min) 2.27 ± 0.22 2.64 ± 0.48
Km (uM) 255.53 ± 52.03 551.6 ± 149.91
Clint (ml/min/mg protein) 0.0089 ± 0.0017 0.0050 ± 0.0004
Cls estimated (ml/min) 2.10 ± 0.39 1.19 ± 0.21
Abbreviations: Vmax, maximal velocity; Km, Michaelis-menten constant; Clint, 
 intrinsic clearance; Cls, systemic clearance 
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2.2.5 Effect of Temperature on CYP2E1 Enzyme Kinetics 
There were no significant differences in CYP2E1 Vmax for 37oC (2.27 ± 0.22 nmol/mg/min) 
versus 30oC (2.65 ± 0.48 nmol/mg/min), Table 5.  However, when the Km was analyzed, an 
increase was observed between the 30oC group (551 ± 150 µM) vs. the 37oC group (255 ± 52 
µM;**p<0.01). For visual inspection, an Eadie-Hofstee plot was constructed (Figure 10) and the 
difference in the slope of the lines between the 37oC and 30oC groups represents the changes 
observed in the Km values.  The y-intercept represents the Vmax of each group and shows no 
statistical differences.   
The Clint was decreased in the hypothermia group, 37oC (0.00890 ± 0.0017 ml/min/mg 
protein) and 30oC (0.00500 ± 0.00040 ml/min/mg protein; **p<0.01), as depicted in Table 5.  
An in vitro/in vivo correlation was performed using equations 3 and 4 (Tong, Abbott et al. 2001).  
Microsomal protein content has been previously estimated to be 40 mg protein/ g of liver.  The 
average weight of liver in our rats was estimated to be 47 g/ kg body weight (Bachmann and 
Sarver 1996).  These predicted in vivo Clint parameters were multiplied by the fu of CZN in order 
to predict an in vivo ClS of 2.10 ± 0.39 ml/min at 37oC incubation temperature and 1.19 ± 0.21 
ml/min at 30oC incubation temperature, shown in Table 3.   
2.3 DISCUSSION 
Our results demonstrate three novel findings.  The first is that in a CA rat model, moderate 
hypothermia markedly alters the pharmacokinetics of the CYP2E1 probe drug, CZN.   The 
second finding is that hypothermia treatment resulted in a decrease in ClS of CZN and this 
reduction is due to a decrease in the Clint of the CYP2E1 enzyme.  The third finding is that the 
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reductions of Clint measured in vitro due to hypothermia, accurately predicted the magnitude of 
decrease observed in ClS of CZN in the CA rat model in vivo.  These results represent the first in 
a series of designed experiments to identify certain changes in drug metabolizing enzymes in 
order to provide algorithms for dose adjustments of commonly used medications in the critical 
care patient receiving hypothermic therapy.    
We showed a significant impact of moderate hypothermia on the pharmacokinetics of 
CZN after CA in rats treated with hypothermia versus normothermia.  We observed reductions in 
the K, urine excretion rate, and the ClS, and observed an increase in the Vd.  These effects have 
been substantiated by previous in vivo studies demonstrating the inhibition of hepatic drug 
elimination (Koren, Barker et al. 1985; Koren, Barker et al. 1987; Heier, Caldwell et al. 1991; 
Caldwell, Heier et al. 2000; Iida, Nishi et al. 2001; Michelsen, Holford et al. 2001; Statler, 
Alexander et al. 2003; Fukuoka, Aibiki et al. 2004).  Fukuoka et al. showed a 5-fold increase in 
plasma concentrations of midazolam when the core temperature of brain-injured patients was 
maintained below 35oC (Fukuoka, Aibiki et al. 2004).  Collectively, these studies show that 
hypothermia impacts the disposition of certain hepatically eliminated drugs, more specifically by 
decreasing the ClS. 
Reductions in drug clearance by moderate hypothermia may represent a key toxicity that 
limits the putative benefit of this therapy.  Statler et al. performed a study to evaluate the effects 
of hypothermia on lesion volume in TBI rats using fentanyl anesthesia (Statler, Alexander et al. 
2003).  Contrary to previous studies showing decreased lesion volume with hypothermia in the 
TBI isoflurane anesthesia rat, Statler et al. observed a larger lesion volume in the hypothermia 
group when fentanyl was used as the anesthetic agent.  This study further showed that in the 
hypothermia group, there was an increase in serum concentrations of fentanyl versus 
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normothermia.  The authors indicate that this increase in serum fentanyl concentrations could 
contribute to toxicity and may be the potential mechanism underlying the increase in lesion 
volume (Kofke, Garman et al. 1999); thereby, demonstrating a critical need for full knowledge of 
the adverse events of therapeutic hypothermia in order to optimize care after injury. 
Our in vivo findings show a reduction in the ClS of CZN due to hypothermia in the CA 
model.  Hypothermia affects the CYP450 system as reported in previous studies (Heier, Caldwell 
et al. 1991; Heier, Caldwell et al. 1994; Leslie, Sessler et al. 1995).  A series of studies by Heier 
et al. demonstrated that the duration of action of vecuronium, metabolized by the CYP450 
system, is greater than 3-fold longer in hypothermic (34.5oC) versus normothermic (36.5oC) 
surgical patients (Heier, Caldwell et al. 1991).  Subsequent studies by Heier et al. showed that 
the changes in duration of action is due to pharmacokinetic alterations, specifically reductions in 
Cls, with no observed differences in the pharmacodynamic measures (Heier, Caldwell et al. 
1994).  These studies indicate that hypothermia alters the clearance of drugs through a reduction 
in hepatic elimination. 
In order to elucidate the mechanism of these reductions, the parameters which dictate the 
ClS of CZN were further investigated.  Hepatic clearance (ClH) of drugs with low clearance 
depend upon the fu, and the Clint, as predicted by the well-stirred model of ClH (Pang and 
Rowland 1977; Pang and Rowland 1977; Pang and Rowland 1977).  The Clint is a measure of the 
intrinsic ability of the enzyme to actively clear drug from the body and can be calculated by 
Vmax/Km.  The temperature difference in this study had no effect on the protein binding of CZN 
and the Vmax of the CYP2E1 enzyme, which was consistent with previous reports (Rockich and 
Blouin 1999; Tanaka 2001).  However, at an incubation temperature of 30oC, Km is significantly 
increased when compared to 37oC.  The observed increase in Km due to hypothermic conditions 
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is consistent with a study by McAllister et al. who demonstrated that when propranolol and 
verapamil were incubated at 26oC vs. 37oC, the Km was significantly increased at the lower 
temperature (McAllister and Tan 1980).  Collectively these results imply that moderate 
hypothermic temperatures decrease the CYP2E1 affinity for CZN, defining a key mechanism for 
the reduction of drug metabolism by this intervention. 
The observed reductions in the ClS of the CA Hypothermia group can be explained by 
changes in the Clint of CYP2E1 due to hypothermia, using an in vitro/in vivo correlation analysis 
(Obach, Baxter et al. 1997).  The in vitro Clint of each group showed a two-fold decrease in the 
microsomes incubated at 30oC versus 37oC.  The magnitude of change in the predicted in vivo 
Cls between normothermia and hypothermia treated microsomes is approximately a 2-fold 
decrease from in vitro results.  This implicates that the changes in the in vitro Clint can accurately 
predict the changes observed in the in vivo analysis. 
We showed a significant increase in the Vd in the CA Hypothermia group compared to 
the CA Normothermia group.  The Vd is a term which relates the amount of drug in the body to 
the concentration in the blood or the plasma.  Hypothermic therapy increased the Vd in the CA 
Hypothermia group versus CA Normothermic controls, which has been observed for other 
medications (Fukuoka, Aibiki et al. 2004).  A higher Vd indicates that the drug is more widely 
distributed out of the plasma and into the tissues.  This could be due to multiple factors such as 
changes in plasma protein binding, global blood perfusion to organs, diffusion across 
membranes, or drug-tissue binding.  We showed no difference in plasma protein binding at 
hypothermic temperatures and the other factors have never been investigated.  
There are several possible limitations of our study.  First, many of the pharmacokinetic 
parameters in the CA Normothermia group are different than historic control values, in naïve rats 
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(Rockich and Blouin 1999).  These deviations are likely due to CA affects on CYP2E1-mediated 
metabolism of CZN.  CA is a global ischemia/reperfusion injury.  Reperfusion causes a systemic 
inflammatory response, resulting in large releases of cytokines and nitric oxide, both of which 
have been shown to affect CYP450-mediated metabolism (Abdel-Razzak, Loyer et al. 1993; 
Khatsenko 1998; 2000; Adrie, Adib-Conquy et al. 2002; Qi, Chaiyakit et al. 2004).   The role of 
these mediators in our CA model has been evaluated as outlined in Chapter 3.  Hepatic damage, 
due to CA, could also play a role in the decrease in metabolic activity, and histological 
assessments can be employed to evaluate this.  Another limitation is the choice of anesthetic used 
in our CA model.  Halothane has been shown to inhibit CYP2E1 in previous studies.(Tateishi, 
Watanabe et al. 1997)  Since halothane has a very short half-life and that our CA model is 
conducted under a halothane washout period for 45 minutes prior to administration of CZN, we 
suggest that halothane is not contributing importantly to our observations.  Another limitation is 
the duration of study as the half-life in the CA/hypothermia group exceeded the duration of 
sampling.  Future studies are being developed to increase the duration of analysis in order to 
accurately capture changes in the half-life.  Lastly, we conducted these experiments under 
moderate hypothermic conditions.  Future experiments are being designed to identify the effect 
of mild hypothermia on CYP450-mediated metabolism, as this temperature range has been 
shown to be beneficial.  
2.4 CONCLUSION 
We report that hypothermia after CA alters the pharmacokinetic parameters of CZN, specifically 
showing reductions in the ClS, t1/2, and K, and increases in the Vd.  Our studies indicate that the 
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reductions in ClS are a result of temperature effects on the CYP2E1 enzyme, specifically, a 
decrease in the affinity of CZN for the CYP2E1 isoform. This is the first systematic investigation 
into the acute effect of hypothermic therapy on CYP2E1-mediated metabolism and the first 
mechanistic insight into hypothermia induced reductions in CZN clearance.  Future studies are 
needed to asses the acute effects of hypothermia on other CYP450 isoforms as well as other 
enzymes which are involved in the metabolism of clinically relevant drugs.  Although controlled 
clinical trials need to be employed in order to fully understand the effects of hypothermic therapy 
on the disposition of medications in the CA patient population, these data imply that clinically 
significant hypothermia-drug interactions are a likely factor to consider in the therapeutic course 
of these patients.  
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3.0  CHAPTER 3 
 
 
Moderate Hypothermia Prevents Cardiac Arrest-Mediated CYP3A2 and CYP2E1 
Suppression and Interleukin-6 Induction in the Rat 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[Tortorici, MA, Kochanek PM, Xie W, and Poloyac SM.  Moderate Hypothermia 
Prevents Cardiac Arrest-Mediated CYP3A2 and CYP2E1 Suppression and Interleukin-6 
Induction.  In preparation. 
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INTRODUCTION 
 
 
The work outlined in Chapter 2, demonstrates that the application of moderate hypothermia 
(30oC) in a CA rat model, dramatically decreases the ClS of the CYP2E1 probe substrate, CZN 
(Tortorici, Kochanek et al. 2006).  Furthermore, the mechanism behind the change in ClS was 
due to a decrease in the affinity of CYP2E1 for the substrate, CZN.  These data from our study, 
along with data from other studies, demonstrate that during cooling there are dramatic changes in 
the disposition of medications metabolized by CYP450 enzymes in both animal and clinical 
models of injury (Koren, Barker et al. 1987; Iida, Nishi et al. 2001; Fukuoka, Aibiki et al. 2004).  
However, it is not known what happens to CYP450-mediated metabolism in the acute phase 
(immediately after re-warming, 5 hr after injury), the sub-acute phase (12-24 hrs after injury), the 
delayed phase (24-72 hrs after injury) or the chronic phase (72 hrs – 2 weeks after injury).  As 
outlined in Chapter 1, one previous study investigated the effects of mild hypothermia on 
phenytoin pharmacokinetics in TBI patients and suggested that as a patient’s core temperature is 
re-warmed to 37oC, the pharmacokinetic parameters of phenytoin normalize (Iida, Nishi et al. 
2001).  This may be due to the protective effects of therapeutic hypothermia on organs involved 
in drug metabolism.  In order to fully understand the effects of hypothermia on drug metabolism 
it is also important to investigate the effects of hypothermia on drug disposition and metabolism 
once the patient’s core temperature has been re-warmed, in order to optimize care.     
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Local or global inflammatory insults, such as CA, chronically regulate CYP450 
expression and activity through the production of the acute phase response (APR), namely the 
release of pro-inflammatory cytokines, including  interleukins 1 and 6 (IL-1 and IL-6) and tumor 
necrosis factor-α (TNF-α) (Carlson and Billings 1996; Khatsenko and Kikkawa 1997; Oppert, 
Gleiter et al. 1999; Roe, Poloyac et al. 2001; Frye, Schneider et al. 2002; Van Ess, Mattson et al. 
2002; Haas, Kaufman et al. 2003).  Furthermore, nitric oxide (NO) is an important biological 
mediator that is induced by multiple inflammatory stimuli and decreases the activity of CYP450 
isoforms in experimental models of ischemia and endotoxemia (Carlson and Billings 1996; 
Khatsenko and Kikkawa 1997; Zhu, Deng et al. 2002).  Hypothermia reduces the production of 
the acute phase response, specifically, pro-inflammatory cytokine production and NO after injury 
(Gundersen, Vaagenes et al. 2001; Han, Karabiyikoglu et al. 2003; Shima, Fujisawa et al. 2003; 
Truettner, Suzuki et al. 2005). Thus, we hypothesize that hypothermia treatment may provide 
protective effect on CYP450-metabolism after a global inflammatory insult, such as CA, in the 
acute and sub-acute phase after injury. 
As mentioned in Chapter 1, CYP3A and CYP2E1 are both constitutively expressed in the 
rat and are regulated through transcriptional mechanisms (Rancid 2002).  CYP3A2 is regulated 
through transcriptional mechanisms via hepatocyte nuclear factor- 4α (HNF-4α) (Miyata, Nagata 
et al. 1995).  CYP2E1 is also regulated through transcriptional mechanisms via hepatocyte 
nuclear factor-1α (HNF-1α) as well as post-translational events (Eliasson, Johansson et al. 1988; 
Eliasson, Mkrtchian et al. 1992; Roe, Poloyac et al. 2001; Cheng, Wang et al. 2003).  Disease 
states which produce a potent APR, such as TBI and endotoxin administration, have been shown 
to decrease the expression and activity of both CYP3A2 and CYP2E1 in rat liver (Toler, Young 
et al. 1993; Roe, Poloyac et al. 2001; Cheng, Wang et al. 2003).  However, the effects of CA on 
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CYP450 activity and expression as well as the potential protective effects of hypothermia 
applied after injury on this enzyme system have not been previously reported. 
Based on this, we set out to examine the regulatory effects of CA and hypothermia on 
hepatic CYP3A2 and CYP2E1-mediated metabolism in the rat, in the acute and sub-acute phases 
after injury.  The purpose of this study was to 1) examine the effects of CA and moderate 
hypothermia on the functional activity and mRNA expression of CYP3A2 and CYP2E1 in the rat 
liver at 5 and 24 hrs after injury, 2) examine if these changes are associate with induction of IL-6 
and NO plasma concentrations as part of the acute phase inflammatory response in the rat after 
CA injury, and 3) determine if there are CA/hypothermia-mediated changes in HNF-4α and 
HNF-1α expression. 
 
3.1 METHODS 
3.1.1 Materials and Methods 
Male Sprague-Dawley rats (body weight, 300-400 g) were purchased from Hilltop Laboratories 
(Scottdale, PA).  Chlorzoxazone (CZN), 6-hydroxychlorzoxazone (6-OH CZN), umbelliferone, 
and testosterone (TST) were purchased from Sigma Aldrich (St Louis, MO.)  6β-
hydroxytestosterone (6β-OH TST) and 11β-hydroxytestosterone (11β-OH TST) were purchased 
from Steraloids (Newport,RI).  Organic solvents were purchased from Fisher Scientific 
(Pittsburgh, PA).  All other chemicals were purchased from Sigma Aldrich unless otherwise 
specified. 
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3.1.2 Animal Cardiac Arrest and Hypothermia Protocol 
The CA and Hypothermia protocol is outlined in detail in Chapter 2 and were similar in this 
study with modifications.  Rats were allowed free access to food and water before and after 
surgery.  The University of Pittsburgh Animal Care and Use Committee approved all studies.  
Sterile technique was used for all surgical procedures.  
CA was conducted as previously described (Fink, Alexander et al. 2004; Katz, Young et 
al. 2004).  Rats were anesthetized with 3% halothane via a nose cone, endotracheally intubated, 
and mechanically ventilated to maintain PaCO2 between 35 to 45 mmHg.  Halothane 
concentration was then reduced to between 0.5 to 1%.  The right femoral artery was cannulated 
for measurement of mean arterial pressure and the femoral veins were cannulated bilaterally for 
drug administration and blood sampling.  Neuromuscular blockade was induced with 
vecuronium 2 mg/kg (IV).  A rectal probe was inserted for body temperature measurements.  
After preparative surgery, halothane was washed out with 100% O2 for 3 minutes and room air 
for 2 minutes.  Rats were randomized to receive either, anesthesia control normothermia 
(Control), CA with normothermia (CA Normothermia), or CA with hypothermia (CA 
Hypothermia), n=6.  The use of a control hypothermia group was not warranted in this study due 
to the lack of clinical relevance.  Animals received another vecuronium 1 mg/kg IV dose and CA 
was initiated by asphyxiation via disconnection of the mechanical ventilation in the animals in 
the CA treated groups.  Asphyxial arrest was conducted for 8 minutes, with 5 minutes of 
asystole, confirmed by ECG trace as previously described (Fink, Alexander et al. 2004).  
Resuscitation was started by reconnecting the rat to the ventilator, administering epinephrine 
(0.005 mg/kg), IV and bicarbonate (1mEq/kg), IV and performing manual chest compressions 
for about one minute until restoration of spontaneous circulation (ROSC).  Halothane was not 
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resumed after asphyxiation based on prior documentation of a burst-suppression pattern on EEG 
during early recovery (Fink, Alexander et al. 2004).  Arterial blood gases and glucose 
measurements were taken prior to asphyxia and at the end of the re-warming phase.  Acidosis 
was corrected via bicarbonate replacement to maintain pH at 7.4.   
After ROSC, rats were either maintained at 37oC normothermia or body temperature was 
decreased to 30oC hypothermia over 30 minutes via surface cooling as depicted in Figure 11.  
Control rats core temperature was maintained at 37oC normothermia and received the same 
preparative surgery protocol without asphyxiation.   Rats remained hypothermic over the entire 3 
hour period after temperature stabilization.  Intensive care management was performed in all 
animals and included as needed doses of vecuronium, bicarbonate, and butorphanol.   
Rats were also randomized to one of two sacrifice time points, either 5 or 24 hrs after 
injury.  Rats randomized to the 5 hr sacrifice group were sacrificed via decapitation at which 
time liver tissue was excised for analysis.  Blood samples (0.3ml) were obtained from these rats 
via the left femoral venous cannula with a heparanized syringe at 60, 70, 90, 120, 180, 210, 240, 
270, and 285 minutes after injury for IL-6 and NO plasma concentration analysis.  Rats 
randomized to the 24 hr sacrifice group were gradually weaned from mechanical ventilation at 
the end of re-warming, extubated, and then returned to their cages.  Rats were then sacrificed 24 
hrs after injury via decapitation and liver tissue was excised for analysis. 
  
3.1.3 Microsomal Preparation 
Microsomes were prepared from liver tissue collected as previously described by Rockich et al 
(Rockich and Blouin 1999), via differential centrifugation in a Beckman L8-70 ultracentrifuge 
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(Beckman Instruments, Fullerton, CA).  Total protein was determined by Lowry et al. (Lowry, 
Rosebrough et al. 1951). 
3.1.4 CYP3A2 Enzyme Activity Analysis 
Rat liver microsomal incubations contained 400 µg microsomal protein, 1 mM NADPH and 
250µM of TST.  These samples were incubated for 10 minutes at 37oC in a circulating water 
bath.  The reaction was stopped by placing the samples on ice, followed by the addition of the 
internal standard, 11β-OH TST (50mcg/ml).  6β -OH TST was measured by a modified HPLC 
method described by Sonderfan et al. (Sonderfan, Arlotto et al. 1987). Briefly after the 
incubation and the addition of internal standard, 5 ml of dichloromethane was added to each 
sample.  The organic phase was transferred and evaporated to dryness under a stream of 
nitrogen.  Samples were then reconstituted with 200 µl of 50:50 methanol:ddH20.  Mobile phase 
A consisted of filtered ddH20 and Mobile phase B consisted of filtered methanol at a flow rate of 
1.2 ml/min and 20 µl was injected onto the HPLC system.  A gradient was established starting at 
50:50 methanol:ddH20 for 9 minutes, ramping over the next 3 minutes to 80:20 methanol:ddH20 
holding for 2 minutes, then ramping back to 50:50 methanol:ddH20 over 2 minutes.  6β-OH 
TST, 11β-OH TST, and TST were separated using a Nova Pak C-18 reverse phase (5µm, 3.9 X 
150mm) column (Waters, Millford, MA).  The HPLC system consisted of a Waters 2695 with a 
2487 UV detector, set at 254 nm.  The ratio of 6β -OH TST to 11β-OH TST was used for 
quantitative analysis.  The C.V. was less than 10% for this assay 
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3.1.5 CYP2E1 Enzyme Activity Analysis 
CYP2E1 enzyme activity analysis was similar as outlined in Chapter 2, subsection 2.2.5 with 
modifications.  Rat liver microsomal incubations contained 400 µg microsomal protein, 1 mM 
NADPH and 400µM of CZN.  These samples were incubated for 20 minutes at 37oC in a 
circulating water bath.  The reaction was stopped by adding 50 µl of 42.5% o-phosphoric acid, 
followed by the addition of the internal standard, umbelliferone (78µM).  6-OH CZN was 
measured by a modified HPLC method described by Rockich et al. (Rockich and Blouin 1999). 
Briefly, after the incubation and the addition of internal standard, 5 ml of diethyl ether was added 
to each sample.  The organic phase was transferred and evaporated to dryness under a stream of 
nitrogen.  Samples were then reconstituted with 200 µl of mobile phase A, consisting of 78% of 
a 0.25% acetic acid solution and 22% acetonitrile, and 20 µl was injected onto the HPLC system.  
Mobile phase B consisted of 95% acetonitrile and 5% of a 0.25% acetic acid solution and a 
gradient was established.  CZN, umbelliferone, and 6-OH CZN were separated using a Nova Pak 
C-18 reverse phase (5µm, 3.9 X 150mm) column (Waters, Millford, MA).  The HPLC system 
consisted of a Waters 2695 with a 2487 UV detector, set at 287 nm for CZN and 296 nm for 6-
OH CZN.  The ratio of CZN or 6-OH CZN to umbelliferone was used for quantitative analysis.  
The C.V. was less than 10% for this assay 
3.1.6 Northern Blot Analysis 
Total RNA was isolated from the liver of each rat using the TRIZOL method as previously 
described.  Total RNA (20µg) was fractionated by electrophoresis on a 1.1% agarose gel, 
followed by a transfer onto a nylon membrane.  Northern blots were hybridized with 32P-labeled 
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oligonucleotides for CYP3A2 (5’-CGACTTGGAACCCATAGA-3’), CYP2E1 (5’- 
CTCCTCGTCATATCCATCTG-3’), as previously reported (Caron, Rioux et al. 2005), HNF-4α 
(5’-TGACTACAGTGCTGCCTTGG-3’), HNF-1α (5’-GAGAGGTGGTAGCAATTC-3’), and 
GAPDH (5’-ATCCCGCTAACATCAAATGG-3’) as previously described (Podrig 2004).  Semi-
quantification was performed using a bio-imaging analyzer (Fluor-Chem).  
3.1.7 Analysis of Interleukin-6 Plasma Concetrations 
IL-6 concentrations were measured in the plasma of rats sacrificed 5 hours after injury using an 
enzyme linked immunosorbent assay (ELISA) kit specific for Rat IL-6 (R&D Systems, 
Minneapolis, MN).  Briefly, plasma samples (50 µL) was added to the assay diluent (50 µL) and 
incubated for 2 hrs at room temperature.   IL-6 conjugate (100 µL) was added to each well and 
incubated for an additional 2 hrs, followed by the addition of 100 µL of the substrate solution.  
The optical density was determined using a microplate reader set at 450 nm plus a correction at 
540 to 570 nm.       
3.1.8 Analysis of Nitrate and Nitrite Plasma Concentrations 
NO3 and NO2 concentrations were measured in the plasma of rats sacrificed 5 hrs after injury.  
Plasma (100µl) was treated with 100 µl of methanol and centrifuged at 8,000 rpm for 20 minutes.  
The supernatant of each sample was added to filter eppendorf tubes and then re-centrifuged at a 
speed of 14,000 rpm for 25 minutes.  The supernatant of each sample was injected (10µl) using a 
Waters 717 autosampler (Waters, Milford, MA) and detected using a ENO-20 NOx UV detector 
(EiCOM Corporation, San Diego).  Total nitrate/nitrite concentrations were measured by 
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reducing the nitrate to nitrite with an in-line reduction column and detected at 540 nm using the 
Griess reaction.   
 
3.1.9 Statistical Analysis 
For comparisons of physiological variables and IL-6, NO3 and NO2 plasma concentrations 
analysis over time, a two-way analysis of variance (ANOVA) for repeated measures with a 
Bonferroni correction was used to compare Control, CA normothermia, and CA hypothermia 
groups.  For comparisons of CYP2E1 and CYP3A2 activity and densiometric analysis of mRNA 
a one-way ANOVA with a Bonferroni correction was used to compared Control, CA 
normothermia, and CA hypothermia groups.  We considered p<0.05 to be statistically 
significant.  Data are presented as mean ± SD.  All analyses were conducted using the software 
program Prism (GraphPad Software, San Diego, CA).  
3.2 RESULTS 
3.2.1 Time Course of Hypothermia in Cardiac Arrest Treated Rats 
As depicted in Figure 11, Control and CA Normothermia rats were maintained at 37oC and CA 
Hypothermia rats were cooled to 30oC over 30 minutes and maintained for 3 hours followed by 1 
hour of re-warming. 
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3.2.2 Physiologic Variables Cardiac Arrest and Hypothermia Treated Rats 
Physiological parameters (MABP, blood pH, PaO2, PaCO2, and glucose) were measured (Table 
6) in Control, CA Normothermia, and CA Hypothermia groups.  The pre-CA/hypothermia 
measurements were drawn after preparative surgery and immediately prior to the initiation of 
CA.  The post-CA/hypothermia measurements were drawn in the acute-phase after injury and at 
the analogous time points in other experimental groups.  No differences in physiologic 
parameters measured between all 3 groups before CA.  However, post-CA/hypothermia 
parameters demonstrate that CA Normothermia and CA Hypothermia  groups have an 
anticipated significant increase in PaO2 and decrease in PaCO2, when compared to pre-
CA/hypothermia parameters (***p<0.01) (Fink, Alexander et al. 2004).  Furthermore, post-
CA/hypothermia values of PaO2 and PaCO2 in CA Normothermia and CA Hypothermia groups 
were significantly different from the Control group (***p<0.001).  There were no other 
differences between groups. 
 
 
 
 
 
 
 
 
 
 
Figure 11: Time-course of rectal temperature beginning 15 minutes after asphyxial arrest   
 
Control  and CA Normothermia rats were maintained at 37oC, and CA  Hypothermia rats were 
 maintained at 30oC for 3 hrs followed by 1 hr re-warming   
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3.2.3 Effect of Cardiac Arrest and Hypothermia on 6β-hydroxytestosterone Formation 
 Rate in Rat Liver 5 and 24 Hours After Injury 
Figure 12, Panel A depicts the formation rate of 6β-OH TST in liver microsomes from the 3 
treatments groups, Control, CA Normothermia, and CA Hypothermia (n=6) in rats sacrificed in 
the acute phase, 5 hrs after injury.  6β-OH TST formation rate showed no difference between 
Control (2388 ± 513 pmol/mg/min), CA Normothermia (2374 ± 299 pmol/mg/min), and CA 
Hypothermia (2521 ± 689 pmol/mg/min) groups.  Figure 12, Panel B depicts the formation rate 
of 6β-OH TST in liver microsomes from the 3 treatment groups, (n=6) in rats sacrificed in the 
sub-acute phase, 24 hrs after injury.  6β-OH TST formation rate was significantly decreased in 
the CA Normothermia rats compared to Control rats (1484 ± 942.9 pmol/mg/min vs. 3174 ± 
Table 6: Physiological variables in rats 
Experimental Group Pre-CA/hypothermia Post-CA/hypothermia
MABP (mmHg) Control 98.58 ± 8.55 102.8 ± 13.7
CA Normothermia 105.0 ±  13.7 122.5 ±  20.1
CA Hypothermia 105.8 ± 8.49 111.7 ±  34.5
pH Control 7.37 ± 0.022 7.36 ± 0.077
CA Normothermia 7.38 ±  0.032 7.39 ±  0.047
CA Hypothermia 7.38 ±  0.19 7.37 ±  0.085
PaCO2 (mmHg) Control 39.93 ± 3.84 39.85 ± 7.83
CA Normothermia 38.16 ±  2.55 25.22 ±  6.89
CA Hypothermia 38.50 ± 3.50 21.81± 5.71
PaO2 (mmHg) Control 244.4 ± 15.7 227.38 ± 58.7
CA Normothermia 236.3 ±  25.8 417.54 ±  76.2
CA Hypothermia 234.4 ± 38.1 463.54 ± 67.4
Glucose (mg/dL) Control 114.5 ± 20.2 121.9 ± 27.1
CA Normothermia 120.6 ±  32.5 108.5 ±  24.4
CA Hypothermia 116.3 ±  16.9 136.5 ± 28.2
***,‡‡‡
***,‡‡‡
***,‡‡‡
***,‡‡‡
Abbreviations: MABP, mean arterial blood pressure; PaCO2, pressure of carbon dioxide; 
PaO2, pressure of oxygen 
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965.4 pmol/mg/min;*p<0.05, respectively).  6β-OH TST formation rate (4345 ± 1198 
pmol/mg/min) was not significantly different between CA Hypothermia and Control rats, 
however a significant difference was observed between CA Hypothermia and CA Normothermia 
rats; ‡p<0.05. 
 
3.2.4 Effect of Cardiac Arrest and Hypothermia on CYP3A2 mRNA Expression in Rat 
Liver 5 and 24 Hours After Injury 
Rats sacrificed in the acute phase, 5 hrs after injury in all three groups (Control, CA 
Normothermia, and CA Hypothermia) demonstrated no difference in CYP3A2 mRNA expression 
as shown in Figure 13, Panel A.  There was no difference in band density between groups 
(Figure 13, Panel B; n=6).   However, significant differences were observed in the sub-acute 
phase, 24 hrs after injury, demonstrating a decrease in CA Normothermia group in CYP3A2 
mRNA expression compared to both Control and CA Hypothermia as depicted in Figure 13, 
Panel C.  Figure 13, Panel D (n=6), demonstrates a significant difference in the band density of 
CYP3A2 mRNA expression in the CA Normothermia rats (*p<0.05), compared to Control rats.  
Furthermore, no difference was observed in the sub-acute phase, 24 hrs after injury in the CA 
Hypothermia rats compared to Control rats.   
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3.2.5 Effect of Cardiac Arrest and Hypothermia on 6-hydroxychlorzoxazone Formation 
Rate in Rat Liver 5 and 24 Hours After Injury 
Figure 14, Panel A depicts the formation rate of 6-OH CZN in liver microsomes from the 3 
treatments groups, Control, CA Normothermia, and CA Hypothermia (n=6) in rats sacrificed 
acute phase, 5 hrs after injury.  No significant difference in 6-OH CZN formation rate was 
observed between Control (1.59 ± 0.34 nmol/mg/min), CA Normothermia (1.62 ± 0.31 
nmol/mg/min), and CA Hypothermia (1.73 ± 0.36 nmol/mg/min) groups.  Figure 14, Panel B 
depicts the formation rate of 6-OH CZN in liver microsomes from the 3 treatment groups, (n=6) 
in rats sacrificed in the sub-acute phase, 24 hrs after injury.  CA Normothermia showed a 
significant decrease in 6-OH CZN formation rate compared to Control (0.472 ± 0.11 
nmol/mg/min versus 0.931 ± 0.144 nmol/mg/min;p<0.05, respectively).  6-OH CZN formation 
rate was not significantly different between CA Hypothermia and Control rats, however a 
significant difference was observed between CA Hypothermia and CA Normothermia rats; 
‡p<0.05. 
3.2.6 Effect of Cardiac Arrest and Hypothermia on CYP2E1 mRNA Expression in Rat 
Liver at 5 and 24 Hours After Injury 
Rats sacrificed in the acute phase, 5 hrs after injury in all three groups (Control, CA 
Normothermia, and CA Hypothermia) demonstrated no difference in CYP2E1 mRNA expression 
as shown in Figure 15, Panel A & B (n=6).  A trend towards a decrease in CYP2E1 mRNA 
expression was observed in the sub-acute phase, 24 hrs after injury between CA Normothermia 
as compared to the Control and CA Hypothermia; Figure 15, Panel C.  However, these 
differences in density were not statistically significant as depicted in Figure 15, Panel D (n=6).   
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 Figure 12: CYP3A2 activity in rat liver microsomes 
 
 Panel A depicts 6β-hydroxytestosterone formation rate in rats sacrificed 5 hrs 
after injury.  Data demonstrates no differences were observed between Control 
(2388 ± 513 pmol/mg/min), CA Normothermia (2374 ± 299 pmol/mg/min, and 
CA Hypothermia (2521 ± 689 pmol/mg/min).  Panel B depicts 6β-
hydroxytestosterone formation rate in rats sacrificed 24 hrs after injury.  Data 
demonstrates that activity in CA Normothermia (1484 ± 942 pmol/mg/min) 
was significantly decreased compared to both Control (3174 ± 965.4;*p<0.05) 
and CA Hypothermia (4345 ± 1198; ‡p<0.05) rats. All data are presented as 
mean ± SD   
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 Figure 13: CYP3A2 mRNA expression in rat liver  
 
 Panel A depicts CYP3A2 mRNA expression 5 hrs after injury in all 3 groups.  Data demonstrates no 
difference between groups, as shown upon densitometric analysis in Panel B.  Panel C depicts CYP3A2 
mRNA expression 24 hrs after injury in all 3 groups.  Data demonstrates a significant decrease CYP3A2 
relative hepatic expression in the CA Normothermia rats compared to Control and CA Hypothermia, as 
shown upon densitometric analysis in Panel D;p<0.05. All data are presented as mean ± SD 
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 Figure 14: CYP2E1 activity in rat liver microsomes. 
 
 Panel A depicts 6-hydroxychlorzoxazone formation rate in rats sacrificed 5 hrs 
after injury.  Data demonstrates no differences were observed between Control 
(1.59 ±  0.34 nmol/mg/min), CA Normothermia (1.62 ± 0.31 nmol/mg/min, and 
CA Hypothermia (1.73 ± 0.36 nmol/mg/min).  Panel B depicts 6-
hydroxychlorzoxazone formation rate in rats sacrificed 24 hrs after injury.  Data 
demonstrates that activity in CA Normothermia (0.472 ± 0.11 nmol/mg/min) 
was significantly decreased compared to both Control (0.931 ± 0.14 
nmol/mg/min;*p<0.05) and CA Hypothermia (0.931 ± 0.36 nmol/mg/min; 
‡p<0.05) rats.  All data are presented as mean ± SD   
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3.2.7 Effect of Cardiac Arrest and Hypothermia on IL-6 Plasma Concentrations 
Figure 15 depicts the time-course of plasma concentrations of IL-6 in 3 groups, Control, CA 
normothermia, and CA hypothermia; n=6 after injury.   CA normothermia produced significant 
increases in IL-6 concentrations compared to control 60, 70, and 90 minutes after 
injury;***p<0.001.   After 90 minutes post-injury, IL-6 plasma concentrations returned to levels 
comparable to the Control group and were maintained throughout the rest of the study.  
Figure 15: CYP2E1 mRNA expression in rat liver 
 
Panel A  depicts CYP2E1 mRNA expression 5 hrs after injury in all 3 groups.  Data demonstrates no difference between 
 groups, as shown upon densitometric analysis in Panel B.  Panel C depicts CYP2E1 mRNA expression 24 hrs after injury 
 in all 3  groups.  Data demonstrates a trend  towards a decrease CYP2E1 relative hepatic expression in the CA 
 Normothermia rats compared to Control and CA Hypothermia, but did not reach significance as shown upon 
 densitometric analysis in Panel D.  All data are presented as mean ± SD 
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Interestingly, when hypothermia was applied in the CA model, IL-6 levels demonstrated no 
difference compared to Control animals at all time points.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 16: Plasma interleukin-6 (IL-6) plasma concentrations 
 
 Data demonstrates that in CA Normothermia there were significant increases in IL-6 plasma 
concentrations at 60, 70, and 90 minutes after injury, compared to Control (***p<0.001) and CA 
Hypothermia (‡‡‡p<0.001).  All data are presented as mean ± SD.   
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3.2.8 Effect of Cardiac Arrest and Hypothermia on NO2 and NO3 Concentrations in Rat 
Plasma 
Figure 17A and 17B depicts a time course of NO2 and NO3 concetrations in rat plasma in all 3 
groups; Control, CA normothermia, and CA hypothermia, n=6.  A trend towards an increase was 
observed in the CA Normothermia rats; however this did not reach significance.  No differences 
in NO2 were observed between groups at all time points.   
3.2.9 Effect of Cardiac Arrest and Hypothermia on HNF-4α Expresssion in Rat Liver 24 
Hours After Injury 
Significant differences were observed in the sub-acute phase, 24 hrs after injury, demonstrating a 
significant decrease in CA Normothermia group in HNF-4α mRNA expression compared to both 
Control and CA Hypothermia as depicted in Figure 18, Panel A.  Figure 18, Panel B (n=6), 
demonstrates a significant difference in the band density of HNF-4α mRNA expression in the 
CA Normothermia rats, compared to Control (***p<0.001) and CA Hypothermia (‡p<0.05) rats.  
Furthermore, no difference was observed in the sub-acute phase, 24 hrs after injury in the CA 
Hypothermia rats compared to Control rats.   
3.2.10 Effect of Cardiac Arrest and Hypothermia on HNF-1α Expresssion in Rat Liver 24 
Hours After Injury 
There were no differences observed in the sub-acute phase, 24 hrs after injury, in HNF-1α 
mRNA expression in all three groups as depicted in Figure 19, Panel A.  Figure 19, Panel B 
(n=6), demonstrates no difference in the band density of HNF-1α mRNA expression in all three 
groups. 
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3.3 DISCUSSION 
Our results demonstrate four major findings.  First, CA produces a significant decrease in the 
hepatic activity of CYP3A2 and CYP2E1 in rats, in the sub-acute phase, 24 hrs after injury 
compared to Control rats.  Second, there is an increase in IL-6 plasma concentrations early after 
CA.  IL-6 is known to decrease CYP3A2 and CYP2E1 expression.  Third, CA produced a 
decrease in the expression of the constitutive transcription factor, HNF-4α, 24 hrs after injury, 
but did not change the expression of HNF-1α.  Fourth, moderate hypothermia applied to CA rats, 
prevented both the transcriptional down-regulation of CYP3A2 and CYP2E1-metabolism and 
blocked the early increase in IL-6 seen after CA Normothermia.  These findings suggest that by 
blocking the inflammatory response to tissue injuries after CA, hypothermia may favorably alter 
the natural course of disease and normalize CYP450-mediated drug metabolism.    
CA produces a decrease in hepatic activity and expression of CYP3A2 and CYP2E1 in 
Rat Liver in the sub-acute phase, 24 hrs after injury.  CA produces a significant decrease in the 
activity of both CYP3A2 and CYP2E1 in the sub-acute phase, 24 hours after injury.  
Furthermore, we demonstrated that this decrease in activity was paralleled by a decrease in 
CYP3A2 mRNA, whereas, significant changes in CYP2E1 mRNA were not observed.  This is the 
first investigation which has specifically identified the 
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Figure 17: Nitrate and nitrite plasma concentrations 
 
Panel A: Plasma nitrate (NO3) concentrations in all three groups, Control, CA Normothermia, 
 and CA Hypothermia after injury.  A trend towards an increase was observed in the CA 
 Normothermia rats; however this did not reach significance.  Panel B: Plasma nitrite (NO2) 
 concentrations in all three groups, Control, CA Normothermia, and CA Hypothermia after 
 injury.  No differences were observed between groups at all time-points.   All data are presented 
 as mean ± SD.   
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Figure 18: HNF-4α expression in rat liver 
 
Data shows a significant decrease in CA Normothermia rats 24 hours after injury 
 in HNF-4α expression compared to Control (p<0.001) and CA Hypothermia 
 (p<0.05) after densitometric analysis.  No difference was observed between 
 Control and CA Hypothermia rats.  
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Figure 19: HNF-1α expression in rat liver 
No difference was observed between all 3 groups in HNF-1α expression, 24 
 hours after injury.  
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effects of CA injury on CYP450-mediated metabolism; however studies have shown that in other 
models of ischemic injury, such as TBI, decreases in the expression and activity of multiple 
CYP450 isoforms are evident (Toler, Young et al. 1993; Boucher and Hanes 1998; Kalsotra, 
Turman et al. 2003).  Toler et al, showed that in TBI rats, hepatic CYP2C11 and CYP3A mRNA 
expression were decreased ~50% of control, 24-hours after injury.  Interestingly, they 
demonstrated no difference in hepatic activity of either isoform, 24 or 48 hours after injury 
(Toler et al., 2003).  Kalsotra et al showed that after TBI, rats demonstrated no difference in 
hepatic CYP3A protein and activity 24 hrs after injury, but showed a dramatic increase in both 
hepatic activity and protein content 2 weeks after injury (Kalsotra, Turman et al. 2003).   Poloyac 
et al demonstrated that there was no change in the hepatic activity of CYP2E1, 24 hrs after TBI 
in rats (Poloyac, Perez et al. 2001).  Unlike TBI, CA is a global ischemic event to the entire 
organism and therefore, may elicit a greater systemic acute phase response, potentially resulting 
in greater effects on hepatic CYP450-mediated metabolism (Oppert, Gleiter et al. 1999; 
Wilcockson, Campbell et al. 2002).  Compared to Control, our CA rat model demonstrated a 
reduction of ~55% in CYP2E1 activity and 47% in CYP3A2 activity.  Collectively, these studies 
suggest that ischemic and traumatic injuries, such as CA and TBI, down-regulate CYP450 
activity and expression in the sub-acute phase, 24 hrs after injury.  
CA produces increases in IL-6 plasma concentrations after injury.  CA produces a potent 
acute phase response (Oppert, Gleiter et al. 1999).  We found that CA produced a ~10-fold 
increase in IL-6 plasma concentrations at 60, 70, and 90 minutes after injury compared to 
Control.  IL-6 mediates the majority of the hepatic alterations of the acute phase response and is 
most potent inhibitor of CYP450s of all the pro-inflammatory cytokines (Hakkola, Hu et al. 
2003).  Other models of ischemic injury have shown that increased plasma concentrations of IL-
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6 after injury is associated with a decreased activity of CYP450 isoforms (Toler, Young et al. 
1993).  Supporting cause and effect, the addition of IL-6 to hepatocytes decreases the mRNA 
expression of both CYP2E1 and CYP3A2 (Abdel-Razzak, Loyer et al. 1993).  The mechanism of 
the decreases in CYP450 activity have been shown to be due to a cytokine-mediated down-
regulation in the transcription of CYP450 isoforms (Abdel-Razzak, Loyer et al. 1993; Toler, 
Young et al. 1993; Hakkola, Hu et al. 2003).  In addition, our data demonstrates that CA did not 
produce a significant increase in both NO2 and NO3 early after injury.  It has been well 
established that NO production increases after injury in models of ischemia and endotoxemia, 
and has been shown to suppress CYP450 functional activity (Carlson and Billings 1996; 
Khatsenko and Kikkawa 1997).  Interestingly, these studies show that peak production of NO is 
~ 24-48 hrs after ischemia or LPS injection.  It is possible that our results do not show a 
difference because we analyzed plasma at the early time-points (1-3 hrs) after CA.  However, 
this does not rule out the role of NO on the decrease in CYP activity we observed.  Collectively, 
our results suggest that cytokine alterations after a global ischemic insult may produce a 
reduction in the functional regulation of CYP3A2.  
CA decreases the expression of the constitutive transcription factor, HNF-4.  Our data 
demonstrates a decrease in the expression of HNF-4α, 24 hrs after CA compared to Control.  
However, we did not observe any change in the expression of HNF-1α, 24 hrs after CA 
compared to Control.  HNF-4α and HNF-1α have both been shown to constitutively regulate 
CYP3A2 and CYP2E1, respectively (Miyata, Nagata et al. 1995; Roe, Poloyac et al. 2001).  
Mizuguchi et al determined that the addition of IL-6 to rat hepatocytes decreased the expression 
of HNF-4, however did not affect the expression of HNF-1α (Mizuguchi, Mitaka et al. 1998).  
Other studies have supported this finding, demonstrating that IL-6 is not involved in the 
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reduction of HNF-1α binding (Green, Beier et al. 1996; Trauner, Arrese et al. 1998).   Therefore, 
the reduction in the activity of CYP2E1 24 hrs after injury cannot be explained by changes in 
transcriptional regulation.  Although other cytokines, such as IL-1β and TNF-α, may be 
important inflammatory mediators after CA, our data lends evidence to the finding that the 
production in IL-6 after injury is followed by a decrease in the expression of HNF-4α, 24 hrs 
after injury.  Collectively, these results propose a potential mechanism in the down-regulation of 
CYP3A2 after CA.    
Moderate hypothermia provides a protective effect on CYP3A2 and CYP2E1 activity and 
expression.  When rats were treated with moderate hypothermia after CA, we observed no 
difference in the activity and expression of both CYP3A2 and CYP2E1 compared to Control.  
Few studies have been conducted to evaluate the effect of hypothermia on CYP regulation.  
However, a clinical study that provides insight into these effects was performed by Iida, Nishi et 
al. (2001).  This study investigated the both the acute and chronic effects of mild hypothermia in 
TBI patients on phenytoin pharmacokinetics.  Phenytoin is metabolized primarily through the 
CYP2C9 and CYP2C19 isoforms.  Acutely, hypothermia decreases the ClS of phenytoin; 
however, after the patients core temperature was returned to normothermic temperatures, the ClS 
of phenytoin was returned to normal.  Our laboratory has demonstrated that during cooling, 
moderate hypothermia decreases the ClS ~2-fold, of the CYP2E1 probe substrate, CZN 
(Tortorici, Kochanek et al. 2006).  Hypothermia has been shown to attenuate the release of 
certain pro-inflammatory cytokines after TBI and hemorrhagic shock in rats, which may play a 
role for the protection incurred by hypothermia in our model (Gundersen, Vaagenes et al. 2001).  
Our data supports these studies, as we showed that the application of moderate hypothermia in a 
CA rat model prevented the increase in IL-6 concentrations we observed in CA Normothermia 
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rats.  Collectively, these data show that hypothermia applied to ischemic injury models, 
normalizes drug metabolism in the sub-acute phase after injury.  This suggests that after various 
insults such as CA, hypothermia may inhibit drug metabolism during cooling, but that the 
benefits of moderate hypothermia on tissue injury and inflammation may favorably alter the 
pathogenic processes of the disease, thereby ultimately normalizing drug metabolism. 
Limitations. There are several limitations of our study.  First, we investigated the 
effects of CA and hypothermia on CYP3A2 and CYP2E1 metabolism at two time-points after 
injury, 5 and 24- hours.  Animal models of inflammation have demonstrated changes in CYP450 
expression due to the acute phase response at multiple time-points after LPS administration (Roe, 
Poloyac et al. 2001; Cheng, Wang et al. 2003).  Although we chose relevant time-points, a 
complete time-course of alterations in CYP450 activity and expression after CA injury and 
hypothermia is necessary for a full understanding of these alterations. This could have substantial 
importance to clinical application since cooling is induced for 12-24 hrs (Bernard, Gray et al. 
2002).  Second, we investigated one pro-inflammatory cytokine, (IL-6), due to the fact that it is 
thought to be the most important mediator of hepatic changes of the acute phase response 
(Ramadori and Christ 1999).  Other cytokines, such as IL-1β and TNF-α have also been shown 
to contribute importantly to the down-regulation of CYP450 enzymes (Hakkola, Hu et al. 2003).  
In addition, we showed no difference in NO plasma concentrations in CA rats at early time 
points after injury.  As mentioned above, NO production peaks between 24-48 hrs after ischemic 
injury making it possible that we did not characterize a change which may contribute importantly 
to the decrease in CYP3A2 and CYP2E1 activity (Khatsenko and Kikkawa 1997).  Further 
investigation of multiple cytokines and NO concentrations at multiple time-points after CA will 
provide a greater understanding of the multiple factors resulting from this global ischemic injury.  
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Lastly, although our data are consistent with results other models of inflammation on CYP450 
alterations, future studies are needed to fully elucidate the effects of CA on CYP450 metabolism 
and the protective effects of therapeutic hypothermia.  
3.4 CONCLUSION 
This study shows that after CA, a decrease in both the hepatic activity and expression of 
CYP3A2 and CYP2E1 isoforms in the sub-acute phase, 24 hrs after CA as compared to Control.   
A potential mechanism is via an IL-6-mediated down-regulation of the expression of HNF-4α 
resulting in a decrease in CYP3A2 transcription.  In addition, no difference was observed in the 
early production after injury of NO2 and NO3 in CA-rats compared to Control.  Furthermore, the 
use of moderate therapeutic hypothermia attenuated the CA-mediated decrease in CYP3A2 and 
CYP2E1 activity.  These data suggest that hypothermia is mitigating potential tissue damage in 
organs involved in drug metabolism in the sub-acute phase after injury.  Future studies will 
provide greater insight into the time-course of these alterations as well as other mechanisms 
behind the changes observed in this study.  Although controlled clinical trials need to be 
employed in order to fully understand the effects of hypothermic therapy on the disposition of 
medications in the CA patient population, these data imply that clinically significant 
hypothermia-drug interactions are a likely factor to consider in the therapeutic course of these 
patients. 
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4.0  CHAPTER 4 
 
 
 
Mild and moderate hypothermia alters CYP2E1 and CYP3A4 enzyme kinetics in human 
hepatic microsomes  
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INTRODUCTION 
 
 
 
 
In Chapter 2, we showed that hypothermia produces a significant decrease in the ClS of the 
CYP2E1 substrate CZN, in CA rats under hypothermic temperatures vs. CA rats maintained 
under normothermic temperatures (Tortorici, Kochanek et al. 2006).  Furthermore, we 
demonstrated that the mechanism of this decrease in the ClS of CZN was a decrease in the 
affinity of CYP2E1 for CZN.  This work also investigated the application of using in vitro-in 
vivo scaling techniques to accurately predict hypothermia-mediated in vivo alterations from an in 
vitro enzyme kinetic analysis using rat liver microsomes.  This work showed that we could 
predict the ~2-fold decrease in the ClS of CZN observed in the CA rat from in vitro enzyme 
kinetic analysis.  Therefore, we set out to expand upon these results in order to identify the 
effects of mild and moderate hypothermia on CYP450-mediated metabolism in human liver 
microsomes using in vitro techniques to predict potential changes in patients during 
hypothermia.  The objectives of this study were to evaluate the effects of hypothermia on the in 
vitro enzyme kinetics of CYP2E1 and CYP3A4 using CZN and testosterone (TST) as probe 
substrates, respectively, in 1) pooled human liver microsomes and 2) individual human liver 
microsomes.   
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4.1 METHODS 
4.1.1 Materials and Chemicals 
Pooled human liver microsomes were purchased from XenoTech (Lenexa, KS) with a sample 
number of 50 donors per batch.  Chlorzoxazone (CZN), 6-hydroxychlorzoxazone (6-OH CZN), 
umbelliferone, testosterone (TST) were purchased from Sigma Aldrich (St Louis, MO.)   6β-
hydroxytestosterone (6β-OH TST) and 11β-hydroxytestosterone (11β-OH TST) were purchased 
from Steraloids (Newport,RI).  Organic solvents were purchased from Fisher Scientific 
(Pittsburgh, PA).  All other chemicals were purchased from Sigma Aldrich (St. Louis, MO) 
unless otherwise specified. 
4.1.2 Individual Human Liver Microsomal Preparation 
Liver tissue was collected from 4 human liver donors and microsomes were prepared as 
previously described by Rockich and Blouin (1999) via differential centrifugation in a Beckman 
L8-70 ultracentrifuge (Beckman Instruments, Fullerton, CA).  Livers were obtained from donors 
who had consented for use of liver tissue for research purposes.  IRB approval for use of tissue 
for in vitro studies was also obtained by the University of Pittsburgh IRB.  Total protein 
concentration was determined as described by (Lowry, Rosebrough et al. 1951).  
4.1.3 CYP2E1 Kinetic Analysis 
Pooled and individual human liver microsomes were used in these experiments and analysis was 
performed as outlined in Chapter 2 with some modifications. Briefly, microsomal incubations 
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contained 400 µg microsomal protein and 1 mM NADPH.  CZN was added to microsomal 
samples in increasing concentrations of 50, 75, 100, 200, 300, 400, and 500 µM.  These samples 
(n= 6 for pooled human hepatic microsomes and n=4 for individual human hepatic microsomes) 
were incubated for 20 minutes at 37oC, 33oC, or 30oC in a circulating water bath.  The reaction 
was stopped by adding 50 µl of 42.5% o-phosphoric acid, followed by the addition of the internal 
standard, umbelliferone (78µM).   
6-OH CZN was measured by a modified HPLC method described by Rockich and Blouin 
as described in Chapter 2, subsection 2.1.3 (Rockich and Blouin 1999).  Briefly, after the 
incubation and the addition of internal standard, 5 ml of diethyl ether was added to each sample.  
The organic phase was transferred and evaporated to dryness under a stream of nitrogen.  
Samples were then reconstituted with 200 µl of mobile phase A, consisting of 78% of a 0.25% 
acetic acid solution and 22% acetonitrile, and 20 µl was injected onto the HPLC system.  Mobile 
phase B consisted of 95% acetonitrile and 5% of a 0.25% acetic acid solution and a gradient was 
established.  Chlorzoxazone, umbelliferone, and 6-OH CZN were separated using a Nova Pak C-
18 reverse phase (5µm, 3.9 X 150mm) column (Waters, Millford, MA).  The HPLC system 
consisted of a Waters 2695 with a 2487 UV detector, set at 287 nm for CZN and 296 nm for 6-
OH CZN.  The ratio of 6-OH CZN to umbelliferone was used for quantitative analysis.  The 
C.V. was less than 10% for this assay 
4.1.4 CYP3A4 Enzyme Kinetic Analysis 
Pooled and individual human liver microsomes were used in these experiments.  Microsomal 
incubations contained 400 µg microsomal protein and 1 mM NADPH.  Testosterone was added 
to microsomal samples in increasing concentrations of 6.25, 12.5, 25, 50, 75, 100, 150, 200, and 
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250 µM.  These samples (n= 6 for pooled human hepatic microsomes and n=4 for individual 
human hepatic microsomes) were incubated for 10 minutes at 37oC, 33oC, or 30oC in a 
circulating water bath.  The reaction was stopped by placing the samples on ice, followed by the 
addition of the internal standard, 11β-OH TST (12.5 µM).   
6β-OH TST was measured by a modified HPLC method described by Sonderfan et al, as 
previously mentioned in Chapter 3, subsection 3.1.4 (Sonderfan, Arlotto et al. 1987).  Briefly 
after the incubation and the addition of internal standard, 5 ml of dichloromethane was added to 
each sample.  The organic phase was transferred and evaporated to dryness under a stream of 
nitrogen.  Samples were then reconstituted with 200 µl of 50:50 methanol: ddH20.  Mobile phase 
A consisted of filtered ddH20 and Mobile phase B consisted of filtered methanol at a flow rate of 
1.2 ml/min and 20 µl was injected onto the HPLC system.  6β-OH TST, 11β-OH TST, and TST 
were separated using a Nova Pak C-18 reverse phase (5µm, 3.9 X 150mm) column (Waters, 
Millford, MA).  The HPLC system consisted of a Waters 2695 with a 2487 UV detector, set at 
254 nm.  The ratio of 6β -OH TST to 11β-OH TST was used for quantitative analysis.  The C.V. 
was less than 10% for this assay  
4.1.5 CYP2E1 and CYP3A4 Enzyme Kinetic Analysis 
A formal Michaelis-Menten kinetic analysis was performed from the formation rates of 6-OH 
CZN and 6β-OH TST using WinNonlin version 4.1 (Pharsight Corp, Mountain View, CA).  
Maximum velocity (Vmax) and Michaelis-Menten constant (Km) were calculated via non-linear 
regression of the raw data.  The data was then linearized for visual inspection, via an Eadie-
Hofstee plot.  
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The classic Michaelis-Menten equation was used for CYP2E1 pooled and individual 
human liver microsomal analysis: 
 
            (1) 
 
where v is the velocity and [S] is the substrate concentration.  The in vitro Clint for CYP2E1 was 
calculated using the equation: 
 
                           (2) 
 
For CYP3A4 pooled microsomal analysis the following equation was used due to the 
sigmoidal shape of the saturation curves (Houston and Kenworthy 2000): 
                          (3)                      
 
where n is the Hill coefficient.  For sigmoidal models, CLintmax was calculated using the 
following equation as described by Houston and Kenworthy (Houston and Kenworthy 2000): 
            
             (4) 
 
   
The analysis of CYP3A4 and CYP2E1 from individual human liver donors utilized a 
nonlinear mixed effects modeling approach (as implemented in NONMEM®) to obtain the Vmax 
and Km parameters for each human liver donor.  This approach preserved the within and between 
Vmax X [S]
Km + [S]
V =
Vmax * [S]n
(Km + [S])n
V=
Vmax
Km
Clint=
Vmax
Km
(n-1)
n(n-1)1/nX
Clintmax =
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individual variance present in this longitudinal measurement data across the assessed 
temperatures.  The nonlinear mixed effects modeling approach utilizes every data point to 
determine a population “average” and variance for the group and simultaneously determines 
individual specific estimate of parameters based on these population characteristics.  Therefore, 
balance in the groups is not as critical (weighting across individual contributions to this model is 
based on the data contributed as well as the informativeness of the data to a particular 
parameter).  In this approach, a population average and variance that in the case of the 
exponential model comprised a population average Vmax and Km and their variance between 
individuals in this group.  Initially, the model did not account for temperature and lumped 
estimates were determined.  Subsequent to this, each temperature was tested as a covariate in the 
model to examine whether or not that temperature had improved the description of the data 
significantly.  The effect on the statistical fitness of the model was determined by the change in 
the Objective Function returned by NONMEM (see statistical section below for detail).   
The in vitro Clint or Clintmax was used to estimate the in vivo ClS in a human for CYP2E1 
and CYP3A4 as described by (Obach, Baxter et al. 1997).  The following equation explains the 
predicted in vivo parameters from in vitro estimates:  
    (5) 
 
Where Clint’ is the estimated in vivo intrinsic clearance.  The estimated ClS was then 
calculated by multiplying the Clint’ and the fraction unbound (fu). All results are given as means 
± S.D. 
Clint X
mg microsomal protein
X
gram liver
liver weight (g)
body weight (kg)
X
incubation volume (ml)
mg microsomal protein 
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4.1.6 Statistical Analysis 
For analysis of pooled human microsomal data a one-way ANOVA with a Tukey’s post hoc test 
was utilized.  For individual human liver microsomal data, the threshold for determining the 
significance was based on the Objective Function returned by the NONMEM program.  This 
Objective Function approximates -2 times the log likelihood and thus provides a means of 
statistically comparing the temperature effects across models.  The difference in this term 
between nested models approximates a χ2 distribution (Edwards 1972).  A change in the 
objective function of at least 3.84 for 1 degree of freedom (i.e., one change in a model versus 
another for nested models) was used as a threshold for determining statistical significance at the 
α=0.05 level when using the first-order conditional estimation algorithm with interaction. 
Data are presented as mean ± S.D.  All non-NONMEM analyses were conducted using 
the software program Prism (GraphPad Software, San Diego, CA). 
4.2 RESULTS 
4.2.1 Effect of Temperature on CYP2E1 Enzyme Kinetics in Pooled Human Liver 
Microsomes 
As shown in Table 7, there were significant decreases in the Vmax of CZN in microsomes 
incubated at both 33oC (1.37 ± 0.152 nmol/mg/min;***p<0.001), and 30oC (1.86 ± 0.456 
nmol/mg/min;*p<0.05) when compared to 37oC (2.41 ± 0.245 nmol/mg/min).  There was also a 
significant decrease in the Vmax of CZN between microsomes incubated at 33oC compared to 
30oC; ‡p<0.05.  Table 7 also shows that the Km of CYP2E1 showed no difference in microsomes 
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incubated at 37oC and 33o, 80.6 ± 23.6 µM and 85.4 ± 18.5 µM, respectively.  However, when 
human liver microsomes were incubated at 30oC, the Km was significantly increased, 159 ± 48.2 
µM; **,‡‡p<0.01, when compared to both 37oC and 33oC.  These results are more easily 
visualized in an Eadie-Hofstee plot depicted in Figure 20, Panel B.  These parameters were used 
to calculate Clint using Equation 2 and data demonstrated a decrease in the Clint of CYP2E1 at 
33oC (0.0164 ± 0.00206 ml/min/mg protein; ***p<0.001) and 30oC (0.0128 ± 0.00534 
ml/min/mg protein;***p<0.001), when compared to 37oC (0.0314 ± 0.00715 ml/min/mg 
protein).  After performing an in vitro-in vivo correlation, using Equation 5, the estimated ClS of 
CZN was 531.07 ± 120 ml/min at 37oC and significantly decreased at 33oC (276.74 ± 34 
ml/min;***p<0.001) and 30oC (215.65 ± 90;***p<0.001). 
4.2.2   Effect of Temperature on CYP2E1 Enzyme Kinetics in Human Liver Microsomes 
from Individual Liver Donors 
Each individual human liver microsome incubated at the 3 different temperatures showed a rank 
order decrease from 37oC to 33oC to 30oC in the Clint of CYP2E1 as depicted in Figure 21.   
Each individual demonstrated a decrease in Clint of CZN at 33oC (22.95 ± 0.001% of 37oC) and  
 
 
 
 
 
 
Table 7: CYP2E1 enzyme kinetic parameter estimates in pooled human liver microsomes incubated at 37oC, 33oC, or 30oC 
* = statistically significant compared to 37oC 
‡ = statistically significant differences between 33oC and 30oC 
 
Abbreviations: Vmax, maximal velocity; Km, Michaelis-Menten constant; Clint, intrinsic clearance 
 37 Degrees 33 Degrees 30 Degrees
Vmax (nmol/mg/min) 2.41 ± 0.25 1.37 ± 0.15 1.86 ± 0.46
Km (uM) 80.59 ± 23 85.36 ± 18 159.35 ± 48
Clint (ml/min/mg protein) 0.031 ± 0.0072 0.016 ± 0.0021 0.013 ± 0.0053
Cls estimated (ml/min) 531.07 ± 120 276.74 ± 34 215.65 ± 90
p<0.05 *, ‡ p< 0.01**, ‡‡, p<0.001 ***
***,‡ *
**, ‡‡
*** ***
*** ***
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30oC (55.67 ± 0.001% of 37oC).  The individual estimates here were taken from the Bayesian 
estimates returned from the NONMEM model using the FOCE option.  The population estimates 
for Vmax demonstrate a significant decrease at 30oC, (0.697 nmol/mg/min, 36.3% standard error 
(se); p<0.0001, chi-square test, df=2) compared to 33oC (0.901 nmol/mg/min, 34.2% se) and 
37oC (0.929 nmol/mg/min, 42.1% se). There was a trend towards a decrease in the Vmax at 33oC 
compared to 37oC; however, it did not demonstrate significance.  The population estimates for 
Km demonstrated a significant rank order increase as temperature decreases (p<0.0001, chi-
square test, df=2).  These estimates were 70.6 µM (6.9% se) at 37oC, 89.6 µM (9.4% se) at 33oC, 
and 120 µM (12.5% se) at 30oC.  Inspection of the individual sample parameters demonstrated 
similar results in the Vmax and Km as temperature decreases, as shown in Table 8.  Inter-
individual variability was estimable for Vmax (~80%) but not for the Km.   Individual 1 
demonstrated a decrease in the estimated ClS at 33oC and 30oC, 338 ml/min and 194 ml/min, 
respectively, when compared to 37oC, 438 ml/min.  .Individual 2 demonstrated a decrease in the 
estimated ClS at 33oC and 30oC, 263 ml/min and 151 ml/min, respectively, when compared to 
37oC, 341 ml/min.   Individual 3 demonstrated a decrease in the estimated ClS at 33oC and 30oC, 
188 ml/min and 108 ml/min, respectively, when compared to 37oC, 244 ml/min.  Individual 4 
demonstrated a decrease in the estimated ClS at 33oC and 30oC, 51.3 ml/min and 29.5 ml/min, 
respectively, when compared to 37oC, 66.6 ml/min.   
Figure 20: Michaelis-Menten saturation curves in human liver microsomes for 
CYP2E1 
 
Panel A depicts saturation curves in human liver microsomes for CYP2E1 incubated at 37oC, 
33oC, and 30oC, n=6.  Panel B depicts an Eadie-Hofstee plot constructed from the non-linear 
regression analysis of the raw data reported in Table 7.  Decreases in Vmax can be observed 
upon visual inspection of the Eadie-Hofstee plot, as all three lines have different y- 
intercepts.  The change in Km at 30oC can be observed as the slope of the line compared to 
33oC and 37oC. 
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Figure 21: Intrinsic clearance of CYP2E1-mediated metabolism in individual human liver 
microsomes 
 
Using the in vitro parameter estimates (Vmax and Km) obtained from the NONMEM analysis, Clint was 
calculated by the equation Vmax/Km.  This data depicts a rank order decrease in the Clint of CYP2E1 
incubated at 33oC or 30oC, compared to 37oC.  
Table 8: CYP2E1 enzyme kinetic parameters estimates in individual human liver microsomes incubated at 37oC, 
33oC, or 30oC 
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Abbreviations: Vmax, maximal velocity; Km, Michaelis-menten constant; Clint’, estimated intrinsic clearance; Cls, 
estimated systemic clearance 
Sample (temp) Vmax (nmol/mg/min) Km (uM) Clint' (ml/min/kg) Cls' (ml/min)
1   (37 degrees) 1.83 70.6 58.4 438
1   (33 degrees) 1.79 89.6 45.0 338
1   (30 degrees) 1.38 120 25.9 194
2  (37 degrees) 1.43 70.6 45.5 341
2  (33 degrees) 1.40 89.6 35.1 263
2  (30 degrees) 1.07 120 20.2 151
3  (37 degrees) 1.02 70.6 32.6 244
3  (33 degrees) 1.00 89.6 25.1 188
3  (30 degrees) 0.767 120 14.4 108
4  (37 degrees) 0.278 70.6 8.87 66.6
4  (33 degrees) 0.272 89.6 6.84 51.3
4  (30 degrees) 0.209 120 3.93 29.5
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4.2.3 Effect of Temperature on CYP3A4 Enzyme Kinetics in Pooled Human Liver 
Microsomes 
As depicted in Table 9, there were significant decreases in the Vmax of CYP3A4 in microsomes 
incubated at both 33oC (3.56 ± 0.707 nmol/mg/min), and 30oC (3.87 ± 0.307 
nmol/mg/min;***p<0.001) when compared to 37oC (9.28 ± 1.2 nmol/mg/min).  Table 9 also 
demonstrates that the Km of CYP3A4 shows no significant difference in microsomes incubated at 
37oC, 33oC, and 30oC, 46.9 ± 17.6 µM, 35.7 ± 17.3 µM, and 22.4 ± 5.35 µM, respectively.  
Figure 22, Panel B demonstrates a hooked Eadie-Hofstee plot for all three incubation 
temperatures.   The Hill coefficient demonstrated no differences between temperatures.  These 
changes in Vmax, Km and the Hill coefficient resulted in no changes in the Clintmax of CYP3A4 at 
all three temperatures. After performing an in vitro-in vivo correlation, the estimated ClS of 
testosterone did not differ based on temperature. 
 
 
 
 
Table 9: CYP3A4 enzyme kinetic parameter estimated in pooled human liver microsomes incubated at 37oC, 33oC, or 30oC 
Vmax (nmol/mg/min) 9.28 ± 1.20 3.56 ± 0.707 3.87 ± 0.307
Km (uM) 46.9 ± 17.6 35.7 ± 17.3 22.4 ± 5.35
Hill coefficient 1.56 ± 0.25 1.58 ±  0.18 1.75 ±  0.43
Clint max(ml/min/mg protein) 0.0306 ± 0.0136 0.0172 ± 0.00832 0.0284 ± 0.0110
Cls estimated (ml/min) 713 ± 149 398 ± 186 605 ± 115
*** ***
p<0.001 ***
37oC 33oC 30oC
Abbreviations: Vmax, maximal velocity; Km, Michaelis-menten constant; Clint, intrinsic clearance; Cls, estimated systemic 
clearance. 
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4.2.4 Effect of Temperature on CYP3A4 Enzyme Kinetic in Human Liver Microsomes 
from Individual Donors 
Each individual human liver microsome incubated at 3 different temperatures showed a rank 
order decrease from 37oC to 33oC to 30oC in the Clint of CYP3A4 as depicted in Figure 23.  
Each individual demonstrated a decrease in the Clint of CYP3A4 at 33oC (13.65 ± 0.001% of 
37oC) and 30oC (27.09 ± 0.001% of 37oC).  The population estimates for Vmax demonstrated a 
significant decrease as temperature decreases (p<0.0001, chi-square, df=2).  These estimates 
were at 5.93 nmol/min/mg (48.5% se) at 37oC, 5.12 nmol/mg/min at 33oC (47.9% se) and 4.32 
nmol/mg/min (46.5% se) at 30oC.  The population estimates for Km were not distinguishable 
between temperatures.  Inspection of the individual sample parameters demonstrated similar 
results in the Vmax and Km as temperature decreases as depicted in Table 10.  Inter-individual 
variability was estimable for Vmax (~98%) but not for the Km.  Individual 1 demonstrated a 
decrease in the estimated ClS at 33oC and 30oC, 1223 ml/min and 1032 ml/min, respectively, 
when compared to 37oC, 1416 ml/min.  Individual 2 demonstrated a decrease in the estimated 
ClS at 33oC and 30oC, 558.8 ml/min and 471.8 ml/min, respectively, when compared to 37oC, 
647.1 ml/min.  Individual 3 demonstrated a decrease in the estimated ClS at 33oC and 30oC, 
65.99 ml/min and 55.72 ml/min, respectively, when compared to 37oC, 76.43 ml/min.  Individual 
4 demonstrated a decrease in the estimated ClS at 33oC and 30oC, 9.484 ml/min and 8.008 
ml/min, respectively, when compared to 37oC, 10.98 ml/min.   
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Figure 22: Michaelis-Menten saturation curves in human liver microsomes for CYP3A4    
 
Panel A depicts the Michaelis-Menten saturation curves in human liver microsomes for CYP3A4 
incubated at 37oC, 33oC, or 30oC, n=6.  Panel B depicts an Eadie-Hofstee plot constructed from 
the non-linear regression analysis of the raw data reported in Table 9.  Decreases in Vmax can be 
observed upon visual inspection of the Eadie-Hofstee plot, as all three lines have different y-
intercepts. 
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Figure 23: Intrinsic clearance of CYP3A4-mediated metabolism in individual human liver 
microsomes 
 
Using the in vitro parameter estimates (Vmax and Km) obtained from NONMEM analysis, Clint was 
calculated by the equation Vmax/Km. This data depicts a rank order decrease in the Clint of CYP3A4 
incubated at 33oC or 30oC, compared to 37oC.  The inset allows for inspection of liver samples 3 
and 4 on a smaller scale. 
Table 10: CYP3A4 enzyme kinetic parameters estimates in individual human liver microsomes 
incubated at 37oC, 33oC, or 30oC 
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Abbreviations: Vmax, maximal velocity; Km, Michaelis-menten constant; Clint’, estimated intrinsic 
clearance; Cls, estimated systemic clearance 
Sample (temp) Vmax (nmol/mg/min) Km (uM) Clint' (ml/min/kg) Cls' (ml/min)
1   (37 degrees) 15.2 36.2 944 1416
1   (33 degrees) 13.1 36.2 815 1223
1   (30 degrees) 11.1 36.2 688 1032
2  (37 degrees) 11.7 61.1 431 647.1
2  (33 degrees) 10.1 61.1 373 558.8
2  (30 degrees) 8.54 61.1 315 471.8
3  (37 degrees) 1.12 49.6 51.0 76.43
3  (33 degrees) 0.969 49.6 44.0 65.99
3  (30 degrees) 0.818 49.6 37.1 55.72
4  (37 degrees) 0.204 62.8 7.32 10.98
4  (33 degrees) 0.177 62.8 6.32 9.484
4  (30 degrees) 0.149 62.8 5.34 8.008
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4.3 DISCUSSION 
 
Our results demonstrate three novel findings. First, mild and moderate hypothermia decreased 
the Clint of CYP2E1-mediated metabolism of CZN however, did not affect Clintmax of CYP3A4-
mediated metabolism of TST in pooled human hepatic microsomes.  When an in vivo-in vitro 
correlation analysis was performed, the estimated ClS for CZN demonstrated a decrease at both 
mild and moderate hypothermia and no difference in the estimated ClS of TST was observed 
between temperatures.  Second, temperature-mediated alterations were due to decreases in the 
Vmax of both CYP3A4 and CYP2E1 and an increase in the Km of the CYP2E1 enzyme.  Third, 
individual human liver microsomes incubated at both mild and moderate hypothermic 
temperatures demonstrated a rank order decrease in the Clint of both CYP2E1 and CYP3A4.   
We demonstrated that mild (33oC) and moderate hypothermia (30oC) decreased the Clint 
of CYP2E1, ~1.9-fold and ~2.5-fold, respectively, compared to 37oC in pooled human liver 
microsomes.  This further translated into a decrease at both mild and moderate hypothermic 
temperatures in the estimated ClS of CZN.  This is consistent with our previous finding 
demonstrating a ~1.7-fold decrease at 30oC compared to incubation at 37oC in the Clint of 
CYP2E1 in rat liver microsomes (Tortorici, Kochanek et al. 2006).  Together, these results 
suggest that both mild and moderate hypothermia decreases the intrinsic ability of CYP2E1 to 
metabolize the probe substrate CZN.     
This study also showed that when pooled human liver microsomes were incubated at 
33oC and 30oC, the Vmax of CYP2E1 was decreased ~1.7 and ~1.3-fold, respectively, compared 
to 37oC.  This is in contrast to our previous finding in which the Vmax of CYP2E1 in rat liver 
microsomes did not differ when incubated at 30oC versus 37oC (Tortorici, Kochanek et al. 2006).  
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Changes in Vmax represent a change in the capacity of the enzyme, more specifically alterations 
in the functionality of the heme group.  It has been postulated that cooling decreases enzymatic 
processes by a factor of approximately 1.5 to 3 per 10oC temperature decreases (Zachariassen 
1991).  The rate of the redox reaction of the iron atom present in the heme prosthetic group may 
be affected by mild and moderate reductions in temperature.  Furthermore, these data provide 
evidence that temperature may differentially affect human and rat liver CYP450 metabolism.  
We observed that the Km of CYP2E1 in pooled microsomes incubated at 30oC 
significantly increased compared to incubations conducted at 37oC and 33oC.  The observed 
increase in Km due to hypothermic conditions is consistent with a study by McAllister et al., who 
demonstrated that when propranolol and verapamil were incubated at 26oC versus 37oC in rat 
liver microsomes, the Km was significantly increased at the lower temperature (McAllister and 
Tan 1980).   As outlined in Chapter 2, when CZN was incubated at 30oC in rat liver microsomes, 
a ~2.1-fold increase in the Km was observed compared to microsomes incubated at 37oC 
(Tortorici, Kochanek et al. 2006).  The ability of an enzyme to bind a substrate depends on a 
specific geometry which allows the interaction of the active site and substrate (Fields 2001). 
Variation in the flexibility of the active site of the enzyme due to moderately hypothermic 
temperatures could be a potential cause of the difference we observed in our Km values of 
CYP2E1.  Collectively, these results demonstrate that mild and moderate hypothermic 
temperatures reduce the capacity of CYP2E1 in human liver microsomes.  Furthermore, at 
moderate hypothermia, the affinity of CYP2E1 for CZN is also decreased. 
Testosterone is metabolized by CYP3A4 and has demonstrated atypical enzyme kinetics 
in previous reports (Korzekwa, Krishnamachary et al. 1998; Shou, Mei et al. 1999; Houston and 
Kenworthy 2000).  This observation is evident upon visual inspection of the Eadie-Hofstee plot, 
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Figure 20, Panel B, which shows a hooked shape.  Testosterone has been shown to exhibit 
autoactivation, which is defined as an increase in the reaction velocity as more molecules of TST 
bind to the active site (Korzekwa, Krishnamachary et al. 1998; Houston and Kenworthy 2000).   
Our data demonstrated that mild and moderate hypothermia did not affect the Clintmax of TST.  
We showed that under both mild and moderate hypothermic conditions, the Vmax was decreased 
~2.6 and ~2.3 fold respectively.  As mentioned above, this could be caused by hypothermic 
temperatures decreasing the rate of redox reaction of the iron atom of the heme prosthetic group.  
We did not observe any differences in the Km or Hill coefficient at 33oC or 30oC, which is in 
contrast to CYP2E1.  This discrepancy between CYP3A4 and CYP2E1 could be related to the 
difference in the size of the active site.  It is known that CYP2E1 has a small binding pocket, 
with one binding site for CZN (Tan, White et al. 1997).  In contrast, CYP3A4 has a large binding 
pocket, with multiple binding sites for TST (Scott and Halpert 2005).  For CYP3A4, even though 
the flexibility of the binding pocket might be altered by hypothermic conditions (Fields 2001), 
the fact that TST has multiple binding sites which demonstrate positive co-operativity, could be 
an explanation of why a decrease in temperature does not change the affinity of CYP3A4 for 
TST (Houston and Kenworthy 2000).  Together, these results show that hypothermia produces a 
consistent decrease in the capacity of multiple isoforms of CYP450; however our findings allude 
to the fact that hypothermia-mediated alterations may be isoform specific, depending on the 
structure of the substrate binding pocket.   
Lastly, we performed these analyses in individual human liver donor samples to confirm 
our findings observed in pooled microsomes.  For CYP2E1, we demonstrated a significant rank 
order increase in Km and decrease in Vmax from 37oC to 33oC to 30oC.  These differences resulted 
in significant decreases in Clint at both 33oC and 30oC compared to 37oC, which is consistent 
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with data generated from the pooled liver microsomes.  For CYP3A4 in individual human liver 
donor microsomes, we demonstrated a significant rank order decrease in the Vmax from 37oC to 
33oC to 30oC.  However, the Km was not significantly different between temperatures.  Due to 
the dramatic decreases in Vmax, these differences resulted in significant decreases in the Clint at 
both 33oC and 30oC compared to 37oC, which is in contrast to the data generated from pooled 
liver microsomes.  These differences between CYP isoforms (CYP2E1 and CYP3A4) are 
possibly related to the differences in the size of the active site as described above (Houston and 
Kenworthy 2000; Scott and Halpert 2005). 
There are several possible limitations of our study.  First, the results from the CYP3A4 
pooled microsomal analysis revealed an unexpected variability in the Km values, which could be 
due to the limited number of concetrations analyzed around the Km.   This could limit some of 
the conclusions; however, when the individual human liver microsomes were analyzed using 
NONMEM, the Km across temperatures could not be differentiated, lending support to the results 
from the pooled microsomal analysis.  Second, our results for Clint of CYP3A4 are inconsistent 
between pooled and individual human liver microsomes.  This could be due to the small sample 
size in the individual human liver microsome (n=4) analysis compared to pooled human liver 
microsomes (n=50), demonstrating greater decreases in Vmax compared to pooled microsomes.  It 
is also noteworthy to mention that the data from the individual liver microsomes fit to hyperbolic 
kinetic model and the data from the pooled liver microsomes fit to sigmoidal kinetic model, 
which could account for the differences observed.  Lastly, we only investigated two CYP 
isoforms, CYP2E1 and CYP3A4.  It is possible that other CYP isoforms behave differently than 
the two isoforms investigated and future studies are in place to evaluate these effects.   
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4.4 CONCLUSION 
This study reports that incubating pooled and individual human liver microsomes at mild (33oC) 
and moderate (30oC) hypothermic temperatures alters the enzyme kinetic profile of CYP2E1, 
specifically decreases in the Clint.  In pooled microsomes, we demonstrated alterations in enzyme 
kinetics of CYP3A4, specifically decreases in the Vmax.  Individual human liver microsomal 
analysis for both CYP2E1 and CYP3A4 demonstrated significant decreases in Clint at mild and 
moderate hypothermic temperatures.  The magnitude of these changes in Clint  parallel previously 
published clinical data. Fukuoka et al reported ~5-fold increase in plasma concentrations of 
midazolam (CYP3A4 substrate) in traumatic brain injured patients treated with mild 
hypothermia (33oC) compared to normothermia (Fukuoka, Aibiki et al. 2004).  Iida et al 
observed a ~67% decrease in the ClS of phenytoin (CYP2C9) in traumatic brain injured patients 
treated with mild hypothermia (~34oC) compared to normothermia (Iida, Nishi et al. 2001).  
Similarly, Caldwell et al. demonstrated a ~11% decrease per degree Celsius in the ClS of 
vecuronium in patients (Caldwell, Heier et al. 2000).  Future studies involving additional 
CYP450 isoforms and other pathways of metabolism are ongoing to fully elucidate the effects of 
hypothermic therapy on drug disposition and metabolism. 
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5.0  CHAPTER 5 
 
 
The Effects of Mild Hypothermia on Midazolam Pharmacokinetics in Normal Healthy 
Subjects: A Pilot Study 
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INTRODUCTION 
 
 
It has been well documented that therapeutic hypothermia (32oC-35oC) decreases neurological 
damage in patients experiencing out-of-hospital CA (Bernard, Gray et al. 2002; Group 2002).  
Due to the positive results from these two landmark clinical trials, interest in therapeutic 
hypothermia has expanded its use to other ischemic insults, such as in stroke and TBI, with the 
goal of reducing neurological damage.  Animal models have been used to refine the use of 
hypothermia (ie. optimal depth, duration, and method of cooling) in these ischemic insults.  
Multiple methods of cooling a patient have been developed in order to achieve goal core 
temperature quickly.  One method is surface cooling, which is non-invasive and potentially the 
safest method for inducing mild hypothermia.  However, this technique has a limited ability to 
quickly bring the patient to target temperature, which has been shown to be critical in the benefit 
of hypothermia therapy (Nozari, Safar et al. 2006).  Additionally, surface cooling requires 
substantial resources such as large quantities of ice, chemical icepacks, or powered cooling 
blankets.  Another method is endovascular cooling, which delivers chilled saline directly to the 
body (Al-Senani, Graffagnino et al. 2004).  This is a less costly and resource intensive 
alternative, this method of cooling could be initiated quickly after injury, resulting in more 
favorable outcomes. 
As mentioned above, mild hypothermia is currently under investigation as a potential 
therapy after stroke.  As with CA, the goal core temperature range is 32oC-35oC; however, unlike 
CA, patient’s experiencing a stroke will defend their temperature via the shivering response.  The 
reason for this is that stroke patients’ are typically not administered neuromuscular blockers 
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under general anesthesia.  One method of cooling that has been developed to reach goal 
temperature in stroke patients is to administer benzodiazepines at the same time the infusion of 
ice cold saline is started, to prevent the shivering response.     
Another critical component in the development of a method to cool patients via ice-cold 
saline infusion is the effect of mild hypothermia on the pharmacokinetics of the drugs which are 
commonly employed in these patients.  The majority of these medications are hepatically 
eliminated by the CYP450 enzyme system, including sedatives and anesthetics such as 
midazolam and fentanyl, both metabolized by CYP3A4.  The work presented throughout this 
dissertation has demonstrated that moderate to mild hypothermic temperatures alter CYP450-
mediated metabolism.  In Chapter 2, we demonstrated a ~2-fold decrease in the ClS of CYP2E1 
for CZN, in a CA rat model and the mechanism behind this alteration is due to hypothermia-
mediated decrease in the affinity of CYP2E1 for CZN.  In Chapter 4, we further demonstrated in 
human liver microsomes that both mild and moderate hypothermia decreases the capacity of 
CYP2E1 and CYP3A4 ability to metabolize probe substrates, CZN and TST, respectively.  In the 
development of an endovascular cooling protocol it is also important to optimize the drug dosing 
regimen.  The drug regimen must be comfortable for the patient and suppress or diminsh the 
shivering response without jeopardizing patient safety.  Various drugs are available that may 
suppress the shivering response and yet still be safe to administer to patients who are awake 
during acute illness.  Options include drugs such as meperidine, narcotics, benzodiazepines, and 
buspirone.  In order to optimize this protocol and provide maximum comfort to the patient, it is 
crucial to understand the effect of cooling on the disposition and metabolism of drugs commonly 
utilized in these patients.  Therefore, the objectives of this pilot analysis were to investigate the 
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effects of mild hypothermia on the pharmacokinetics of midazolam in normal healthy subjects 
after ice-cold saline administration.   
5.1 METHODS 
5.1.1 Subjects 
The studies were approved by the biomedical institutional review board of the University of 
Pittsburgh.  Subjects participated in these studies after providing written informed consent.  All 
subjects underwent a screening evaluation including a complete medical history, physical 
examination, and biochemical analysis.  Eligibility criteria include male subjects’ age 18-39 
years old, without known medical problems.  Exclusion criteria included females, any individual 
with a history of known medical problems including but not limited to; cardiac disease, cardiac 
arrthymia or heart murmur, hypotension or hypertension, pulmonary diseases including asthma, 
diabetes mellitus, thyroid disease, renal disease, liver disease, neurologic disease or seizures, 
connective tissue disorder or Raynaud’s disease, sickle cell disease, anemia, or hematologic 
disorders, subjects who are HIV positive, subjects taking any medications (including St Johns 
Wort, MAO inhibitors, antidepressants, cimetidine) with the exception of ibuprofen, or 
acetaminophen, subjects with history of cardiac disease in family members below the age of 
forty, allergy to benzodiazepines, subjects currently ill with viral or other infection, subjects who 
currently smoke, subjects who are morbidity obese (BMI ≥ 36).  All participants were instructed 
to abstain from alcohol, caffeine-containing products, and grapefruit products for at least 48 
hours prior to and during the study period.  Three normal healthy male subjects were recruited 
for study participation. 
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5.1.2 Study Design 
This study utilized a prospective, randomized, cross-over study design to determine if therapeutic 
hypothermia affected the pharmacokinetics of midazolam.  Normal healthy male subjects were 
admitted to the Department of Emergency Medicine the morning after an overnight fast.  The 
subjects were randomized on each study day to receive one of 2 treatment arms as outlined in 
Figure 24.  Subjects were to receive, on each consecutive visit, either ice-cold saline (4oC) with 
sedation or warm saline (37oC) with sedation.  Protocols were completed in a temperature and 
pressure controlled room with an ambient temperature of ~ 23.5°C.  Subjects voided and were 
weighed.  Two 18-gauge catheters were placed in superficial vein near the anterior aspect of the 
elbow for drug administration and blood draws.  Each subject ingested a single-use CorTemp 
(HQ Inc, FL) capsule.  A minimum of 30 minutes was provided for the capsule to enter the GI 
tract.  Three consecutive readings within 0.1°C were obtained prior to initiating the protocol.  
Thermisters were placed on the skin on the opposite side of the infusion arm over the sternal 
head of the pectoralis major, the supraspinatis, the midpoint of the triceps brachii, and the 
midpoint of the vastus intermedius muscles to measure skin temperature. 
 
 
 
 
 
Figure 24: Randomization scheme of sedation and  fluid temperature 
37oC Saline
+ sedation
Randomization
4oC Saline 
+ sedation
Visit 1/Visit 2 Visit 2/Visit 1
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Each subject was administered 30ml/kg of either warm (37oC) or cold (4oC) saline based 
on group assignment.  Midazolam (MDZ) at a dose of 2 mg IV was administered at the onset of 
the infusion.  Midazolm is a well-established in vivo CYP3A4 probe substrate because it is 
exclusively metabolized by CYP3A4 and has a short half-life. Additional 2 mg doses were 
administered at 10, and 20 minutes following the first dose.  Blood samples (5ml) were collected 
for analysis of midazolam concentrations as depicted in Figure 25.  Blood samples were 
collected at 5, 15, 25, 30, 50, 80, 140, 200, and 260 minutes after the first dose.  Blood was 
separated using a microcentrifuge and plasma was stored at -80oC.  Following the saline 
infusion, a lorazepam of infusion of 1mg/hr was initiated to maintain sedation for 3 hours.  The 
dose was titrated to maintain a Ramsey sedation scale rating of 2, which indicates the subject 
responded to verbal stimuli.  At the end of the experimental period, subjects were actively 
warmed with blankets and heating pads for at least one hour once the maintenance infusion of 
lorazepam ended.  The subjects were asked to void and were weighed.  The study physician 
assessed each subject to determine whether or not the subject could leave the Department of 
Emergency Medicine. 
 
 
 
 
 
Figure 25: Timeline of blood sampling, induction and maintenance of hypothermia.  
Midazolam bolus 
q10 min
25 30 50 80 140 200 210 260 270
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5.1.3 Sample Analysis 
Plasma concentrations of midazolam were determined using a modified and validated HPLC 
technique previously described by Quintela et al (Quintela, Cruz et al. 2004).  Briefly a 0.25-ml 
aliquot of plasma was combined with 2N sodium hydroxide (0.25 ml), buffer (750 ml) and 
internal standard (50 ng of [2H4] -midazolam).  Methy-terbutyl-ether (5 mL) was added and 
samples were centrifuged at 3000g for 10 minutes.  Samples were evaporated to dryness under a 
gentle stream of nitrogen at 40°C, and reconstituted in 200 µL of 80:20 0.1% formic acid in 
ddH20:acetonitrile and 20 µL was injected onto the HPLC system.  Separation of analytes was 
achieved on a ThermoFinnigan BetaBasic C18 column and detected using a MSQ single 
quadrupole mass spectrometer (ThermoFinnigan, San Jose, CA).  The mass spectrometer was 
operated under positive electrospray ionization mode with a probe voltage of 3.0 kV, cone 
voltage of 80 kV and cone temperature of 350oC for MDZ.  Analysis was carried out using 
selected ion monitoring (SIM) for specific m/z 325.9 (midazolam) and 329.9 ([2H4 -midazolam).  
The limit of quantification for MDZ in plasma was 2 ng/ml.  The within- and between 
coefficients of variance were less than 15%. 
 Urine concentrations for validation of 1-hydroxymidazolam (1-OH MDZ) were 
determined using a modified technique as mentioned above for midazolam.  Briefly, a 1 mL 
aliquot of urine was used and internal standard (50 ng of [2H4] -midazolam) and methy-terbutyl-
ether (5 mL) was added and samples were centrifuged at 3000g for 10 minutes.  Samples were 
evaporated to dryness under a gentle stream of nitrogen at 40°C, and reconstituted in 200 µL of 
80:20 0.1% formic acid in ddH2O:acetonitrile and 20 µL was injected onto the HPLC system.  
Separation of analytes was achieved on a ThermoFinnigan BetaBasic C18 column and detected 
using a MSQ single quadrupole mass spectrometer (ThermoFinnigan, San Jose, CA).  The mass 
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spectrometer was operated under positive electrospray ionization mode with a probe voltage of 
3.0 kV, cone voltage of 65 kV and temperature of 350oC.  Analysis was carried out using 
selected ion monitoring (SIM) for specific m/z 341.9 (1-OH midazolam) and 329.9 ([2H4] -
midazolam).  The limit of quantification for 1-OH MDZ in urine was 125 ng/ml.  The within- 
and between coefficients of variance were less than 15%. 
5.1.4 Pharmacokinetic Analysis 
The plasma concentrations of midazolam were fit to a non-compartmental model using the non-
linear regression program WinNonlin Professional (version 4.1, PharSight, Mountain View, CA).  
The area under the plasma concentration-time curve (AUC) was calculated with the use of log-
linear trapezoidal methods up to infinity.  Systemic MDZ clearance (CLS) was calculated as the 
intravenous dose (DOSEiv) divided by the AUC.  The amount of 1-OH MDZ in the urine was 
determined by multiplying the urinary concentration by the volume voided.  Other parameters 
calculated were the terminal elimination rate constant (λz), estimated by the linear regression of 
the terminal phase of the logarithmic plasma-concentration time curve, and the t1/2, calculated as 
0.693/ λz. 
Data are presented as mean ± standard deviation (SD).  Demographic information and PK 
parameters between individual subjects when normothermic core temperatures and hypothermic 
core temperatures using a paired Student’s t-test.  All statistical calculations were performed with 
GraphPad Prism v.3.03 (GraphPad Software, Inc., San Diego, CA).  A p value < 0.05 was 
considered statistically significant.  
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5.2 RESULTS 
5.2.1 Validation of a HPLC-MS Assay for Detection of Midazolam in Plasma 
5.2.1.1 Chromatographic Separation for Plasma Analysis of Midazolam 
Representative chromatograms of plasma samples by SIM mass spectrometric detection are 
shown in Figure 26.  Retention times for [2H4] –midazolam (internal standard, IS) and MDZ 
were 10.01 and 10.03 minutes, respectively.  The peaks of the compounds of interest were well 
separated and there was no interference from endogenous compounds during the elution window 
for the analytes and IS.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26: Representative SIM chromatatograms of internal standard and midazolam 
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5.2.1.2 Linearity, Precision, and Calibration for Midazolam 
Linear calibration curves were obtained for MDZ over the concentration range of 2 to 125 
ng/mL.  The mean regression equations (± SD) were as follows:   
  
 y = [0.0396 (± 0.0007)]x – 0.0091 (± 0.018) 
 
Correlation coefficients (r) were ≥ 0.989 for standard curves.  The lower limit of quantification 
(LOQ) for MDZ (2 ng/mL or 40 pg on column) demonstrated acceptable reproducibility (%RSD 
< 5) and a signal-to-noise ratio of 35:1.  The intra- and inter-day precision and accuracy were 
less than ± 10% for midazolam (Table 11). 
Table 11: Intra- and inter-day precision and accuracy for midazolam  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Intra-assay reproducibility
Quality controls
Midazolam
Inter-assay reproducibility
Quality controls
Midazolam
Standards
Midazolam
Amount (ng/mL)
Added Observed (mean ± S.D.)
% R.S.D. % Bias
a
b
a Ten quality control samples per concentration
b Five to ten quality control sample or two standards per day per concentration for 3
days
100 98.1 ± 6.4 6.6 -1.9
37.5 33.4 ± 0.99 3.0 -10.0
7.5 7.24 ± 0.56 7.8 -3.5
100 96.4 ± 4.6 4.8 -3.6
37.5 35.3 ± 2.5 7.2 -5.9
7.5 6.99 ± 0.49 6.9 -6.7
2 2.64 ± 0.21 8.1 32.2
5 4.37 ±  0.44 9.9 -12.6
10 9.75 ±  1.1 11.8 -2.5
25 23.6 ±  2.3 9.6 -5.8
50 51.8 ±  3.9 7.6 3.6
75 76.7 ±  5.8 7.6 2.1
125 125 ±  7.7 6.2 0.2
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5.2.1.3 Selectivity and Stability for Midazolam 
No endogenous interfering peaks were present in six sources of blank human plasma, and there 
was no carry-over evident in any of the blank reagent samples; therefore, the assay can be 
regarded as selective against possible matrix constituents.   
5.2.1.4 Extraction Recovery  
The mean extraction recovery of MDZ in plasma at 5 ng/mL was 152 ± 31.9 %.  Recovery at 25 
ng/mL for MDZ in plasma was 83.0 ± 1.32 %. 
5.2.2 Validation of a HPLC-MS Assay for Detection of 1-Hydroxymidazolam in Urine 
5.2.2.1 Chromatographic Separation for Urine Analysis of 1-Hydroxymidazolam 
Representative chromatograms of plasma samples by SIM mass spectrometric detection are 
shown in Figure 27.  Retention times for 1-OH MDZ and [2H4] –midazolam (internal standard, 
IS) were 6.79 and 6.97 minutes, respectively.  The peaks of the compounds of interest were well 
separated and there was no interference from endogenous compounds during the elution window 
for the analytes and IS. 
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5.2.2.2 Linearity, Precision, and Calibration for 1-Hydroxymidazolam 
Linear calibration curves were obtained for 1-OH MDZ over the concentration range of 125 to 
2000 ng/mL.  The mean regression equations (± SD) were as follows: 
 
 y =  [0.005 (± 0.001)]x – 0.707 (± 0.503) 
 
Correlation coefficients (r) were ≥ 0.974 for all standard curves.  The lower limit of 
quantification (LOQ) for 1-OH MDZ (125 mg/mL or 2500 pg on column) demonstrated an 
Figure 27: Representative SIM chromatatograms of internal standard and 1-hydroxymidazolam  
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acceptable reproducibility (< 5%) and a signal-to-noise ratio of 12:1.  The intra- and inter-day 
precision and accuracy were less than ± 15% (Table 12). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.2.2.3 Selectivity and Stability 
No endogenous interfering peaks were present in six sources of blank human urine, and there 
was no carry-over evident in any of the blank reagent samples; therefore, the assay can be 
regarded as selective against possible matrix constituents.  
Table 12: Intra- and inter-day precision and accuracy for 1-hydroxymidazolam
Intra-assay reproducibility
Quality controls
1-OH Midazolam
Inter-assay reproducibility
Quality controls
1-OH Midazolam
Standards
1-OH Midazolam
Amount (ng/mL)
Added Observed (mean ± S.D.)
% R.S.D. % Bias
a
b
a Ten quality control samples per concentration
b Five to ten quality control sample or two standards per day per concentration for 3
days
1750 1778 ± 216 12.2 1.6
650 597.9 ± 42.5 7.1 -8.0
200 221.2 ± 9.88 4.5 10.6
1750 1758 ± 218 12.4 0.5
650 594.9 ± 39.6 6.7 -8.5
200 220.3 ± 7.92 3.6 10.2
125 189.2 ± 47.3 25.0 51.3
250 282.9 ± 33.9 12.0 13.2
500 468.1 ±  39.3 8.4 -6.4
750 639.1 ±  58.2 9.1 -14.8
1000 828.6 ±  184 22.2 -17.1
1500 1526 ±  98.9 6.5 1.8
2000 1994 ±  262 13.1 -0.3
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5.2.2.4 Extraction Recovery  
The mean extraction recovery of 1-OH MDZ from urine at 250 ng/mL was 94 ± 2.7 %.  
Recovery at 1000 ng/mL for 1-OH MDZ in plasma was 70 ± 8.23 %. 
 
5.2.3 Subject Recruitment 
A total of 3 subjects were included in this study.  All subjects were between 18 and 39 years old 
and no demographic differences were noted. 
5.2.4 Core Temperature in Subjects 
Figure 28 depicts the time-course of temperature after administration of warm saline and cold 
saline in each subject.  Data depicts that the degree of cooling achieved 1.23 ± 0.25oC. when 
subjects were administered cold saline.  The average duration of hypothermia below 36.5oC 
during cold saline infusion was 80 ± 17.4 min.  Subjects 1 and 3 had a greater duration of time 
below 36.5 oC compared to Subject 2 (Subject 1: 88 min; Subject 3: 92 min; vs. Subject 2: 60 
min).   
5.2.5 Pharmacokinetics of Midazolam in Subjects 
Midazolam pharmacokinetic parameters are presented in Table 13, and plasma concentration-
time curves for each subject are shown in Figure 29.  Subject 1 demonstrated a decrease in ClS 
during cold saline infusion (54.8 ml/min) compared to warm saline (76.2 ml/min) as shown in 
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Figure 30.  Subject 3 also demonstrated a decrease in the ClS of MDZ when administered cold 
saline (117 ml/min) compare to warm saline (133 ml/min).  The ClS of MDZ in Subject 2 was  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28: Core temperature during warm ( ) and cold saline infusion ( ) 
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 Figure 29: Plasma concentration-time curve for midazolam in subjects 
0
100
200
300
400
500
600
0 50 100 150 200 250 300
Subject 1
Time (min)
C
on
ce
nt
ra
tio
n 
(n
g/
m
l) = warm saline
=cold saline
0
100
200
300
400
500
600
700
0 50 100 150 200 250 300
Subject 2
C
on
ce
nt
ra
tio
n 
(n
g/
m
l)
Time (min)
= warm saline
=cold saline
0
75
150
225
300
375
450
525
0 50 100 150 200 250 300
Subject 3
C
on
ce
nt
ra
tio
n 
(n
g/
m
l)
= warm saline
=cold saline
Time (min)
 137 
increase during cold saline administration vs. warm saline (108.4 vs. 63.2 ml.min). When the 
data was combined, there was no statistically significant difference in the ClS of MDZ when 
subjects were warm (90.8 ± 37.1 ml/min) vs. cold (93.4 ± 33.7 ml/min). Both Subjects 1 and 3 
demonstrated increases in the AUC(0-infinity) of MDZ when administered cold saline (Subject 1: 
109,528.9 vs. 78,739.2 ng*min/ml, Subject 2: 51,303.1 vs. 45,127.5 ng*min/ml) vs. warm saline.  
Subject 2 showed a decrease in the AUC(0-infinity) of MDZ when administered cold saline 
(55,348.4 ng*min/ml) vs. warm saline (94,900.8 ng*min/ml).  When the data was combined, 
there was no statistically significant difference in the AUC(0-infinity) of MDZ when subjects were 
warm (73,920 ± 26,716 ng*min/ml) vs. cold (72,059 ± 32,511 ng*min/ml).  Additionally, there 
was a decrease in the Vss when administered cold saline (13.1 ± 3.7) vs. warm saline (15.2 ± 2.8).   
 
 
 
Table 13: Midazolam pharmacokinetic parameters 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cmax (ng/ml) tmax (min) t1/2 (min) AUC (ng*min/ml) Vss (L) ClS (ml/min) λz (min
-1)
subject 1
warm (37oC) 546.4 25 126.0 78739.2 14.2 76.2 0.0055
cold (4oC) 571.0 50 123.8 109528.9 10.4 54.8 0.0056
subject 2
warm (37oC) 469.5 25 144.4 94900.8 13.0 63.2 0.0048
cold (4oC) 584.6 25 77.9 55348.4 11.6 108.4 0.0089
subject 3
warm (37oC) 328.0 50 99.0 45127.5 18.3 133.0 0.007
cold (4oC) 454.6 25 144.4 51303.1 17.4 117.0 0.0048
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Figure 30: Systemic clearance (ClS) of midazolam in normal healthy subjects 
 
Data depicts ClS during warm saline infusion and cold saline infusion.  Mean value is represented by solid 
 line.  No statistical differences were observed. 
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5.3 DISCUSSION 
This pilot study demonstrated three important findings.  First, a rapid, sensitive, and selective 
method for determining MDZ in human plasma in normal-healthy males was developed using 
HPLC-MS methodology.  Second, the administration of cold saline (4oC) to normal-healthy 
males decreases the core temperature by 1.23 ± 0.25 oC for 80 ± 17.4 min.  Third, mild 
hypothermia does not alter the pharmacokinetics of the CYP3A4 probe substrate, MDZ, in 
normal healthy volunteers.  These results represent the a preliminary clinical investigation to 
identify certain changes in drug metabolizing enzymes.     
Development of a rapid, sensitive, and selective HPLC-MS assay for determining MDZ 
concentrations in human plasma and urine.  MDZ is a short acting benzodiazepine commonly 
employed as a sedative.  In humans, it is extensively metabolized by CYP3A4 and CYP3A5 
isoforms to 1-OH MDZ and to a lesser extent 4-OH MDZ (Wandel, Bocker et al. 1994).  MDZ is 
an established probe substrate for phenotyping CYP3A4 and CYP3A5 activity in human subjects 
(Lee, Chaves-Gnecco et al. 2002; Lepper, Baker et al. 2005).  Thus, a rapid, sensitive, and 
selective analytical technique for the detection of MDZ is warranted.  Although there have been 
multiple techniques reported, there have been a lack of HPLC-MS methods developed for 
determining plasma and urine concentrations of MDZ and 1-OH MDZ.  The studies that have 
been reported typically use LC-MS-MS methods, which may not be available to all investigators.  
Additionally, other LC-MS techniques have been developed using high volumes of plasma (1 
ml), which can be costly if multiple analyses are required.  We have developed a rapid, sensitive 
and selective HPLC-MS method, using a smaller volume of plasma for determining MDZ and 1-
OH MDZ concetrations.  In addition, our method is the first HPLC-MS method for determining 
1-OH MDZ in human urine.     
 140 
Administration of ice-cold saline plus sedation decreases the body’s core temperature.  
One of the goals of this work was aimed at determining if the use of sedatives could prevent 
shivering and therefore, decrease and maintain hypothermia in normal healthy subjects over a 3 
hr time period.  The protocol used in this study achieved ~loc of hypothermia and was 
maintained for ~70 minutes.  Caldwell et al showed longer period of hypothermia in normal 
healthy volunteers due to the administration of neuromuscular blockers, such as vecuronium.  
Leslie et al achieved hypothermic temperatures (34oC) for ~ 104 minutes using surface cooling 
devices; however time to goal temperature was ~ 140 minutes.  Our results indicate that our 
current protocol, hypothermia was not maintained for the entire 3 hrs.  A solution to this problem 
would be the use of endovascular cooling for induction of hypothermia coupled with surface 
cooling devices to maintain hypothermia in order to achieve and maintain cooling at goal 
temperature.  Furthermore, the use of other medications may inhibit the shivering response to a 
greater degree than the combination of MDZ and lorazepam.  Future work is currently underway 
to optimize the protocol in order to provide longer duration of hypothermia in normal healthy 
subjects.   
Preliminary analysis suggests that mild hypothermia does not alter MDZ 
pharmacokinetics.  Our preliminary analysis does not demonstrate an impact of mild 
hypothermia on the pharmacokinetics of MDZ in normal healthy subjects.  Specifically, we 
observed reductions in the ClS and VSS and an increase in the AUC, in two of the 3 subjects.  As 
outlined in Chapter 1, studies have shown that hypothermia decreases the ClS of drugs such as 
vecuronium, remifentanil, and phenytoin (Caldwell, Heier et al. 2000; Iida, Nishi et al. 2001; 
Michelsen, Holford et al. 2001).  Fukuoka et al. showed a 5-fold increase in plasma 
concentrations of MDZ when the core temperature of brain-injured patients was maintained 
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below 35oC (Fukuoka, Aibiki et al. 2004).  This study cooled patients to 32 – 34oC for 3-4 days.  
Our results are consistent with this study demonstrating a decrease in the ClS of MDZ during 
hypothermia.  Interestingly, our study shows that small decreases in core temperature 
(approximately 1oC of hypothermia for 75 min) alter the pharmacokinetics of MDZ in normal 
healthy males.  Subject 2 demonstrated an increase in the ClS of MDZ and a decrease in the 
AUC; however the duration of hypothermia in this subject was much shorter than the other 2 
subjects, which could possibly explain why these results are inconsistent with the other subjects.  
As mentioned earlier, MDZ is an established probe substrate with a low extraction ratio that is 
exclusively hepatically metabolized (Lee, Chaves-Gnecco et al. 2002; Lepper, Baker et al. 2005).  
Therefore, the ClH of MDZ approximates the ClS and is dependent on fu and the Clint of 
CYP3A4.  Results in Chapters 2 and 4 suggest that hypothermia alters the affinity of certain 
probe substrates for CYP450 isoforms.  One potential explanation for the hypothermia-mediated 
decrease in the ClS of MDZ is that hypothermia decreases the affinity of MDZ for the CYP3A4 
isoform.  Collectively, these studies show that hypothermia impacts the disposition of certain 
hepatically eliminated drugs, more specifically by decreasing the ClS.   Future goals of this work 
are to better control the duration of hypothermia and to increase the sample size.    
Mild hypothermia decreased the Vss of MDZ in normal healthy subjects.  We showed a 
decrease in the Vss during hypothermia.  This is consistent with a study by Fukuoka et al, that 
demonstrated an increase in the Vd of MDZ when TBI patient’s core temperature was below 
35oC vs. when core temperature was normothermic (Fukuoka, Aibiki et al. 2004).  The Vd is a 
term which relates the amount of drug in the body to the concentration in the blood or the 
plasma.  The Vd calculated at steady state relates the concentration in the plasma with the amount 
in the body at one time point.  A lower Vss indicates that the drug is less distributed out of the 
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plasma.  This is most likely due to the peripheral vasoconstriction due to the administration of 
ice-cold saline.  Additional factors which could also affect the Vd are changes in protein binding, 
global blood perfusion to organs, diffusion across membranes, or drug-tissue binding.  Previous 
studies have shown that hypothermia does not affect the protein binding of certain drugs and the 
other factors have never been investigated (Iida, Nishi et al. 2001; Tortorici, Kochanek et al. 
2006).  
5.4 CONCLUSIONS 
We report that mild hypothermia does not alter the pharmacokinetic parameters of MDZ.  This is 
the first systematic investigation into the effects of hypothermic therapy during cooling on 
CYP3A4-mediated metabolism in normal healthy volunteers.  In addition, we also demonstrate 
that our cooling protocol induces mild hypothermia in normal healthy volunteers but does not 
maintain hypothermia over 3 hrs.  Future studies are needed to asses the effects of hypothermia 
during cooling on other CYP450 isoforms as well as other enzymes which are involved in the 
metabolism of clinically relevant drugs.  Although this is a pilot study, clinical trials are needed 
in order demonstrate if these effects are present in a larger number of subjects.  However, these 
data imply that clinically significant hypothermia-drug interactions are a likely factor to consider 
in the therapeutic course of these patients.  
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6.0  CHAPTER 6 
 
 
Conclusions and Future Directions 
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The purpose of this research was to examine both the effects of therapeutic hypothermia on 
CYP450-mediated metabolism, during cooling and after re-warming.  In order to begin to 
systematically evaluate these effects, a CA rat model was utilized to examine these effects on 
CYP2E1 and CYP3A2 metabolism.  In addition, human liver microsomes were then utilized to 
examine the effects of mild and moderate hypothermia on CYP2E1 and CYP3A4 enzyme 
kinetics.  Furthermore, this analysis was also used to predict temperature-mediated changes in 
patients treated with therapeutic hypothermia.  Lastly, a pilot study was conducted to investigate 
the effects of mild hypothermia on CYP3A4 activity by analyzing the pharmacokinetics of MDZ 
in normal-healthily volunteers treated with ice-cold saline.   
 Results from Chapter 2 suggest that the application of moderate hypothermia in a CA rat 
model dramatically alters the pharmacokinetics of the CYP2E1 probe drug, CZN.  Interestingly, 
we observed a ~2-fold reduction in the ClS of CZN.  A potential mechanism behind these 
temperature-mediated changes was a decrease in the affinity of CYP2E1 for CZN.  From this in 
vitro analysis, we accurately predicted changes in the in vivo ClS of CZN in a rat.  This is the first 
systematic investigation into the acute effects of hypothermic therapy on CYP2E1-mediated 
metabolism and the first mechanistic insight into hypothermia induced reductions in CZN 
clearance.   
Chapter 3 extended the analysis of the work performed in Chapter 2, investigating the 
post re-warming effects in the acute and sub-acute phases after CA injury on CYP3A2 and 
CYP2E1-mediated metabolism.  This study demonstrated three novel findings.  First, there was 
an increase in IL-6 plasma concentrations early after CA.  IL-6 is known to decrease CYP3A2 
and CYP2E1 expression. Second, CA produced a significant decrease in the hepatic activity of 
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CYP3A2 and CYP2E1 in rats, in the sub-acute phase, 24 hrs after injury compared to Control 
rats.  Third, moderate hypothermia applied to CA rats, prevented both the down-regulation of 
CYP3A2 and CYP2E1-metabolism and blocked the early increase in IL-6 seen after CA 
Normothermia.   
In order to translate the results from Chapter 2 from rat to human, we performed an 
enzyme kinetic analysis in human liver microsomes at both mild and moderate hypothermic 
temperatures.  Mild and moderate hypothermia decreased the Clint of CYP2E1-mediated 
metabolism of CZN however, did not affect Clintmax of CYP3A4-mediated metabolism of TST 
in pooled human hepatic microsomes.  These temperature-induced alterations were due to 
decreases in the Vmax of both CYP3A4 and CYP2E1 and an increase in the Km of the CYP2E1 
enzyme.  Individual human liver microsomes incubated at both mild and moderate hypothermic 
temperatures demonstrated a rank order decrease in the Clint of CYP2E1 and CYP3A4.  These 
data provide insight into temperature-induced alterations on CYP450-mediated in human liver, 
specifically identifying that CYP isoforms may be differentially affected by therapeutic 
hypothermia. 
Lastly, a pilot investigation of the effects of mild hypothermia on the pharmacokinetics of 
MDZ suggests that CYP3A4 activity is not altered in normal healthily volunteers with the 
current model of cooling we are utilizing.  We did observe specific changes in individual 
subjects including, a decrease in the ClS of MDZ in two of 3 subjects compared to when subjects 
were treated with warm saline.  In addition, each subject demonstrated a decrease in the Vss of 
MDZ during ice-cold saline infusion compared to warm saline. 
This body of work provides the foundation for future preclinical studies and clinical 
studies.  One of the major conclusions of this work is that mild and moderate hypothermia alters 
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the enzyme kinetics of CYP450 isoforms.  Additional studies investigating the effects of 
hypothermia on multiple enzyme kinetic models including models of atypical enzyme kinetics 
are warranted.  This will provide mechanistic insight into the effect of mild to moderate cooling 
on CYP450 enzyme functionality.  Additionally, it will be important to investigate the effects of 
hypothermia on other drug metabolizing enzymes such as UDP-glucuronsyltransferase as well as 
drug transporters, such as p-glycoprotein.   
Another future direction of this work includes the further investigation of the effects of 
cardiac arrest with and without hypothermia on the effects of pro-inflammatory cytokines and 
the regulation of CYP450s.   First, further investigation into the role of IL-6 could be analyzed 
using an IL-6 knockout mouse model.  This study would included a control group without 
cardiac arrest or hypothermia, control group receiving cardiac arrest, IL-6 knockout receiving 
cardiac arrest, and IL-6 knockout receiving cardiac arrest plus hypothermia.  The use of this 
model would provide insight into the role of IL-6 on the regulation of CYP450 isoforms after 
cardiac arrest.  The investigation into the role of other pro-inflammatory cytokines (IL-1β and 
TNF-α) and nuclear transcription factors (AP-1 and C/EBP beta) needs to be investigated as 
inflammation is regulated via multiple pathways.    
These preclinical studies are important to provide direction as we develop future clinical 
studies identifying the effects of hypothermia on drug metabolism. The findings of our pilot 
analysis need to be confirmed by enrolling a greater number of subjects and utilizing a CYP450 
cocktail approach in order to assess multiple CYP isoforms in each subject.  In addition, the 
development of a hypothermia model in normal healthy volunteers which would maintain mild 
hypothermia over a longer period of time is warranted to provide a more controlled study.  The 
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use of a pharmacodynamic measure of sedation during hypothermia would provide insight into 
the effects of cooling on drug response and correlate this to the pharmacokinetic alterations.  
These data then can be used to develop a multi-center clinical trial investigating the 
effects of therapeutic hypothermia on CYP450-mediated metabolism in CA patients.  Second, as 
outlined in Chapter 1, the effects of hypothermia on drug disposition are a complex interplay 
between the effects during cooling, and the effects of hypothermia after re-warming) and the 
effects on drug response.  The effects of hypothermia on both pharmacokinetic and 
pharmacodyanmics would As this work has begun to investigate these effects of hypothermia on 
drug metabolism, future work is needed to further elucidate these changes and examine 
hypothermia-mediated changes in drug response.   
In conclusion, the results of the work performed throughout this dissertation could have 
important clinical implications, since reductions in metabolism could lead to drug toxicity and 
adverse events in patients treated with therapeutic hypothermia.  In order to begin to provide 
dosing recommendation during hypothermia therapy, more research is warranted in order to 
optimize patient care.   
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APPENDIX A: Data From All Experimental Analyses 
A.1 STUDY 1: THERAPEUTIC HYPOTHERMIA –INDUCED 
PHARMACOKINETIC ALTERATIONS ON CYP2E1 CHLORZOXAZONE-
MEDIATED METABOLISM IN A CARDIAC ARREST RAT MODEL 
A.1.1 Effects of Moderate Hypothermia on Chlorzoxazone Plasma Concentrations 
(µg/mL) After Cardiac Arrest 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CA Normothermia Animals
1 2 3 4 5 6
Time (minutes)
10 17.8 15.4 14.6 16.5 18.6 18.5
20 12.8 13.6 19.8 17.4 20.9 20.4
30 14.5 13.3 18.9 26.8 24.6 20.2
60 13.8 14.9 16.7 18.5 22.8 17.0
90 17.9 12.8 11.3 17.1 17.1 23.9
120 13.2 10.3 12.7 14.5 14.0 20.8
150 17.4 11.6 9.2 15.9 13.1 16.5
165 20.4 8.5 10.0 18.1 13.0 15.4
CA Hypothermia Animals
1 2 3 4 5 6
10 18.3 16.2 18.3 19.9 21.3 13.9
20 21.4 16.6 15.3 18.9 21.8 9.8
30 18.1 12.8 15.2 15.3 19.1 12.8
60 11.6 8.6 10.4 9.8 16.2 10.9
90 10.7 8.0 8.6 8.4 15.9 10.2
120 8.4 10.3 7.9 6.6 14.9 8.2
150 7.3 9.9 10.0 5.8 13.8 8.0
165 6.4 8.0 8.2 7.9 13.1 5.2
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A.1.2 Urine Analysis of 6-OH Chlorzoxazone of Cardiac Arrest Animals   
 
 
 
 
 
 
 
 
 
 
 
A.1.3 Effects of Moderate Hypothermia on Protein Binding of Chlorzoxazone 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total (ug/mL) Bound (ug/mL) Unbound (ug/mL) Fraction Unbound % Bound
37oC Samples
1 10.93 10.12 0.58 0.05 94.67
2 14.44 12.07 0.64 0.04 95.55
3 15.91 12.95 0.75 0.05 95.30
4 13.04 10.80 0.50 0.04 96.15
30oC Samples
1 10.12 8.86 0.37 0.04 96.32
2 11.96 10.96 0.50 0.04 95.80
3 16.21 13.42 0.71 0.04 95.64
4 13.18 12.33 0.61 0.05 95.35
Concentration (ug/m Volume(mL) Amount (ug) of Excretion (ug/min)
CA Normothermia Animals
1 552.3 0.7 386.6 2.3
2 201.4 0.4 80.56 0.5
3 330.6 0.6 198.3 1.2
4 292.5 0.75 219.4 1.3
5 104.9 0.9 94.39 0.6
6 107.9 0.6 64.76 0.4
CA Hypothermia Animals
1 23.36 0.7 16.35 0.10
2 95.86 0.2 19.17 0.12
3 139.4 0.8 111.5 0.68
4 18.53 0.4 7.410 0.04
5 99.52 0.7 69.66 0.42
6 58.02 0.5 29.01 0.18
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A.1.4 Formation Rates of 6-OH Chlorzoxazone (nmol/mg/min) in Michaelis-Menten 
Enzyme Kinetic Analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
37oC Samples
CZN Conc. (umol) 1 2 3 4
500 1.27 1.25 1.67 1.63
400 1.52 1.15 1.54 1.51
300 1.21 1.05 1.30 1.38
200 0.97 0.96 0.99 1.27
100 0.58 0.55 0.77 0.70
75 0.39 0.36 0.57 0.56
50 0.28 0.18 0.48 0.40
30oC Samples
1 2 3 4
CZN Conc. (umol)
500 0.99 1.57 1.02 1.53
400 0.95 1.45 1.17 1.29
300 0.85 1.35 0.86 0.96
200 0.67 0.94 0.67 0.76
100 0.38 0.46 0.37 0.38
75 0.37 0.28 0.30 0.35
50 0.23 0.14 0.24 0.20
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A.2 STUDY 2: MODERATE HYPOTHERMIA PREVENTS CARDIAC ARREST-
MEDIATED CYP3A2 AND CYP2E1 SUPPRESSION AND INTERLEUKIN-6 
INDUCTION 
A.2.1 Formation Rates of 6-OH Chlorzoxazone (nmol/mg/min) in Cardiac Arrest Rats 24-
hours After Injury  
 
 
 
 
 
 
 
 
 
 
A.2.2 Formation Rates of 6β-OH Testosterone (pmol/mg/min) in Cardiac Arrest Rats 24-
hours After Injury 
 
 
 
 
 
 
 
 
 
 
Normothermia CA Normothermia CA Hypothermia
N2 0.88 CA 1 0.58 CA H1 0.40
N3 0.73 CA 2 0.44 CA H2 1.39
N4 0.64 CA 3 0.30 CA H3 1.21
N5 0.85 CA 4 0.54 CA H4 0.86
N6 1.02 CA 5 0.50 CA H5 0.70
N7 0.98 CA 6 0.47 CA H6 1.03
Average 0.85 Average 0.47 Average 0.93
St.Dev. 0.14 St.Dev. 0.10 St.Dev. 0.36
C ntr l
Normothermia CA Normothermia CA Hypothermia
N2 1026.0 CA 1 1103.9 CA H1 3684.8
N3 1817.1 CA 2 294.0 CA H2 2172.9
N4 1183.0 CA 3 504.8 CA H3 1861.2
N5 1724.7 CA 4 177.1 CA H4 1172.9
N6 1527.9 CA 5 947.0 CA H5 3634.5
N7 2626.6 CA 6 605.2 CA H6 5396.9
Average 1650.9 Average 605.3 Average 2987.2
St.Dev. 567.4 St.Dev. 362.2 St.Dev. 1545.0
Control
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A.2.3 Formation Rates of 6-OH Chlorzoxazone (nmol/mg/min) in Cardiac Arrest Rats 5-
hours After Injury 
 
 
 
 
 
 
 
 
A.2.4 Formation Rates of 6β-OH Testosterone (pmol/mg/min) in Cardiac Arrest Rats 5-
hours After Injury 
 
 
 
 
 
 
 
 
 
 
 
 
 
Normothermia CA Normothermia CA Hypothermia
N1 1.19 CA 1 1.96 CA H1 2.05
N2 1.61 CA 2 1.61 CA H2 1.29
N3 1.16 CA 3 1.75 CA H3 2.21
N4 1.99 CA 4 1.79 CA H4 1.53
N5 1.79 CA 5 1.07 CA H5 1.47
N6 1.79 CA 6 1.55 CA H6 1.81
Average 1.59 Average 1.62 Average 1.73
St.Dev. 0.34 St.Dev. 0.31 St.Dev. 0.36
C ntr l
Normothermia CA Normothermia CA Hypothermia
N2 2012.6 CA 1 2741.2 CA H1 1867.8
N3 2660.8 CA 2 2588.3 CA H2 2521.2
N4 2153.7 CA 3 2361.6 CA H3 3510.6
N5 3166.7 CA 4 2496.2 CA H4 2186.7
N6 2582.9 CA 5 1946.7 CA H5 1865.3
N7 1756.2 CA 6 2112.1 CA H6 3171.5
Average 2388.8 Average 2374.4 Average 2520.5
St.Dev. 512.6 St.Dev. 299.0 St.Dev. 688.6
C ntr l
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A.2.5 Interleukin-6 Plasma Concentrations (pg/ml) in Cardiac Arrest Rats After Injury 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Time (min)
Control 1 2 3 4 5 6
60 42.8 81.2 158.2 6.6 125.7 0.0
70 10.9 0.0 103.8 7.0 90.4 0.0
90 31.1 32.4 49.2 9.6 22.5 0.0
120 56.5 23.9 30.4 0.0 0.0 0.0
180 21.9 16.1 28.5 28.5 0.0 0.0
210 12.2 25.9 19.1 47.9 0.0 0.0
240 53.9 43.4 35.1 39.9 0.0 45.0
270 34.3 33.7 77.1 53.1 29.0 27.3
285 16.7 0.0 0.9 89.6 16.1 37.8
CA Normothermia 1 2 3 4 5 6
60 958 812 386 566 985 877
70 543 873 412 385 2233 826
90 714 569 262 161 651 518
120 298 465 201 46 294 249
180 204 242 180 11 160 215
210 341 350 326 40 164 399
240 129 495 204 30 336 314
270 33 271 170 25 254 340
285 109 216 180 36 211 297
CA Hypothermia 1 2 3 4 5 6
60 121.4 35.1 29.3 9.9 15.8 91.1
70 83.8 41.7 6.1 18.4 8.7 80.2
90 45.6 43.9 6.6 16.8 9.5 61.3
120 27.8 35.5 13.6 28.4 8.3 74.0
180 19.7 46.6 12.7 25.8 9.5 71.2
210 48.3 36.0 21.0 38.4 12.3 47.2
240 32.0 22.3 30.7 47.6 7.4 52.3
270 35.2 0.0 43.2 83.0 10.4 57.5
285 14.4 0.0 32.4 22.3 8.1 65.1
 155 
A.2.6 Nitrate Plasma Concentrations (µmol) in Cardiac Arrest Rats After Injury 
 
 
 
 
 
 
 
 
 
 
 
 
 
A.2.7 Nitrite Plasma Concentrations (µmol) in Cardiac Arrest Rats After Injury 
 
 
 
 
 
 
Time (min)
Control 1 2 3 4 5 6
60 4.8 6.9 17.5 13.2 30.3 0.0
70 5.2 7.0 18.2 11.2 15.9 9.1
90 5.9 6.2 23.2 14.8 11.6 11.5
120 5.5 7.7 24.1 11.2 13.0 0.0
180 7.5 8.3 19.9 11.8 9.9 0.0
CA Normothermia 1 2 3 4 5 6
60 6.3 0.0 12.4 12.6 15.2 19.0
70 8.9 28.9 13.8 16.8 11.4 13.6
90 8.3 25.7 10.6 8.4 14.2 17.2
120 14.2 30.4 16.5 20.5 14.9 23.3
180 15.4 37.3 13.7 15.8 29.7 0.0
CA Hypothermia 1 2 3 4 5 6
60 12.1 11.3 11.9 0.0 15.8 0.0
70 0.0 10.8 11.0 15.1 8.7 11.4
90 0.0 0.0 17.1 16.3 9.5 0.0
120 0.0 13.2 12.2 20.1 8.3 13.0
180 16.1 15.7 12.5 15.7 9.5 17.7
Time (min)
Control 1 2 3 4 5 6
60 0.03 0.00 4.7 4.1 11.4 0.0
70 0.03 0.00 3.5 5.8 9.2 7.4
90 0.00 0.00 3.6 5.2 8.2 9.7
120 0.05 0.00 4.2 3.9 8.7 0.0
180 0.00 0.00 3.8 4.3 6.0 0.0
CA Normothermia 1 2 3 4 5 6
60 0.0 0.0 6.3 8.8 10.6 11.8
70 0.1 7.8 4.4 14.2 7.8 8.0
90 0.0 6.1 10.4 6.3 8.3 8.0
120 0.1 5.2 6.5 14.9 8.9 9.4
180 0.0 10.0 4.0 10.0 13.0 0.0
CA Hypothermia 1 2 3 4 5 6
60 3.9 5.7 4.3 0.0 0.0 0.0
70 3.6 0.0 3.8 18.2 14.5 14.5
90 2.9 0.0 0.0 13.8 0.0 0.0
120 4.2 0.0 5.7 13.9 15.9 15.9
180 2.6 0.0 7.7 16.1 0.0 0.0
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A.3 STUDY 3: MILD AND MODERATE HYPOTHERMIA ALTERS CYP2E1 AND 
CYP3A4 ENZYME KINETICS IN HUMAN HEPATIC MICROSOMES 
A.3.1 Effect of Mild and Moderate Hypothermia on CYP2E1 Michaelis Enzyme Kinetics: 
Formation Rates of 6-OH Chlorzoxazone (nmol/mg/min) in Pooled Human Hepatic 
Microsomes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
37oC Samples 1 2 3 4 5 6 Average St.Dev.
CZN Conc. (umol)
500 1.94 1.80 2.06 1.94 1.74 2.40 1.98 0.23
400 1.97 1.78 2.18 1.94 1.69 2.37 1.99 0.25
300 1.81 1.84 2.11 1.95 1.89 2.25 1.98 0.17
200 1.96 2.01 2.07 1.87 1.75 1.90 1.93 0.11
100 1.65 1.23 1.71 1.33 1.31 1.46 1.45 0.20
75 1.12 1.13 1.28 0.92 0.92 0.77 1.02 0.19
50 0.80 1.06 0.93 0.72 0.69 0.63 0.81 0.16
33oC Samples 1 2 3 4 5 6 Average St.Dev.
CZN Conc. (umol)
500 1.11 1.16 1.08 1.19 1.16 1.24 1.16 0.06
400 1.00 1.25 1.13 1.21 1.34 0.94 1.14 0.15
300 0.89 1.10 1.07 0.94 1.10 0.96 1.01 0.09
200 0.76 1.12 1.11 0.95 1.14 1.00 1.01 0.15
100 0.85 0.68 0.74 0.72 0.65 0.76 0.73 0.07
75 0.64 0.70 0.59 0.79 0.69 0.61 0.67 0.07
50 0.50 0.43 0.38 0.43 0.48 0.54 0.46 0.06
30oC Samples 1 2 3 4 5 6 Average St.Dev.
CZN Conc. (umol)
500 1.06 0.91 0.87 1.55 1.55 1.57 1.25 0.34
400 0.85 0.95 0.97 1.42 1.92 1.51 1.27 0.42
300 0.87 0.83 0.98 1.26 1.54 1.23 1.12 0.27
200 0.75 0.94 0.68 1.22 1.31 1.09 1.00 0.25
100 0.50 0.50 0.61 0.89 1.04 0.82 0.73 0.22
75 0.46 0.36 0.49 0.85 0.66 0.60 0.57 0.17
50 0.05 0.25 0.39 0.72 0.61 0.37 0.40 0.24
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A.3.2 Effect of Mild and Moderate Hypothermia on CYP3A4 Michaelis Enzyme Kinetics: 
Formation Rates of 6β-OH Testosterone (pmol/mg/min) in Pooled Human Hepatic 
Microsomes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
37oC Samples 1 2 3 4 5 6 Average St.Dev.
TST Conc. (umol)
250 9732.7 7074.3 8376.7 8212.1 7722.6 8884.5 8223.7 984.0
150 9473.8 9970.5 10380.4 7725.6 7295.6 7440.5 8969.2 1378.1
100 5683.3 6914.4 6454.7 8028.8 6251.4 5289.7 6666.5 880.5
75 7880.2 7436.2 6690.5 6187.4 6262.2 6663.8 6891.3 742.7
50 5804.3 5033.3 4169.8 5233.4 5423.9 3051.9 5133.0 608.9
25 2701.7 3945.7 4297.8 2187.0 3003.2 2727.9 3227.1 876.2
12.5 1173.0 991.2 945.9 2010.5 1621.6 1796.5 1348.4 456.4
6.25 414.8 385.2 418.7 434.1 320.9 244.8 394.7 44.9
33oC Samples 1 2 3 4 5 6 Average St.Dev.
TST Conc. (umol)
250 3933.7 4071.5 3322.7 3711.9 3940.1 3727.3 3796.0 294.4
150 3842.2 3763.2 3932.4 3944.0 3570.7 3389.1 3810.5 152.8
100 4279.4 3077.6 3312.0 3457.3 3471.4 3226.9 3519.5 453.3
75 3454.7 3580.0 3354.7 3500.6 3447.6 3530.3 3467.5 82.2
50 2912.1 3429.1 2957.5 3012.9 2442.3 2854.3 2950.8 351.0
25 2090.5 2799.1 2300.5 2062.6 1965.2 2035.9 2243.6 333.8
12.5 992.6 1317.5 1394.7 1052.1 996.7 938.8 1150.7 190.9
6.25 381.6 299.1 547.5 346.0 463.5 383.3 407.5 98.7
30oC Samples 1 2 3 4 5 6 Average St.Dev.
TST Conc. (umol)
250 4071.2 4071.5 3322.7 3711.9 3940.1 3727.3 3807.4 285.5
150 4286.1 3763.2 3932.4 3944.0 3570.7 3389.1 3814.3 315.0
100 3664.5 3077.6 3312.0 3457.3 3471.4 3226.9 3368.3 206.9
75 3815.3 3580.0 3354.7 3500.6 3447.6 3530.3 3538.1 156.1
50 3105.1 3429.1 2957.5 3012.9 2442.3 2854.3 2966.9 323.4
25 2006.3 2799.1 2300.5 2062.6 1965.2 2035.9 2194.9 318.6
12.5 1197.4 1317.5 1394.7 1052.1 996.7 938.8 1149.5 183.2
6.25 412.7 299.1 547.5 346.0 463.5 383.3 408.7 88.2
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A.3.3 Effect of Mild and Moderate Hypothermia on Formation Rates of 6-OH 
Chlorzoxazone (nmol/mg/min) in Individual Human Hepatic Microsomes  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
37oC Samples 1 2 3 4
CZN Conc. (umol)
500 0.95 1.30 1.14 0.23
400 0.92 1.64 1.34 0.19
300 0.78 1.43 1.70 0.16
200 0.71 1.48 1.14 0.15
100 0.75 1.19 0.93 0.14
75 0.48 1.01 0.63 0.13
50 0.40 0.70 0.51 0.10
33oC Samples 1 2 3 4
CZN Conc. (umol)
500 0.82 0.99 1.30 0.24
400 0.92 0.94 1.64 0.26
300 0.82 1.03 1.43 0.27
200 0.84 0.84 1.30 0.16
100 0.70 0.81 1.19 0.12
75 0.52 0.48 0.58 0.14
50 0.22 0.38 0.55 0.11
30oC Samples 1 2 3 4
CZN Conc. (umol)
500 0.59 0.60 1.32 0.20
400 0.50 0.58 1.36 0.19
300 0.57 0.67 1.23 0.17
200 0.41 0.47 1.00 0.12
100 0.37 0.42 0.68 0.10
75 0.22 0.31 0.63 0.09
50 0.23 0.29 0.49 0.08
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A.3.4 Effect of Mild and Moderate Hypothermia on Formation Rates of 6β-OH 
Testosterone (pmol/mg/min) in Individual Human Hepatic Microsomes  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
37oC Samples 1 2 3 4
TST Conc. (umol)
250 3386.6 8167.9 770.0 14130.0
150 3249.1 8744.5 1085.6 11026.5
100 3754.5 7475.8 1200.7 10650.0
75 3916.2 7238.8 700.2 10219.0
50 3566.6 6661.6 602.8 10577.2
25 3093.6 5293.8 546.3 12194.5
12.5 2048.9 3728.8 347.3 9635.0
6.25 908.9 2282.5 188.4 3513.1
33oC Samples 1 2 3 4
TST Conc. (umol)
250 3693.2 6608.0 708.9 9809.9
150 3470.7 12169.4 965.0 11954.2
100 3308.1 5445.7 1024.5 10150.1
75 3533.4 7499.3 571.6 9163.5
50 3452.0 7127.8 499.5 8695.9
25 2406.6 5143.3 435.3 7390.2
12.5 1932.5 2750.0 285.0 4878.5
6.25 745.5 1811.1 172.8 1326.5
30oC Samples 1 2 3 4
TST Conc. (umol)
250 3828.8 6001.4 683.0 8479.1
150 3990.9 6078.4 686.0 8724.5
100 3404.4 6125.3 718.0 9374.9
75 2855.5 5629.6 494.2 8902.2
50 2888.2 5299.4 455.2 8322.6
25 2475.5 3716.2 346.8 7432.3
12.5 830.0 1570.1 275.8 4755.2
6.25 950.3 874.9 192.9 2692.4
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A.4 STUDY 4: THE EFFECTS OF MILD HYPOTHERMIA ON MIDAZOLAM 
PHARMACOKINETICS IN NORMAL HEALTHY SUBJECTS: A PILOT  STUDY 
A.4.1 Midazolam Plasma Concetrations in Subjects 
 
 
 
 
 
 
Midazolam Concentrations
Subject 1 Warm(ng/ml) Cold (g/ml) Subject 2 Warm(ng/ml) Cold (g/ml) Subject 3 Warm(ng/ml) Cold (ng/ml)
5 240 266 5 293 164 5 212 148
15 315 355 15 472 196 15 250 215
25 546 391 25 470 585 25 288 455
30 438 545 30 429 425 30 285 346
50 354 571 50 341 378 50 328 332
80 307 430 80 325 222 80 204 290
140 170 274 140 310 117 140 121 91
200 156 188 200 168 103 200 73 75
260 125 184 260 143 66 260 60 51
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APPENDIX B: Study Approval, Protocol, and Consent Forms 
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Protocol Title:  
 
Induction and maintenance of therapeutic hypothermia and associated pharmacokinetics 
in healthy subjects 
 
 
1.0 SPECIFIC AIMS & OBJECTIVES 
 
Specific Aim 1: Examine the administration of 4°C and 37°C saline in conjunction with 
benzodiazepine sedation or benzodiazepine sedation and magnesium sulfate infusion in an effort 
to blunt the shivering response and discomfort associated with cold saline infusion.   
Specific Aim 2: Determine the pharmacokinetics of midazolam in normothermic and 
hypothermic subjects in order to assess CYP3A4 activity 
 
2.0 BACKGROUND AND SIGNIFICANCE 
  
Mild hypothermia (34-35°C) has been shown to improve neurological outcome after cardiac 
arrest.1,2  Animal studies have shown the therapeutic benefit may be optimized by earlier 
initiation following resuscitation.3  Surface cooling is non invasive and potentially the safest 
mode for inducing mild hypothermia.  However, this technique has a limited ability to quickly 
bring the patient to the target temperature. Additionally, surface cooling requires substantial 
resources such as large quantities of ice, chemical icepacks, or powered cooling blankets.  
Endovascular cooling delivers chilled saline directly to the body core and bypasses the need to 
cool the shell and skeletal muscle.4  Since it is less costly and resource intensive, this mode of 
cooling could be initiated by paramedics in the prehospital setting. 
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Mild hypothermia has also been investigated as a therapeutic agent for stroke and 
myocardial infarction.5,6  As with cardiac arrest, the optimal core temperature is believed to be 
34-35°C. However, unlike the post resuscitation patient, stroke patients will defend their core 
temperature and the shivering response may prevent the attainment of a therapeutic temperature.  
Significant cooling can be achieved under general anesthesia but this procedure is not available 
to paramedics.7  To initiate therapeutic hypothermia at the earliest opportunity it will be 
necessary to identify a regimen that is comfortable for the patient and suppresses or dampens the 
shivering response without jeopardizing patient safety.  Additionally, this regimen must maintain 
therapeutic hypothermia induced in the prehospital setting until the patient can receive 
reperfusion therapy in the hospital. 
Various drugs are available that may suppress the shivering response and yet still be safe 
to administer to awake patients during acute illness such as myocardial infarction or stroke.  
Meperidine has been used but has toxic metabolites.  Other possibilities include narcotics, 
benzodiazepines, and buspirone.  In addition, hypothermia has been shown to dramatically alter 
multiple drug concentrations, including benzodiazepines.8  In order to optimize this protocol and 
provide maximum comfort to the patient, it is crucial to understand the effect of cooling on the 
disposition and metabolism of drugs which are commonly employed by paramedics in the 
prehospital setting.   
 
3.0 RESEARCH DESIGN AND METHODS 
3.1 Drug/Device Information.  This study does not utilize experimental drugs or devices.  
Benzodiazepine administration, normal saline administration, temperature monitoring are 
being provided as an on label indication. 
3.2 Study Protocol  
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This protocol will examine the administration of midazolam to induce mild sedation 
followed by and lorazepam to maintain sedation during cold saline infusion to determine if a 
core temperature of 34-35°C can be achieved in healthy volunteers aged 18 – 35 years after mild 
sedation.  We are utilizing two benzodiazepines to induce and maintain sedation to allow this 
protocol to determine the effects of mild hypothermia on the disposition of midazolam (Figure 
1). Intensive monitoring will be performed to test the safety of this procedure in a patient 
population.  A total of five visits will be required to complete the study. One visit will be 
required for the screening and four additional visits for the experimental protocols. 
A study physician will perform a history and physical exam on each subject to assess for 
the presence of medical conditions.  The screening will take place in the department of 
emergency medicine offices on a visit separate from the experimental protocol and is expected to 
take approximately 60 minutes.  Special focus will be placed on a history of early cardiac death 
in family members or any other signs that an underlying cardiac anomaly may be present. Body 
composition will be assessed by measuring skinfolds at three sites.  Blood samples will be 
collected for sodium, potassium, TSH, SGOT, SGPT, alkaline phosphatase, billirubin, BUN, 
creatinine, and a complete blood count to exclude undiagnosed liver, hematologic, and metabolic 
disease.  A maximum of 30 cc (2 tablespoon) of blood will be collected. Finally, a standard 12-
lead EKG will be obtained and interpreted by a study physician to assess for any other apparent 
cardiac pathology.  Normal lab values used by the University of Pittsburgh Medical Center 
Presbyterian Hospital lab will be accepted as the normal range.  In the event a lab value is 
outside the normal range, but not clinically significant in the study physicians opinion, the 
subject will be allowed to repeat the lab test once.  Two lab tests outside the normal range will 
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exclude the subject.  Any subject excluded from the study will be provided the information 
concerning their exclusion and they will be referred to their primary care physician. 
The subject will be scheduled to complete the four arms of the protocol at a separate time 
from the screening. At least one week will separate each arm of the protocol.  Based on 
availability, protocols will be completed in the UPMC-Presbyterian Emergency Department or at 
the Emergency Responder Human Performance Lab (ERHPL) at 230 McKee Place, Suite 400. 
ERHPL is a fully equipped clinical physiology lab.  Pertaining to this study, ERHPL and has the 
following equipment available 1) ECG monitor with non-invasive blood pressure, 2) ETCO2, 
SPO2 monitor, 3) ACLS medications and reversal agents, 4) suction, oxygen, BLS and ALS 
airway equipment, 5) defibrillator, and 6) a full range of temperature monitoring equipment.  
Both study physicians and a paramedic will be present at all procedures.  In the event a patient 
needs to be transferred to Presbyterian Hospital, Pittsburgh EMS will be contacted through the 
911 system. 
Subjects will be asked to refrain from caffeine and alcohol for 24 hours prior to the 
protocol and from grapefruit juice for 48 hours.  Grapefruit juice is known to alter cytochrome 
P450 metabolism while caffeine and alcohol may alter hydration status. Upon arriving for a 
protocol, subjects will void their bladder and be weighed.  
Overview: After preparation and application of the monitoring equipment the subject will 
receive midazolam sedation and 30 cc/kg of either 4°C or 37°C normal saline over a 30-minute 
period.  Depending on randomization, the subject may receive a magnesium infusion at that time.  
Other than the temperature of the saline and the magnesium infusion, all other procedures are 
identical in all four arms.  Following this induction period, the subject will receive an infusion of 
lorazepam to maintain mild sedation.  This period will allow us to determine the response of core 
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body temperature and the pharmacokinetics of midazolam.  The protocols of interest are those 
using cold saline.  The warm saline arms provide appropriate control groups.  Following the 
three-hour monitoring period, the lorazepam infusion will be discontinued and a study physician 
will monitor the subject until it is safe for them to be discharged from the lab.  The  flow of the 
experiment is schematically shown in Figure 2. 
 
Subjects will then be prepared as follows: 
 
Intravenous Access: An 18-gauge intravenous catheter will be placed in one of the 
subject’s hand, forearm, or antecubital veins using standard technique and universal precautions 
for saline infusion.  A second 18- or 20-gauge intravenous catheter will be placed in the arm or 
hand for blood sampling. 
Temperature monitoring: Core temperature will be monitored by an ingestible capsule 
(CorTemp) administered one hour prior to the infusion.  This commercially available capsule 
transmits temperature to a receiving unit continuously. This capsule is FDA approved.  Skin 
temperature will be measured by placing thermistors on the chest, back, triceps, and anterior 
thigh.  Temperatures will be recorded every two minutes during infusion and every five minutes 
during recovery. 
Vital signs:  Heart rate, respiratory rate, ECG, ETCO2, and SPO2 will be measured 
continuously.  Heart rate, respiratory rate, and SPO2 will be documented every two minutes 
during infusion and every ten minutes during the follow up period. Automatic non-invasive 
blood pressure and the Ramsay sedation scale will be documented every five minutes during 
infusion and recovery. 
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Additional monitoring: The BIS spectral monitor (an adhesive patch placed on the 
subjects forehead to determine the level of sedation) and the Somanetics INVOS tissue 
oxygenation monitor (an adhesive patch placed over the vastus muscles to measure skeletal 
muscle perfusion) will be used.  Surface EMG electrodes will be placed over the vastus muscles 
and connected to a bioamplifier to monitor for cyclical activity indicating shivering.  The muscle 
oxygenation and EMG monitors are not related to subject safety monitoring and are used to 
collect preliminary data for hypothesis generation.  If the logistics of one of these monitors from 
the implementation or data collection for the primary outcomes they will be discontinued.  
Subjective measures: A 10 cm visual analog scale for discomfort will be collected every 
five minutes during infusion and recovery.  Additionally, we will utilize a 9-point thermal 
sensation scale  (1 = very cold, 5 = neutral, 9 = very hot) and a 4-point comfort scale 
(1=comfortable, 4 = very uncomfortable).  Subjects will be familiarized with the scales prior to 
beginning the experiment. 
Randomization: After screening, subjects will complete all arms of the study in a 
randomly generated order. Subjects will be entered sequentially into the randomization scheme 
as they are enrolled (Figure 1).  
 
 
 
 
 
 
 
  
Benzodiazepine/
Saline Infusion
Benzodiazepine +
MgSO4
Saline Infusion
Sedation Alone Sedation +
Vasodilation
Sedation +
Hypothermia
Sedation +
Vasodilation +
Hypothermia
4OC Saline
37OC Saline
1. 2.
3. 4.
Figure 1: Randomization scheme of sedation, vasodilation, 
and fluid temperature
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Induction period: During this 30-minute period, the subject will receive a weight based 
infusion of normal saline and, depending on randomization, a magnesium infusion.  Subjects will 
receive 30mL/kg of cold (4°C) or (37°C) saline administered by peripheral IV.  The total saline 
dose will be delivered over 30 minutes. Subjects will receive midazolam 2 mg administered 
intravenously just prior to initiating the infusion. Additional 2 mg doses will be administered 10 
and 20 minutes into the infusion (total of 6 mg). When randomized to the appropriate arms, 4 g 
of magnesium sulfate will be administered during the 30-minute induction.  Other studies of 
induced hypothermia have demonstrated that the vasodilatory effect of magnesium sulfate 
enhances cooling and increases subject comfort.9 
Maintenance period: Following the 30-minute saline infusion, an infusion of lorazepam 
(1 mg/hr) will be initiated to maintain mild sedation for three hours.  This infusion will be 
titrated to maintain the subject’s sedation so that they respond to questions appropriately. Blood 
samples will be drawn and physiological monitoring will be continued during this period. 
Follow up period: Following the three-hour maintenance period, the lorazepam infusion 
will be discontinued and the subject will be monitored for a minimum of 60 minutes.  
Physiological monitoring will be continued during this period and one final blood sample will be 
obtained. 
Blood Sampling and Analysis: After administration of the third midazolam dose, blood 
samples will be drawn as depicted in Figure 2.  Blood samples, (5 ml) will be obtained via a 
peripheral line, for a total of 40 ml of blood taken. Blood will be separated by a microcentrifuge 
and plasma will be stored at -80oC until further analysis.    
Midazolam concentrations will be determined using liquid chromatography-mass 
spectrometry (LC-MS) methods as previously described.10 Briefly a 0.5-mL aliquot of plasma  
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will be combined with 2N sodium hydroxide (0.25 mL) and internal standard (150 ng of 
flurazepam). Methyl tert-butyl ether (5 mL) will be added, and centrifuged at 3000g for 10 
minutes.  Samples will be evaporated to dryness under a gentle stream of nitrogen at 40°C, and 
reconstituted with 100 µL methanol. The samples will be transferred to a microvolume gas 
chromatography vials, and 4 µL will be injected into the system. The retention times for 
midazolam and flurazepam with use of a DB-5 (5% phenylmethylpolysiloxane) fused silica 
capillary column (30-m length x 0.25-mm inner diameter; 0.25-mm film thickness; J&W 
Scientific, Folsom, Calif) will be approximately 9.6 and 11.1 minutes, respectively. Midazolam 
and flurazepam (internal standard) will be monitored at mass-to-charge ratios of m/z 310 and m/z 
86, respectively.  
Patient safety and protocol termination: Primary endpoints for this protocol are 1) 
attaining a core temperature of 34°C - 35°C and maintaining the temperature for 2-3 hours or 2) 
if the subject requests termination. The secondary endpoint for this protocol is midazolam 
Midazolam bolus 
q10 min
25 30 50 80 140 200 210 260 270
Lorazepam infusion
1 mg/hr
Recovery
Induction Maintenance Follow-up
BDBD BD BD BD BD BD
BD= Blood Draw
BD BD
155 235
BD
Hypothermia Protocol
Figure 2: Blood sampling scheme and hypothermia protocol
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pharmacokinetic alterations.  If the protocol ends early for any reason the subject will continue to 
be monitored by a study physician until it is safe for them to be discharged.   
The following criteria will result in early termination of the study: 1) If at any point in 
time of the study the subject is found to have a heart rate less than 40 or greater than 150, 2) 
systolic blood pressure less than or equal to 80mmHg or greater than 180mmHg, 3) respirations 
less than 7 or more than 30 per minute, 4) pulse oximetry less than 93%, 5) at any sign of 
arrhythmia, or 6) a sedation scale of 4.  The study physician will administer flumazenil for 
subjects who meet these stopping criteria.  
If ETCO2 exceeds 50 mmHg during the protocol or the subject displays a Ramsay 
sedation score of 3, the next scheduled dose of midazolam will be replaced with a placebo saline 
injection and the study will continue.  Additionally, subsequent doses of midazolam may be 
replaced with a placebo saline injection at the study physician’s discretion. 
In the event a subject requires airway management beyond manual jaw thrust, displays 
persistent hypoxia or cardiac arrhythmia, or abnormal vital signs that do not respond to 
flumazenil administration 911 will be called and the subject will be transferred to UPMC-
Presbyterian hospital.  The study physician has the option of calling 911 for other unanticipated 
situations requiring advanced care. 
All subjects will be monitored for a minimum of 60 minutes after completing the three-
hour maintenance period or until the study physician has determined they can be safely 
discharged.  The subject must have a Ramsay Sedation Score of 2 (cooperative, oriented) before 
being discharged from the lab.  Subjects must void their bladder and be weighed prior to 
discharge. No subject will be allowed to drive immediately following the protocol and will be 
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advised not to drive for 24 hours.  Subjects must have arranged for a friend or family member to 
pick them up from the lab.  
 
3.3  Data Analysis  
 This pilot study is descriptive in nature and will be used to determine feasibility, refine 
the protocol, and power a full trial. The primary statistical analysis will compare the change in 
temperature from baseline in the groups using repeated measures ANOVA with group and time 
as factors.  Although unlikely to see significant changes with four subjects, significance is set at 
p ≤ 0.05. Other continuous measures (e.g. heart-rate) will also be compared with ANOVA, and 
nonparametric tests (Kruskall-Wallis) will be used to compare ordinal or non-normally 
distributed data (e.g. sedation scales). 
 Blood samples will be maintained in the laboratory of Dr Samuel Poloyac in the 
University of Pittsburgh School of Pharmacy. Samples will be analyzed by Dr Poloyac,  his 
graduate students, or assistants.  
 
4.0 HUMAN SUBJECTS  
4.1 General Characteristics  
Subjects must be male aged 18 – 39 years. All races and ethnic groups are eligible for 
enrollment. No exclusion criteria shall be based on race, ethnicity. 
 
4.2 Inclusion of Children  
The target group for this intervention is adults with cardiovascular and cerebrovascular 
disease.  These diseases may be qualitatively different in children.  Therefore, we will not enroll 
subjects less than 18 years old. 
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4.3 Inclusion Criteria 
• Subjects must be male between the ages of 18 and 39 years have no known medical 
problems  
 
Exclusion Criteria 
• Abnormal laboratory values or ECGs 
• Those individuals who have any known history of current or previous medical problems, 
including but not limited to:  cardiac disease, history of arrhythmia or heart murmur, 
hypotension or hypertension, pulmonary disease including asthma, diabetes mellitus, 
thyroid disease, renal disease, liver disease, neurologic disease or seizures, connective 
tissue disorder or Raynaud’s disease, sickle cell disease, anemia, or hematologic 
disorders 
• HIV status will not be evaluated specifically for the purpose of this study; however, those 
individuals who are known to be HIV positive or are otherwise immunocompromised for 
any reason will be excluded 
• Subjects taking any medications (including herbal preparations) with the exception of 
allergy medication, ibuprofen or tylenol, or contraceptives.  Subjects will be specifically 
questioned about MAO inhibitor, antidepressant, Cimetidine, and St John’s Wort use. 
• Individuals with a history of cardiac disease in family members below the age of forty 
• Individuals with a known allergy to benzodiazepines  
• Individuals with a history of long-term benzodiazepine use 
• Individuals who are currently ill with a viral or other infection 
• Individuals with renal insufficiency. 
• Individuals who have abnormal vital signs as follows:  systolic blood pressure less than 
90mmHg or greater than 140mmHg, heart rate less than 40 or greater than 100, 
respiratory rate less than 10 or greater than 24.   
• Individuals who currently smoke or use any other recreational drugs 
• Individuals who are morbidly obese (BMI > 36) 
• The CorTemp system is contraindicated in subjects with any history of gastrointestinal 
disorder, including inflammatory bowel disease, esophageal disease, hypomotility 
disorders, history of GI surgery, impaired gag reflex, or who weighs less than 80 pounds 
or is morbidly obese.  Any subjects who met any of these criteria would be excluded 
from the study. 
 
4.4 Recruitment Procedures 
 An announcement will be made in Center for Emergency Medicine, Department of 
Emergency Medicine, and School of Pharmacy courses and grand rounds.  A recruitment flyer 
will be placed in common areas of the University.  Volunteers will be given a phone number to 
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call to arrange for an appointment with an investigator.  Informed consent and screening will 
take place at that meeting.  Subjects will be fully informed of the nature of the research, 
including the risks and benefits of the study and their rights as a research subject prior to 
obtaining their signatures on the informed consent document. 
No private information about the family members of the research subject will be 
obtained, with the exception of asking the subject if any immediate family members have any 
significant medical problems or if there is any history of sudden cardiac death or other cardiac 
disease in family members below the age of forty.  No attempts will be made to contact any 
family members of the research subjects. 
 
4.5 Risk/Benefit Ratio 
The risk of injury or complications with this research study is moderate.  The most 
significant risk associated with this study involves the mild hypothermia and any potential side 
effects of diazepam. 
 
4.5.1 Risk associated with hypothermia: 
 
Discomfort and shivering are the most likely side effect of the cold infusion.  This risk is 
likely to occur in more than 25% of people (more than 25 out of 100 people).  Prolonged mild 
induced hypothermia (temperature of 33-35°C over a period of greater than 12 hours) can affect 
multiple physiological systems.  There may be an increase in metabolic rate and oxygen demand 
secondary to shivering.  However, this should be easily tolerated in young healthy individuals 
with no cardiac problems.  In a study of cardiac arrest subjects, arrhythmias were rare, even with 
those suffering from myocardial infarction and did not differ from control groups.  Pneumonia 
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has occurred in those with prolonged hypothermia (greater than seven days) but is otherwise rare 
- expected to occur in less than 1% of people (less than 1 out of 100 people).  There was no 
increase in pulmonary edema in cardiac arrest subjects or normal volunteers.  Furthermore, these 
effects have all occurred in subjects who were maintained in mild hypothermia for a prolonged 
period of time.  Several studies in normal anesthetized volunteers who received a similar 
infusion via central venous catheters over a period of thirty minutes showed that the hypothermia 
was safely achieved with none of these side effects.  
 
4.5.2 Risks associated with midazolam administration 
The most common side effects of the midazolam include drowsiness and sedation [likely 
- expected to occur in more than 25% of people (more than 25 out of 100 people], apnea and 
respiratory depression [likely - expected to occur in about 15% of people (around 15 out of 100 
people)].  Subjects taking Cimetidine or with renal insufficiency may experience increased 
plasma levels and toxicity and are excluded from the study.  Subjects may also experience 
involuntary movements, nausea, vomiting, hives, rash [infrequent - expected to occur in 1-10% 
of people (1-10 out of 100 people)].  Anti-emetic medication (Phenergan 12.5 mg IV) and anti-
inflammatory medication (ibuprofen 200 mg PO) will be available for subjects experiencing 
nausea or headache secondary to the midazolam.  Other possible and more serious effects [rare - 
expected to occur in less than 1% of people (less than 1 out of 100 people)] include cardiac 
depression or arrest, hypotension, and visual disturbances.  As with any medication, an allergic 
reaction (e.g. rash, itching, swelling, shortness of breath) is always a risk. 
Given that healthy volunteers are being studied these effects are considered unlikely.  
 
4.5.3 Risks associated with lorazepam administration 
 176 
The most common side effects of the lorazepam include sedation [likely - expected to 
occur in more than 25% of people (more than 25 out of 100 people], dizziness, vertigo, 
weakness, or unsteadiness [infrequent - expected to occur in 1-10% of people (1-10 out of 100 
people)]. Subjects taking Cimetidine or with renal insufficiency may experience increased 
plasma levels and toxicity and are excluded from the study.  Subjects may also experience visual 
disturbances, sleep disturbances, depression, disorientation, headache, confusion, crying, 
delirium, or agitation [rare - expected to occur in less than 1% of people (less than 1 out of 100 
people)]. Other possible and more serious effects [rare - expected to occur in less than 1% of 
people (less than 1 out of 100 people)] include either low or high blood pressure, nausea, 
vomiting, blurred vision, or respiratory depression,  As with any medication, an allergic reaction 
(e.g. rash, itching, swelling, shortness of breath) is always a risk. 
Given that healthy volunteers are being studied these effects are considered unlikely.  
 
4.5.4 Risks of phenergan 
This drug is being used for its FDA approved indication.  The side effects from acute 
phenergan toxicity include deep sleep, coma, convulsions, respiratory depression, and 
cardiorespiratory symptoms.  These side effects are rare - expected to occur in less than 1% of 
people (less than 1 out of 100 people).  In our initial series of subjects, nausea has not been 
reported and phenergan has not been requested. 
 
4.5.5 Risks of flumazenil 
This drug is being used for its FDA approved indication.  The side effects of flumazenil 
on the central nervous system include dizziness, agitation, seizures, blurred vision.  Other 
potential side effects include nausea, vomiting, hiccups, shivering, and hypoventilation.  These 
side effects are rare - expected to occur in less than 1% of people (less than 1 out of 100 people). 
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4.5.6 Risks of magnesium sulfate 
The side effects of magnesium sulfate include sedation, confusion, muscle weakness, 
hypotension, and pulmonary edema. These side effects are rare - expected to occur in less than 
1% of people (less than 1 out of 100 people) and were not reported in two previous studies 
utilizing magnesium sulfate to aid in hypothermia induction.9,11 
 
4.5.7 Risks of ibuprofen 
This drug is being used for its FDA approved indication. The central nervous system side 
effects of ibuprofen include headache, dizziness, light-headedness, anxiety, and confusion.  
Cardiovascular side effects include hypertension, palpitations, and congestive heart failure.  
Other side effects include blurred vision, dry mouth, nausea, vomiting, liver damage and kidney 
damage. Subjects with known sensitivity or allergy to ibuprofen will not have it administered 
making the side effects rare - expected to occur in less than 1% of people (less than 1 out of 100 
people) 
 
4.5.8 Risk associated with medical procedures 
Other potential risks include discomfort, infection, bleeding, superficial venous 
thrombosis, or aseptic thrombophlebitis due to the intravenous catheter insertion.  This will occur 
rarely - expected to occur in less than 1% of people (less than 1 out of 100 people).  The 
CorTemp temperature probe to be used carries no more risk than swallowing a pill and will pass 
through the subject’s gastrointestinal system safely within a few days.  Adverse effects from the 
capsule include becoming lodged in the GI tract in subjects with esophageal or intestinal disease.  
This will be rare - expected to occur in less than 1% of people (less than 1 out of 100 people).  
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There is a rare risk of redness, chafing, and irritability associated with the ECG electrodes - 
expected to occur in less than 1% of people (less than 1 out of 100 people).   
 
4.5.9 Risk associated with fluid administration 
For subjects with unknown heart or kidney conditions, infusion of large amounts of 
intravenous fluids could potentially result in congestive heart failure.  This risk will be 
minimized by a physical examination by a physician prior to beginning the study making this a 
rare event.  Infusion of the IV fluids could also cause abnormalities in electrolytes (substances 
normally found in the blood) especially in patients with kidney disease.  Abnormal electrolytes 
can cause a variety of complications ranging from weakness, confusion, and arrhythmia.  
However, these complications are rare (less than 1% or less than 1 per 100) in young healthy 
volunteers with no previous medical problems, especially given the relatively low volume of 
fluids to be given. 
 
4.5.10 Risks associated with confidentiality 
The investigators will insure subject confidentiality. All subjects will be assigned a 
number and will be identified as such rather than by name in all subject files. Only the signed 
consent form will state the subject’s name. All subject files will be locked in file cabinets. No 
record of subject information will appear in the UPMC medical records unless an adverse event 
occurs that would require further medical care. 
 
4.5.11 Benefits 
There will be no direct benefit to the subject for participation in this research study.   
 
4.5.12 Data Safety Monitoring Plan 
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The investigators will meet weekly and after each patient enrollment to ensure the data 
integrity and subject confidentiality has been maintained.   Adverse events, a need to modify the 
protocol, and changes in the risk profile will be reported in compliance with Chapter 3 of the 
IRB manual.  In addition to subject accrual, the following data will be accounted for at these 
meetings: temperature measures, medication administration, adverse events, vital signs, IV 
administration start and stop times. Data and Safety Monitoring reports will be submitted to the 
IRB (at time of annual renewal) and the investigators will comply with the IRB policy for 
reporting adverse events as outlined in Chapter 3.0, sections 3.4 and 3.5 of the IRB Reference 
Manual. 
 
5.0 COST AND PAYMENTS 
 
5.0.1 Costs 
None of the services and/or procedures (labs, medications, temperature monitoring) 
provided for this research study will be billed to the subject or to the subject’s health insurance.  
 
5.0.2 Payments 
Subjects will be paid $400 for completing the entire study.  A partial payment of $100 
per protocol completed will be provided for subjects who withdraw before completing all 
protocols.  Subjects who are not cleared for participation by the study physician or who withdraw 
prior to beginning the infusion will not be paid.   
 
APPENDICES 
 
6.1 Qualifications of Investigators: 
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Clifton Callaway, MD, PhD, is an Assistant Professor for the University of Pittsburgh 
Department of Emergency Medicine and attending physician in Emergency Medicine at 
Presbyterian Hospital.   
 
David Hostler, PhD, NREMT-P, is the Director of Research for the University of 
Pittsburgh Affiliated Residency in Emergency Medicine.  His doctorate was obtained in the field 
of exercise physiology and has extensive experience in conducting human physiology 
experiments. 
 
Samuel Poloyac, PhD, Pharm D is an Assistant Professor of Pharmaceutical Sciences at 
the University of Pittsburgh. 
 
Michael Tortorici, PharmD is a doctoral candidate in clinical pharmacy graduate 
program at the  University of Pittsburgh. 
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B.2 CONSENT FORM 
CONSENT TO ACT AS A SUBJECT IN AN EXPERIMENTAL STUDY 
TITLE: Therapeutic hypothermia induction and pharmacokinetics in healthy human subjects 
 
INVESTIGATORS:  David Hostler, PhD, NREMT-P, CSCS    
Director of Research    
University of Pittsburgh    
Affiliated Residency in Emergency Medicine 
   230 McKee Place Suite 500     
   Pittsburgh, PA  15213      
(412) 352-0224 
 
 Clifton Callaway, MD, PhD  
 Jon C. Rittenberger, MD    
 University of Pittsburgh    
 Department of Emergency Medicine 
 230 McKee Place Suite 500     
 Pittsburgh, PA  15213 
 412-647-9047 
 
 Samuel Poloyac, PhD, PhamD 
 Michael Tortorici, PharmD 
 University of Pittsburgh 
 School of Pharmacy 
 808A Salk Hall 
 Pittsburgh, PA 15213 
 412-624-4595 
  
Source of Support: Department of Emergency Medicine 
 183 
Why is this research being done? 
 
You are being asked to participate in a research study in which we will study the effects in 
healthy people of mild induced hypothermia (i.e., lowering of body temperature) using 
intravenous (IV) fluids and mild sedation.  Hypothermia has been shown to protect the brain in a 
variety of emergency medical situations, including when the heart stops suddenly (cardiac arrest) 
and strokes. IV fluids are an intervention that can easily be started by paramedics early in the 
treatment of these patients.  However, cooling the body causes shivering which may create heat 
making it difficult to make a patient cool enough to see a benefit.  We are therefore determining 
whether hypothermia can be quickly and effectively induced and maintained in normal subjects 
after administering cold IV fluid when using midazolam (Versed) and lorazepam (Ativan) to 
reduce the shivering that occurs when the body becomes cold.  We also want to investigate if 
hypothermia (lowering of body temperature) affects the ability of the liver to breakdown the 
drugs you are going to be given.  This is important because it will help us to understand how the 
liver works when patients’ body temperature is cooled.  This information will also help us to 
figure out the right dose of medications to give to patients treated with hypothermia.    
In this study, we will infuse cold 39°F (4ºC) or warm 98.6°F (37ºC) IV fluids into a vein 
into your arm on four separate occasions while we measure your core body temperature (the 
temperature in the center of your body). You will either be given midazolam (Versed) at three 
specific times during the study and a continuous infusion of lorazepam (Ativan).  Midazolam 
(Versed) and lorazepam (Ativan) is approved by the Food and Drug Administration (FDA) as a 
sedative.  On two visits, we will also give you the medication magnesium sulfate.  This medicine 
will cause your arteries and veins to open slightly bringing more blood to the skin.  Magnesium 
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sulfate is known to relax the muscle cells in your arteries and veins but has not been approved by 
the FDA for this use. 
We will monitor your other vitals signs including heart rate, respiration (breathing) rate, 
blood pressure, end-tidal CO2 (the amount of carbon dioxide you exhale) and pulse oximetry (an 
indicator of how much oxygen your blood is carrying).  We will also take eight (8) teaspoonful 
of blood during the study for a total of 40 ml teaspoonful of blood.  Finally, we will also assess 
the amount of discomfort caused by the fluids.  
 
Who is being asked to take part in this research study? 
 
People invited to participate in this study must be males between the ages of 18 and 39 years of 
age. The study requires five visits to complete.  One visit will be required for the screening and 
the physician exam.  Four additional visits are required to complete the four experiments.   
If you meet any of the following conditions you will also be excluded from the study:   
• If you have any known history of current or previous medical problems, including but not 
limited to:  heart disease, history of abnormal heart rhythm (arrhythmia) or heart murmur, 
low blood pressure, high blood pressure, lung disease including asthma, diabetes 
mellitus, thyroid disease, kidney disease, liver disease, nerve disease or seizures, 
connective tissue disorder or Raynaud’s disease, sickle cell disease, anemia, or other 
blood disorders 
• If you are known to have the human immunodeficiency virus (HIV positive) or are 
otherwise have difficulty fighting infection (weakened immune system). 
• If you take any medications (including herbal preparations) with the exception of allergy 
medication, ibuprofen or tylenol. 
• If you take any of the following medications or over-the-counter items: MAO inhibitors 
(such as Parnate or Nardil) or any other antidepressant, St John’s Wort, or Cimetidine 
(Tagamet).  Participating in the study while on these medicines could cause serious 
illness or death. 
• If there is a history of heart disease in family members below the age of forty 
• If you have a known allergy to midazolam (Versed) or lorazepam (Ativan), or a history of 
other narcotic allergy  
• If you have a history of long term benzodiazepine use 
• If you are currently ill  
• If you have kidney problems or renal insufficiency 
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• If you have abnormal vital signs including systolic blood pressure (the first number given 
when your blood pressure is taken) less than 90mmHg or greater than 140mmHg, heart 
rate less than 40 or greater than 100, or a respiratory rate (the number of times you 
breathe in one minute) less than 10 or greater than 24.   
• If you currently smoke or use any other recreational drugs 
• If you are morbidly obese (very overweight – Body Mass Index > 36) 
• An abnormal amount of sodium (salt) measured in your blood 
• If you have any history of stomach (gastrointestinal) disorder, including inflammatory 
bowel disease, esophageal disease, hypomotility (slow digestion) disorders, history of GI 
surgery, impaired gag reflex 
• You weigh less than 80 pounds 
 
This study is being performed on a total of 4 subjects.   
 
What procedures will be performed for research purposes? 
 
If you decide to take part in this research study, you will undergo the following procedures that 
are not part of standard medical care: 
 
Screening Procedures: 
 
Procedures to determine if you are eligible to take part in a research study are called “screening 
procedures”.   For this research study, the screening procedures include: 
 
1. A brief medical evaluation.  This will include questions about previous and current medical 
problems, medications and allergies, and family history.  A short physical exam will also be 
performed, to assess for the presence of any cardiac or respiratory abnormalities, or any other 
problems. 
2. We will assess your body fat by using calipers to measure the skin in three places (men – 
chest, abdomen, and thigh; women – arm, hip, and thigh). 
3.  An EKG (electrocardiogram) of your heart will be performed to assess for any underlying 
cardiac disorders.  This involves placing twelve stickers on your chest, arm and legs and 
recording your heart’s electrical activity for about twenty seconds. 
4. A blood sample will be collected from a vein in your arm to test for thyroid, liver, and blood 
diseases. The following tests will be performed on this blood: sodium and potassium level, 
thyroid serum hormone, SGOT, SGPT, alkaline phosphatase, billirubin (liver proteins), 
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BUN, creatinine, and a complete blood count. A maximum of 30cc (2 tablespoon) of blood 
will be collected. 
 
These procedures will take about sixty minutes total and will be performed in the Department of 
Emergency medicine offices.  Once you have completed the screening and been approved by the 
study physician you will be scheduled for the experimental protocol. 
 
Experimental Procedures: 
 
If you qualify to take part in this research study, you will undergo the experimental procedures 
listed below four times, each time separated by at least one week.  Each time you arrive you will 
medical monitors attached to follow your temperature and vital signs.  You will receive the 
medication midazolam (Versed) three times.  This medicine might make you sleepy.  You will 
also receive IV fluids for 30 minutes while you get this medication.  On two visits the fluid will 
be cold and on two visits it will be warm.  On two of the four visits you will also receive the 
medication magnesium sulfate.  All the medications will be given through a vein in your arm.   
After 30 minutes you will receive a second medication (lorazepam or Ativan) that may 
continue the sleepy feeling.  During this time we will draw blood samples and monitor your 
temperature and vital signs for three hours.  Following this the medications will be stopped and 
you will be watched by a physician until you wake up and have recovered.   
These procedures will take place in either the Presbyterian Hospital emergency 
department or the Emergency Responder Human Performance Lab at the Department of 
Emergency Medicine.  The experimental procedures will take approximately 5-6 hours including 
preparation, the experiment, and follow up.  Before each protocol, you should not consume 
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alcohol or caffeine for 24 hours or grapefruit juice for 48 hours as these may interfere with the 
study.   
To ensure all subjects are cooled equally during the study, males will be asked to wear 
short pants and no shirt during the study 
 
All subjects will have the following procedures performed 
 
1. We will place several stickers onto your chest, arms, and legs which will enable you to 
be connected to a cardiac monitor and a temperature monitor.  This will provide a constant 
assessment of your heart rate and rhythm throughout the test and skin temperature.  A blood 
pressure cuff will be placed on your arm and another monitor will be placed upon your index 
finger to assess your pulse oximetry (an indication of how much oxygen is being carried by your 
blood).  A small plastic tube (cannula) will be placed at the entrance of your nose to measure 
your exhaled breath. 
 
2. You will be given a capsule approximately the size of a large Tylenol to swallow 
which contains a temperature sensor and transmitter.  It will detect your core temperature (i.e., in 
your stomach and gastrointestinal tract) and transmit this information to a sensor outside of your 
body.  This will pass through your GI tract and be eliminated several days later when you move 
your bowels.  This capsule is FDA approved. 
 
3. You will be weighed after you empty your bladder. 
 
4. An 18-gauge intravenous catheter (IV) will be placed into one of your antecubital 
veins (in the crease of your arm formed by your elbow) or in a forearm or hand vein.  The 
amount of fluid will be adjusted for your body weight (30mL/kg or 0.5 oz per pound), about 2 
liters (about 0.5 gallons) for an average sized adult.  One teaspoonful of blood will be taken from 
this catheter in your vein for a total of ten (10) times throughout the study for a total of fifty ml.  
These samples will be stored in Dr. Poloyac’s lab in the School of Pharmacy and will be 
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analyzed by Dr. Poloyac, his graduate students, or assistants.  The samples will be labeled with a 
number.  The list linking the number to you and your data will be kept in a separate location.  
These samples will not be shared with other researchers.    
 
5. Stickers will be placed on your forehead and thighs to measure and connected to 
monitors to determine how drowsy you become and how much oxygen is in your muscles. 
 
6. You will receive three doses of midazolam (Versed) ten minutes apart.  IV fluids will 
be infused through the IV at a rate of 30cc/kg for thirty minutes.  During this time, we will 
monitor your temperature via the capsule you swallowed every two minutes.  We will also record 
your heart rate every two minutes from the monitors.  Your blood pressure will be checked every 
five minutes in the arm opposite of the IV. 
 
7. You will also be asked to assess your level of discomfort using a number of simple 
scales.  This means that you will be shown a series of numbers with explanation of temperature 
and discomfort. These assessments will be performed immediately prior to starting the fluids, 
every five minutes during the test, and every ten minutes for another half an hour following the 
test. 
 
8. Fluids will stop approximately 30 minutes after beginning.  At that time, you will be 
given an infusion of lorazepam (Ativan) to maintain your relaxed state for 3 hours.  During this 
time we will monitor your temperature and vital signs.  We will draw a tablespoon of blood 
seven times during this period.  Following this period, the medications will be stopped and you 
will be monitored for at least one hour while you recover. 
 
The study will be ended early and you will be given medication to reverse the sedation if 
any of the following occur: 
• Your core temperature goes below 93.2°F (34°C)  
• At your request 
• If your vital signs become significantly abnormal, including a heart rate less 
than 40 beats per minute (bpm) or greater than 150 bpm, systolic blood pressure 
equal or less than 80 or greater than 180, or respirations less than 7 per minute 
or more than 30 per minute.   
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• If you become confused or sleepy to the point that you cannot be easily awoken 
• The pulse oximeter reading becomes less than 93% (there is a decrease in the 
level of oxygen carried by the blood). 
• Any sign of cardiac arrhythmia (irregular or abnormal heart rhythm) 
 
Monitoring/Follow-up Procedures: 
 
Procedures performed to evaluate the effectiveness and safety of the experimental 
procedures are called “monitoring” or “follow-up” procedures.  For this research study, the 
monitoring/follow-up procedures include: 
 
1. For a minimum of 60 minutes after stopping the IV fluids, we will monitor your temperature, 
heart rate, blood pressure, and pulse oximetry, as well as your level of discomfort using the scale 
described above. 
 
2. You will be given warm blankets and or liquids as desired. 
 
3. You will be weighed after you empty your bladder. 
 
4. If after 60 minutes, your temperature is above 96.8°F (36°C), your vital signs are all within 
normal limits, you feel physically comfortable, and the study physician has determined you are 
well enough to leave you may leave with no further follow-up required.   
 
5. You will not be permitted to drive immediately following the study and should not drive for 
12 hours after completing the study.  You must have alternate transportation available before you 
begin the study. 
 
 
What are the possible risks, side effects, and discomforts of this research study? 
 
As with any experimental procedure, there may be adverse events or side effects that are 
currently unknown and certain of these unknown risks could be permanent, severe, or life 
threatening.   
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The possible risks of this research study may be due to the decrease in core body 
temperature (hypothermia), the medications given, and the placement of the IV line and blood 
tests. 
 
Risks of Mild Induced Hypothermia: 
The most common effects of hypothermia include discomfort or pain (especially in fingers and 
toes) and shivering. Chances are likely (more than 25%, or 25 in 100) that you will experience 
shivering and/or discomfort while receiving the saline.  
Long periods of mild cooling (temperature of 91.4-95°F (33-35°C) over a period of 
greater than 12 hours) can affect different parts of the body.  There may be an increase in 
metabolism (the rate at which your body burns fuel and oxygen) required during shivering. 
Pneumonia (a lung disease) has occurred in those with prolonged hypothermia (greater than 
seven days) but is otherwise rare - expected to occur in less than 1% of people (less than 1 out of 
100 people). The period of cooling in this study is less than one hour making this rare - expected 
to occur in less than 1% of people (less than 1 out of 100 people). 
 
Risks associated with midazolam administration: 
The most common side effects of the midazolam include drowsiness, sedation [likely - expected 
to occur in more than 25% of people (more than 25 out of 100 people], apnea (brief pauses in 
your breathing) or a decrease in the rate of your breathing,  [likely - expected to occur in about 
15% of people (around 15 out of 100 people)], involuntary movements,  nausea, vomiting, hives, 
rash, [infrequent - expected to occur in 1-10% of people (1-10 out of 100 people)]. You may also 
experience visual disturbances [rare - expected to occur in less than 1% of people (less than 1 out 
of 100 people)]. Other possible and more serious effects [rare - expected to occur in less than 1% 
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of people (less than 1 out of 100 people)] include cardiac depression (poor heart function) or 
arrest, hypotension (low blood  pressure).  As with any medication, an allergic reaction (e.g. 
rash, itching, swelling, shortness of breath) is always a risk. 
A physician and emergency drugs and equipment will be readily available should you 
experience any adverse reactions from administration of the study drug. You will be offered the 
medication Phenergan if you become nauseated during the study or ibuprofen if you have a 
headache.  If you become too drowsy you will be given the medication flumazenil. 
The medicines that may be provided to treat over sedation, nausea, and headache carry 
their own risks. 
 
Risks of lorazepam (Ativan) administration: 
The most common side effects of the lorazepam include sedation [likely - expected to occur in 
more than 25% of people (more than 25 out of 100 people], dizziness, vertigo, weakness, or 
unsteadiness [infrequent - expected to occur in 1-10% of people (1-10 out of 100 people)]. You 
may also experience visual disturbances, sleep disturbances, depression, disorientation, 
headache, confusion, crying, delirium, or agitation [rare - expected to occur in less than 1% of 
people (less than 1 out of 100 people)]. Other possible and more serious effects [rare - expected 
to occur in less than 1% of people (less than 1 out of 100 people)] include either low or high 
blood pressure, nausea, vomiting, blurred vision, or respiratory depression,  As with any 
medication, an allergic reaction (e.g. rash, itching, swelling, shortness of breath) is always a risk. 
A physician and emergency drugs and equipment will be readily available should you 
experience any adverse reactions from administration of the study drug. You will be offered the 
medication Phenergan if you become nauseated during the study or ibuprofen if you have a 
headache.  If you become too drowsy you will be given the medication flumazenil. 
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The medicines that may be provided to treat over sedation, nausea, and headache carry 
their own risks. 
 
Risks of phenergan (promnmethazine) administration: 
This drug is being used for its FDA approved indication.  Phenergan will be administered if you 
become nauseated during the protocol.  This is the normal use for this medication.  The side 
effects from phenergan include deep sleep, coma, convulsions, slow breathing, abnormal 
heartbeat, high blood pressure, or low blood pressure.  These side effects are rare - expected to 
occur in less than 1% of people (less than 1 out of 100 people).  
 
Risks of flumazenil (Romazicon): 
This drug is being used for its FDA approved indication.  Flumazenil will be given if you 
become too sedated.  This is the normal use for this medicine. The side effects of flumazenil 
include dizziness, agitation, seizures, blurred vision.  Other potential side effects include nausea, 
vomiting, hiccups, shivering, and slow breathing.  These side effects are rare - expected to occur 
in less than 1% of people (less than 1 out of 100 people). 
 
Risks of ibuprofen (Advil): 
This drug is being used for its FDA approved indication.  Ibuprofen will be given if you develop 
a headache.  This is the normal use of this medicine.  The side effects of ibuprofen include 
headache, dizziness, light-headedness, anxiety, and confusion.  Side effects of the heart include 
high blood pressure, palpitations, and heart failure.  Other side effects include blurred vision, dry 
mouth, nausea, vomiting, liver damage and kidney damage. These side effects rare - expected to 
occur in less than 1% of people (less than 1 out of 100 people) 
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Risks of the Intravenous Catheter Placement: 
Bruising and soreness occur infrequently and infection, bleeding, or a condition known as aseptic 
thromboplebitis (blood clots in the vein) may rarely occur as a result of the needle sticks to 
obtain blood from your vein or to start an IV to give fluids and medication.  These risks are rare 
(less than 1% or less than 1 per 100) and they are minimized by having blood drawn by trained 
physicians and paramedics.  There is a risk you could pass out while having your blood drawn 
[infrequent - expected to occur in 1-10% of people (1-10 out of 100 people)].  You will sit in a 
special chair to ensure you do not fall if this happens.  You will placed laying down, face up and 
have your feet elevated until you recover.   
 
Risks of the IV Fluids: 
If you have an unknown heart or kidney condition, infusion of large amounts of intravenous 
fluids could potentially result in congestive heart failure, or a build up of fluid in your lungs and 
other tissues.  This could result in difficulty breathing and potentially further damage to your 
heart and kidneys.  You will be given a physical examination by a physician prior to beginning 
the study making this a rare event.  Infusion of the IV fluids could also cause abnormalities in 
electrolytes (substances normally found in the blood) especially in patients with kidney disease.  
Abnormal electrolytes can cause a variety of complications ranging from weakness, confusion, 
and arrhythmia.  However, these complications are rare (less than 1% or less than 1 per 100) in 
young healthy volunteers with no previous medical problems, especially given the relatively low 
volume of fluids to be given. 
 
Other potential risks: 
The CorTemp temperature probe to be used carries no more risk than swallowing a pill and will 
pass through your stomach and intestines safely within a few days.  There is a risk the capsule 
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will become lodged in your digestive system if you have a disease of the esophagus or intestine.   
This is rare and expected to occur in less than 1% of people (less than 1 out of 100 people).  
There is a rare risk of redness, chafing, and irritability associated with the ECG electrodes - 
expected to occur in less than 1% of people (less than 1 out of 100 people).   
 
What are possible benefits from taking part in this study? 
 
You will likely receive no direct benefit from taking part in this research study.   
 
If I agree to take part in this research study, will I be told of any new risks that may be 
found during the course of the study? 
 
You will be promptly notified if, during the conduct of this research study, any new information 
develops which may cause you to change your mind about continuing to participate.  
Furthermore, you will be informed of any findings or health concerns that may be found during 
your screening history and physical, screening blood work, or during cardiac monitoring. 
 
Will my insurance provider or I be charged for the costs of any procedures performed 
as part of this research study? 
 
The study will pay for research-only costs. Neither you, nor your insurance provider, will be 
charged for the costs of any of the procedures performed for the purpose of this research study 
(i.e., the Screening Procedures, Experimental Procedures, or Monitoring/Follow-up Procedures 
described above).   
 
Will I be paid if I take part in this research study? 
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You will be paid a total of $400 if you pass the screening and complete all four scheduled 
session.  You will be paid $100 for each session you complete if you do not complete all four 
sessions.  If you are found to be ineligible during the initial exam, pregnancy test, or EKG 
screen, you will not be paid. 
 
Who will pay if I am injured as a result of taking part in this study? 
 
University of Pittsburgh researchers and their associates who provide services at the UPMC 
recognize the importance of your voluntary participation in their research studies.  These 
individuals and their staffs will make reasonable efforts to minimize, control, and treat any 
injuries that may arise as a result of this research.  If you believe that you are injured as a result 
of the research procedures being performed, please contact immediately the Principal 
Investigator or one of the co-investigators listed on the first page of this form. 
Emergency medical treatment for injuries solely and directly related to your participation 
in this research study will be provided to you by the hospitals of the UPMC.  It is possible that 
the UPMC may bill your insurance provider for the costs of this emergency treatment, but none 
of these costs will be charged directly to you.  If your research-related injury requires medical 
care beyond this emergency treatment, you will be responsible for the costs of this follow-up 
care unless otherwise specifically stated below.  You will not receive any monetary payment for, 
or associated with, any injury that you suffer in relation to this research.   
 
Who will know about my participation in this research study? 
 
Any information about you obtained from this research will be kept as confidential (private) as 
possible.  All records related to your involvement in this research study will be stored in a locked 
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file cabinet.  Your identity on these records will be indicated by a case number rather than by 
your name, and the information linking these case numbers with your identity will be kept 
separate from the research records.  You will not be identified by name in any publication of the 
research results unless you sign a separate consent form giving your permission (release). 
 
 
Will this research study involve the use or disclosure of my identifiable medical 
information? 
 
This research study will not access your medical records nor will information from this research 
study be placed in your medical records.  However, a medical record could be generated in the 
unlikely event a complication occurs. 
 
Who will have access to identifiable information related to my participation in this 
research study? 
 
In addition to the investigators listed on the first page of this authorization (consent) form and 
their research staff, the following individuals will or may have access to identifiable information 
related to your participation in this research study: 
Authorized representatives of the University of Pittsburgh Research Conduct and 
Compliance Office may review your identifiable research information for the purpose of 
monitoring the appropriate conduct of this research study.  
In unusual cases, the investigators may be required to release identifiable information 
related to your participation in this research study in response to an order from a court of law.  If 
the investigators learn that you or someone with whom you are involved is in serious danger or 
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potential harm, they will need to inform, as required by Pennsylvania law, the appropriate 
agencies. 
Authorized representatives of the sponsor of this research study, the University of 
Pittsburgh General Clinical Research Center, may review and/or obtain identifiable information 
related to your participation in this research study for the purpose of monitoring the accuracy and 
completeness of the research data and for performing required scientific analyses of the research 
data.  Authorized representatives of the study sponsor may also be present during your 
participation in the procedures performed as part of this research study.  While the study sponsor 
understands the importance of maintaining the confidentiality of your identifiable research and 
medical information, the UPMC and University of Pittsburgh cannot guarantee the 
confidentiality of this information after it has been obtained by the study sponsor.  The 
investigators involved in the conduct of this research study may receive funding from the 
sponsor to perform the research procedures and to provide the sponsor with identifiable research 
and medical information related to your participation in the study.  
Authorized representatives of the UPMC hospitals or other affiliated health care 
providers may have access to identifiable information related to your participation in this 
research study for the purpose of (1) fulfilling orders, made by the investigators, for hospital and 
health care services (e.g., laboratory tests, diagnostic procedures) associated with research study 
participation; (2) addressing correct payment for tests and procedures ordered by the 
investigators; and/or (3) for internal hospital operations (i.e. quality assurance). 
 
For how long will the investigators be permitted to use and disclose identifiable 
information related to my participation in this research study? 
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The investigators may continue to use and disclose, for the purposes described above, 
identifiable information related to your participation in this research study for a minimum of 5 
years and for as long (indefinite) as it may take to complete this research study. 
 
May I have access to my medical information that results from my participation in this 
research study? 
 
No medical information will be placed into your medical records. 
 
Is my participation in this research study voluntary? 
 
Your participation in this research study, to include the use and disclosure of your identifiable 
information for the purposes described above, is completely voluntary.  (Note, however, that if 
you do not provide your consent for the use and disclosure of your identifiable information for 
the purposes described above, you will not be allowed, in general, to participate in the research 
study.)  Whether or not you provide your consent for participation in this research study will 
have no effect on your current or future relationship with the University of Pittsburgh.  Whether 
or not you provide your consent for participation in this research study will have no effect on 
your current or future medical care at a UPMC hospital or affiliated health care provider or your 
current or future relationship with a health care insurance provider. 
These doctors are involved as investigators in this research study.  As both doctors and 
research investigators, they are interested both in your medical care and the conduct of this 
research study.  Before agreeing to participate in this research study, or at any time during your 
study participation, you may discuss your care with another doctor who is not associated with 
this research study.  You are not under any obligation to participate in any research study. 
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May I withdraw, at a future date, my consent for participation in this research study? 
 
You may withdraw, at any time, your consent for participation in this research study. Any 
identifiable research or medical information recorded for, or resulting from, your participation in 
this research study prior to the date that you formally withdrew your consent may continue to be 
used and disclosed by the investigators for the purposes described above.   
To formally withdraw your consent for participation in this research study you should 
provide a written and dated notice of this decision to the principal investigator of this research 
study at the address listed on the first page of this form. 
Your decision to withdraw your consent for participation in this research study will have 
no effect on your current or future relationship with the University of Pittsburgh.  Your decision 
to withdraw your consent for participation in this research study will have no effect on your 
current or future medical care at a UPMC hospital or affiliated health care provider or your 
current or future relationship with a health care insurance provider. 
 
If I agree to take part in this research study, can I be removed from the study without 
my consent? 
 
It is possible that you may be removed from the research study by the researchers if, for 
example, your pregnancy test proves to be positive.  If you are withdrawn from participation in 
this research study due to a positive pregnancy test, or any concerns on your physician exam, you 
will not undergo the subsequent study protocol. 
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************************************************************************ 
 
VOLUNTARY CONSENT 
 
All of the above has been explained to me and all of my current questions have been 
answered.  I understand that I am encouraged to ask questions about any aspect of this research 
study during the course of this study, and that such future questions will be answered by the 
researchers listed on the first page of this form.   
 
Any questions which I have about my rights as a research participant will be answered by 
the Human Subject Protection Advocate of the IRB Office, University of Pittsburgh (1-866-212-
2668).  
 
By signing this form, I agree to participate in this research study.  A copy of this consent 
form will be given to me. 
 
________________________________   __________________ 
Participant’s Signature     Date 
 
CERTIFICATION of INFORMED CONSENT 
 
I certify that I have explained the nature and purpose of this research study to the above-
named individual(s), and I have discussed the potential benefits and possible risks of study 
participation.  Any questions the individual(s) have about this study have been answered, and we 
will always be available to address future questions as they arise.”  
 
___________________________________  ________________________ 
Printed Name of Person Obtaining Consent  Role in Research Study 
 
_________________________________  ____________ 
Signature of Person Obtaining Consent  Date  
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